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ABSTRACT
Susan Beveridge - Metabolite Transport Pathways of 
Plasmodium falciparum
Metabolite transport pathways of the malaria parasite, Plasmodium 
falciparum, are an important area for study in order to further the 
understanding of the parasite’s biology. Identification and characterisation 
of the transporters involved in these pathways may also provide potential 
novel drug targets or drug delivery mechanisms. This is especially valuable 
as chemotherapy remains one of the main management strategies in the 
fight against malaria and the usefulness of the current range of antimalarial 
drugs is seriously threatened by the emergence and spread of resistance.
In this thesis the Xenopus laevis oocyte heterologous expression system 
was used to functionally characterise a gene-specific cDNA library of 48 
putative membrane proteins and the previously annotated putative amino 
acid transporter PFF1430c for the uptake of several amino acids. This 
screening failed to identify any definite amino acid transport by the cDNA 
library or PFF 1430c, however tins could have been due to the fact that 
uptake of a relatively narrow range of amino acids was tested and these 
were used at concentrations lower than found physiologically. Inherent 
issues with the X. laevis expression system may also have been an issue, 
including the expression of endogenous transporters for the substrates 
being investigated.
The uptake of methionine by intact infected RBCs and free P. falciparum 
parasites was also characterised. No increase in uptake by infected RBCs 
compared to uninfected RBCs was found, however this is an unexpected
iv
result compared to other nutrients and further experiments need to be 
carried out before any conclusion can be made. Methionine was found to 
be transported across the parasite plasma membrane via one or more 
saturable systems showing partial similarity to the vertebrate systems L- 
methionine influx into the free parasites was inhibited most effectively by 
cysteine and to a lesser degree by lysine and histidine.
The whole cell membrane transport of substrates related to folate and 
methionine metabolism was studied using a pharmacological approach. 
pABA was the only folate substrate to antagonise sulphadoxine and 
pyrimethamine at physiological concentrations and growth assays with E. 
coli ApabA/AabgT expressing P. falciparum folate transporters PfFTl or 
PfFT2 also showed pABA to be the most efficient folate substrate at 
increasing bacterial growth. These results suggest that the folate precursor 
pABA may be the relevant natural folate intennediate substrate for the 
intraerythrocytic malaria parasite. This is an interesting observation as 
pABA is not significantly utilised or synthesised in humans making pABA 
salvage a potential target for chemotherapy.
v
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CHAPTER 1
INTRODUCTION
1.1 Malaria
Malaria is a vector borne disease caused by apicomplexan parasites of the 
family Plasmodiidae and the genus Plasmodium. There are over two 
hundred species of Plasmodium described, and four for which humans are 
natural hosts: Plasmodium falciparum, Plasmodium vivax, Plasmodium 
ovale and Plasmodium malarias (Garnham, 1966, Abdalla, 2004, Perkins 
and Austin, 2009). The simian malaria parasite Plasmodium knowlesi has 
also recently been found in humans as a zoonotic infection (Singh et ai, 
2004). There have been fatal human infections with this parasite, which 
naturally infects long-tailed macaques and is widespread throughout 
Southeast Asia (Cox-Singh and Singh, 2008). In 2006 there were an 
estimated 3.3 billion people at risk of malaria worldwide, with an estimated 
247 million cases of malaria and an estimated 881, 000 deaths (WHO, 
2008). Cases in Afiica accounted for 91 % of the deaths from malaria, with 
children under five years of ages being the most affected. P. falciparum 
causes the most severe form of disease and is the most widespread species 
affecting humans, being responsible for 92 % of cases worldwide in 2006 
(figure U) (WHO, 2008).
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Figure 1.1. The spatial distribution of P. falciparum malaria endemicity in 2007 
(Hay et al., 2009).
1.1.1 Discovery of the Malaria Parasite
Long before the discovery of the causative agent of malaria evidence of the 
disease is well documented. Descriptions of symptoms of malaria, such as 
splenomegaly and intemrittent fever, are found in the Ebers Papyrus from 
Egypt (ca. 1570 B.C.) and also in the Nei Ching from China in 2700 B.C 
(Sherman, 1998). Further proof of the presence of the malaria parasite in 
Ancient Egypt comes from the detection of a trophozoite derived P. 
falciparum antigen in skin, lung and muscle samples of mummies from 
between 3200 and 1085 B.C. (Miller et al, 1994). Malaria is mentioned in 
Homer’s Iliad and the Greek physician Hippocrates described the quartan 
and tertian fevers of P. malariae and P. vivax in his Book of Epidemics in 
the fifth century B.C. (Sherman, 1998). He also discerned a correlation
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between malaria cases and marshland areas as well as a seasonal pattern of 
disease (Bruce-Chwatt, 1989). Despite noting the link between marshlands 
and malaria Hippocrates did not make the link between the presence of 
mosquitoes and the disease, instead attributing the cause of malaria to the 
drinking of stagnant waters. It was not until 1880 that the cause of malaria 
was correctly discovered. The discovery of the malarial agent, parasites of 
the genus Plasmodium, was made by Alphonse Laveran whilst working at 
a military hospital in Bone in Algeria (Collins and Jeffery, 2007). On post­
mortem examination of blood taken from the spleen of a pernicious 
malaria case he noted that there was not only free pigment (as had 
previously been observed), but also observed leukocytes containing 
ingested particles and pigmented spherical hyaline corpuscles and crescent­
shaped bodies (Bruce-Chwatt, 1981). On the 6th of November 1880 he 
proved that these observed particles were not just degraded erythrocytes by 
observing exflagellation in blood from a soldier suffering from malaria. 
From these observations he concluded that he was seeing living organisms 
in the blood that were the cause of malaria. Examination of blood from 
marsh fever (malaria) cases in Italy showed the same bodies and further 
consolidated Laveran’s claim that malaria was a parasitic disease. 
However, despite extensive searching, including examination of water, soil 
and air, Laveran was unable to discover the parasites outside the patient’s 
body. In the late 1890s Ronald Ross, an army surgeon working in India, 
carried out a series of experiments to attempt to demonstrate the role of the
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mosquito in malaria transmission. In 1887 he made the discovery of 
foreign bodies in the stomach wall of mosquitoes fed on malarious 
patients. Further work on avian malaria and the mosquito vector allowed 
Ross to follow the development of the parasite in the mosquito, and so 
gave further evidence to the theory of mosquitoes as the vectors of human 
malaria.
1.1.2 The Life Cycle of the Malaria Parasite
The human malaria parasite has a two host life cycle, the asexual phase of 
development and replication occurring in the human host and the sexual 
phase within the anopheline mosquito vector (figure 1.2). When the 
mosquito takes a blood meal sporozoites in the mosquito's saliva are 
released into the human host. These sporozoites travel to the liver and 
invade hepatocytes where they differentiate and undergo asexual 
replication. Thousands of merozoites develop within each parasitised 
hepatocyte and are released into the blood stream when the hepatocyte 
ruptures. Free merozoites then invade red blood cells and undergo either a 
round of asexual multiplication through trophozoite and schizont stages or 
else differentiate into sexual forms (micro and macro gametocytes). Once 
mature the schizonts burst releasing merozoites back into the blood stream 
and the asexual intraerythrocytic cycle is repeated. Micro and 
macrogametocytes are ingested by the anopheline mosquito during a blood
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meal and develop in the midgut of the mosquito into gametes, with the 
microgametes undergoing exflagellation. The gametes then fertilise and 
develop into an ookinete which penetrates the midgut wall and further 
develops into an oocyst. Sporogenesis occurs within the oocyst and 
sporozites are released into the salivary glands of the mosquito, which can 
then be transmitted when the mosquito takes a blood meal.
Hepatic stages Blood stages
merozoite invades 
RBC earlytrophozoite (ring)
sporozoite
invades
hepatocyte
macro- _v ____micro-
gametocyte gametocyte
sporozoites 
injected 
with saliva 
of mosquito
sporozoites 
in salivary 
gland
gametocytes 
taken into 
mosquito mid 
gut with blood 
meal
exflagellating
microgametes
mid gut wall
oocyte ruptures and 
sporozoites penetrate 
salivary gland
oocyst
sporogony occurs within 
the oocyte
Figure 1.2. The life cycle of the malaria parasite. Modified from Cox (1993).
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1.2 Malaria Management Strategies
Different strategies to control malaria have been implemented throughout 
the ages. Before the discovery of the malaria parasite and its mosquito 
vector some limited control strategies had already been implemented, for 
example the draining of marshes and simply the avoidance of malarious 
regions. Control strategies over the last century have helped reduce the 
number of people at risk of malaria horn 77 % in 1900 to just under 50 % 
in 2000 (Hay et al., 2004, Enayati and Hemingway, 2010). These control 
strategies have included vector control and chemotherapy with major 
advances, and setbacks, occurring in both of these fields over the past 
hundred years. There is also an ongoing quest to find an effective malaria 
vaccine (Greenwood and Targett, 2009, Haque and Good, 2009).
1.2.1 Vector Control
Long before Ronald Ross identified the mosquito vector responsible for 
transmission of malaria it had been noticed that there was a correlation 
between areas of wetlands and malaria cases. This led to the first malaria 
control strategy of draining marshlands (Griffitts, 1937). After the 
identification of mosquitoes as the vector of malaria significant efforts 
were made to control the insects in an attempt to break the cycle of 
transmission. Early efforts in this sanitation era included focussing on 
reducing mosquito breeding sites by drainage or other modifications and
6
the application of larvicides (Kitron and Spielman, 1989). The discovery of 
the insecticide properties of dichlorodiphenyltrichloroethane (DDT) by 
Paul Muller in 1939 and its widespread use in the 1940s and following 
decades helped to eliminate malaria from previously malarious regions, 
including Greece and Italy (Enayati and Hemingway, 2010). Despite 
successes in the developed world, malaria eradication efforts using DDT 
and subsequent insecticides in combination with chemotherapy were not as 
successful in the developing world. This was mainly due to operational, 
political and economic difficulties faced in sustaining long term campaigns 
of indoor residual spraying (IRS) with insecticides combined with 
chemotherapeutic interventions (Muturi et al, 2008, Enayati and 
Hemingway, 2010). Insecticide treated bed nets (ITNs) are another form of 
vector control that has been developed more recently. These are effective, 
and although not as powerful as IRS are much simpler and easier to 
deploy. ITNs have been improved with the introduction of long lasting 
ITNs (LLINs) that do not require periodic re-treatment with insecticide 
(Enayati and Hemingway, 2010). Other vector control methods are 
currently being developed including sterile insect technique (SIT, the 
release of sterile males to reduce the mosquito population), the release of 
genetically modified mosquitoes that are refractory to malaria parasite 
development and the use of entomopathogenic fungi to kill mosquitoes 
(Kilama, 2009, Mnyone et al., 2010).
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1.2.2 Vaccine Development
People living in malaria endemic regions naturally acquire immunity to 
malaria after repeated infections and this observation has led to the search 
for a potential malaria vaccine candidate. Immunisation with live irradiated 
sporozoites via bites from infected irradiated mosquitoes first demonstrated 
that vaccination against human malaria is possible (Clyde et al., 1973). 
Since then there has been much research into finding suitable antigens as 
vaccine candidates. Three stages of parasite development have been 
targeted for vaccine development so far. The pre-erythrocytic stage 
vaccines target either sporozoites to block invasion of hepatocytes or the 
infected hepatocytes, so preventing infection or clinical disease. 
Erythrocytic stage vaccines inactivate the blood stage merozoites or target 
infected RBCs to prevent or reduce clinical disease. Transmission-blocking 
vaccines target the parasite’s sexual stages, with the resulting antibodies 
being ingested by the mosquito along with the parasite and blocking 
parasite development (Targett and Greenwood, 2008, Greenwood and 
Targett, 2009, Enayati and Hemingway, 2010). Currently there are still no 
licensed vaccines on the market despite decades of research spent on 
vaccine development. However, there are several promising candidates 
currently going through trials.
Current pre-erythrocytic stage vaccine candidates include whole 
sporozoites attenuated genetically or by irradiation and sub-unit vaccines
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based on the sporozoites circumsporozoite protein (CSP) and 
thrombospondin related anonymous protein (TRAP) involved in 
sporozoites motility and invasion of liver cells (Mueller et ah, 2005, 
Targett and Greenwood, 2008). The most promising of the sporozoite 
sub-unit vaccines so far is RTS, S. This vaccine fuses the tandem repeat 
tetra peptide (R) and C-tenninal T-cell epitope containing (T) regions of 
the CSP to the hepatitis B surface antigen (S), with the unfiised S antigen 
included. It has been used successfully in trials with the AS02 adjuvant, 
which is an oil in water emulsion based adjuvant with the 
immunostimulants monophosphoryl lipid A and QS-21 added (Targett 
and Greenwood, 2008).
Merozoite surface proteins have been the most investigated antigens for 
the development of erythrocytic stage vaccines. A phase 2 clinical trial 
with a vaccine containing merozoite surface protein 1 (MSP-1), MSP-2 
and ring-infected erythrocyte surface antigen (RESA) showed a strain 
specific reduction in parasite density but no decrease in the prevalence of 
infection (Genton et aL, 2002). This correlates with the theory that 
erythrocytic stage vaccines would reduce disease but not infection, and 
mimics naturally acquired immunity (Enayati and Hemingway, 2010).
Transmission-blocking vaccines have focussed on using sexual stage 
specific surface molecules involved in fertilisation (Pfs 48/45 and Pfs 230
9
in P. falciparum) and two other proteins expressed by zygotes and 
ookinetes (P25 and P28) as antigens. It has been shown using animal 
models that these antigens induce effective transmission-blocking 
immunity and phase I human clinical trials have also shown promising 
results (Targett and Greenwood, 2008).
1.2.3 Malaria Chemotherapy
With the lack of a licensed vaccine and vector control not effective at 
eliminating malaria alone, malaria chemotherapy remains the main 
management strategy in the fight against malaria. Antimalarial drugs have 
been in use for centimes, with the bark of the cinchona tree being used by 
the native Quechua people of South America as an effective cure for 
malaria. The antimalarial property of the bark of the chinchona tree was 
discovered by Europeans when they travelled to South America and 
witnessed its use in the early 17th century (Foley and Tilley, 1998). Initially 
a ground powder of the bark was used to treat malaria but the active form 
was later discovered and named quinine (Carmargo et aL, 2009).
1.2.3.1 The Status of Current Antimalarial Chemotherapy and the 
Spread of Resistance
Since the discovery of quinine, new antimalarial drugs have been 
developed and improved. Due to the occurrence and spread of parasites
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resistant to antimalarial drugs efforts are ongoing to develop new drugs and 
prevent the further spread of resistance to existing drugs (Biagini et aL, 
2003b).
1.2.3.1 Qumolme-Contaming Drugs
All the quinoline containing drugs act on the erythrocytic stages of the 
parasites, with the exception of the 8-aminoquinoline primaquine which 
also targets hypnozoites of P. vivax and P. ovale (Foley and Tilley, 1998). 
A method for producing synthetic quinine was not discovered until 1944 
when Woodward and van Doering (Carmargo et aL, 2009) discovered a 
pathway that was, however, too complex (and therefore too expensive) for 
commercial use (Foley and Tilley, 1998, Carmargo et al., 2009). Because 
of this delay and difficulty in producing synthetic quinine, research into 
alternative quinoline-containing antimalarials was carried out and the 
discovery of 4-amino quinolines (1), alternative quinoline methanols (2) 
and bisquinolines (3) achieved (Foley and Tilley, 1998, O'Neill et aL, 
1998).
(1) 4-Aminoqumolines
The 4-amino quinoline drugs were discovered during the search for an 
alternative antimalarial to quinine (Greenwood, 1995). The most widely 
used drug of this class of antimalarials is chloroquine, which was
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discovered by Bayer in 1934 (figure 1.3) (Coatney, 1963). It was initially 
known as resoelfin and was thought to be too toxic for human use, until 
demands for antimalarials during World War II led to its re-evaluation and 
trials in 1943. These trials showed that is was safe at therapeutic levels and 
it was renamed chloroquine and brought into use (Foley and Tilley, 1998). 
Chloroquine has been used extensively as it is cheaply produced, safe and 
has efficacy against all human malarias, although problems of resistance 
have since occurred and rendered it ineffective in many areas (Maitland et 
aL, 2004).
Amodiaquine, another 4-anfinoquinoline, was discovered by Parke, Davis 
and Company in the 1950s (figure 1.3) (Greenwood, 1995). It was initially 
used as a prophylactic drug but reports of neutropenia and hepatitis led to 
concerns of toxicity and its use was suspended (Jewell et aL, 1995, Taylor 
and White, 2004). The safety of amodiaquine has been thoroughly 
evaluated since and it was found to be safe and well tolerated (Olliaro and 
Mussano, 2003).
Both chloroquine and amodiaquine target the erythrocytic forms of the 
malaria parasite, specifically the stages ingesting and actively degrading 
haemoglobin (Foley and Tilley, 1998). The site of action of these drugs is 
the parasite’s digestive vacuole and their antimalarial property is due to
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haeme-binding activity but there is still no consensus on how the haeme- 
drug complex is toxic to the parasite (Bray et aL, 2005b).
1 2
Figure 1.3. Structures of the 4-aminoquinolines, chloroquine (1) and 
amodiaquine (2).
Cases of chloroquine resistance were first reported in South America and 
Southeast Asia in the late 1950s and early 1960s (Eyles et aL, 1963, 
Harinasuta et aL, 1965, Foote and Cowman, 1994). Resistance took longer 
to appeal' in Africa but by the late 1970s three cases of resistance had been 
reported in East Africa (Kihamia and Gill, 1982) and resistance is now 
widespread (Bjorkman and Phillips-Howard, 1990). The major mediator of 
chloroquine resistance is thought to be point mutations of the P. falciparum 
chloroquine resistance transporter gene (PfCRT), which codes for an 
integral digestive vacuole membrane protein (Fidock et aL, 2000, Bray et 
aL, 2005b, Bray et aL, 2005a, Hyde, 2007). In parasites from field samples
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a change from lysine to threonine at position 76 is found consistently in 
chloroquine resistant parasites but this is always accompanied by at least 3 
other changes (Hyde, 2007). The levels of chloroquine resistance have 
been shown to be modulated by mutations and copy number amplifications 
of the P. falciparum multi-drug resistance gene (PfMDRl) (Valderramos 
and Fidock, 2006, Hyde, 2007). Resistance to amodiaquine may have 
similar mechanisms to chloroquine resistance due to its similarity in 
structure and this has been shown to be true in some cases (Ochong et aL, 
2003, Holmgren et aL, 2006). Chloroquine resistance is widespread, 
however a study in Malawi has shown that there can be a reversal to the 
wild-type K76 and chloroquine sensitivity after a prolonged break from 
chloroquine use (Mita et aL, 2003).
(2) Quinoline Methanols
Quinine was the first quinoline methanol discovered, and as stated above 
the first globally administered antimalarial drug (figure 1.4). Quinine is 
still in use as a treatment for malaria, especially in combination with other 
drugs including tetracycline (Kremsner and Krishna, 2004). Mefloquine is 
a synthetic quinoline methanol that was discovered by the Walter Reed 
Army Institute of Research and marketed in the 1970s (figure 1.4) 
(Greenwood, 1995). Mefloquine has been, and is still, used as a 
prophylactic drug alone and for treatment either alone or as the partner
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drag in artemisinin-based combination therapy (ACT) (Kremsner and 
Krishna, 2004).
As with the 4-aminoquinolines the quinoline methanols target the 
erythroctic stages of the parasite, but the precise mode of action of the 
quinoline methanols is not fully understood. Unlike the 4-aminoquinolines 
the quinoline methanols do not cause a build up of undigested 
haemoglobin, suggesting that they may inhibit the ingestion of the host cell 
haemoglobin (Famin and Ginsburg, 2002, Bray et al., 2005b).
Figure 1.4. Structures of the quinoline methanols, quinine (1) and mefloquine 
(2).
Decreased sensitivity to quinine was fust reported in Brazil in 1910 
(Bjorkman and Phillips-Howard, 1990) but resistance is not as widespread 
as chloroquine resistance due to it not being used as extensively (Foley and
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Tilley, 1998). In areas where resistance is common, for example South 
East Asia, quinine is often used in combination with tetracycline (Bunnag 
et aL, 1996). Mefloquine resistance has been increasing since its 
introduction in the 1970s, with resistance occurring within five years of its 
introduction in an area of Thailand (White, 1994, Foley and Tilley, 1998). 
Mefloquine is used as a combmation therapy where resistance has been 
noted, being used as an ACT with artesunate as a partner drug (Nosten et 
aL, 2000). Quinine and mefloquine share cross-resistance (O'Neill et aL, 
1998) and resistance has been shown to be conferred by mutations in Pghl, 
an integral membrane protein of the ATP-binding cassette superfamily 
encoded by PfMDRl (Reed et aL, 2000, Bray et aL, 2005b).
(3) Bisquinolines
Piperaquine is a bisquinoline drug that was first synthesised in the 1960s 
and has been widely used in China since 1978 (figure 1.5) (Chen, 1991, 
Basco and Ringwald, 2003, Davis et aL, 2005). As with the other 
quinoline-containing drugs piperaquine targets the erythrocytic stages of 
parasite development.
The exact mode of action of piperaquine is unknown although it does 
accumulate within the parasite’s digestive vacuole suggesting it may have 
a similar mode of action to that observed for the other quinoline-containing 
drugs (Warhurst et aL, 2007). Resistance has been reported in China but in
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vitro tests of some African isolates have shown it to be effective there
(Basco and Ringwald, 2003). There is some suggestion that piperaquine 
may be subject to a chloroquine related resistance mechanism, due to its 
similarity to the 4-aminoquinolines and the fact that it concentrates within 
the parasite’s digestive vacuole, but the exact mechanism has not yet been 
identified (Warhurst et ai, 2007). An ACT partnering piperaquine with 
dihydroartemisinin is currently under development, although issues of 
possible antagonism are still being reviewed (Basco and Ringwald, 2003, 
Fivehnan et al., 2007).
Cl Cl
Figure 1.5. Structure of the bis quinoline, piperaquine.
1.2.3.2 Artemisinins
Artemisinin is a sesquiterpene trioxane lactone that was first isolated from 
the sweet wormwood shrub, Artemisia annua, in China in the 1970s 
(figure 1.6) (O’Neill et al., 2010). Artemisinin itself is poorly soluble in
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oil and water which reduces its therapeutic value, so derivatives of 
artemisinin were prepared to overcome this (Bray et al., 2005b). 
Artemisinins have been shown to be effective against multi-drug resistant 
strains ofP. falciparum (ter Kuile et al., 1993) and are active against both 
the erythrocytic stages and gametocyte stages of the parasite (Kumar and 
Zheng, 1990, O'Neill et al., 2010).
There is considerable debate on the precise mode of action and cellular 
target of artemisinins, although it has been noted that the endoperoxide 
bridge is essential for antimalarial activity (O'Neill et al., 2010). 
Artemisinin derivatives are recommended to be used along with a partner 
drug for artemisinin-based combmation therapy (ACT), with artemether- 
lumefantrine (marketed by Novartis as Coartem®) one of the leading 
combinations (Mueller et al., 2006). Until recently resistance to 
artemisinin derivatives has not been a concern, however, resistance to the 
artesunate-mefloquine has now emerged on the Cambodian-Thai border 
(Alker et al., 2007, O'Neill et al., 2010).
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Dihydroartemisinin, R = (3 + a OH 
Artemether, R = [3-OMe 
Arteether, R = p-OEt
Sodium artesunate, R = a-0C{0}CH2CH2C02Na 
C-10-deoxyartemisinin, R = H
Artemisinin First Generation
Artem isi ni n Ana logues
Figure 1.6. Structures of artemisinin and the first generation artemisinin 
analogues. Modified from Bray et al (2005b).
1.2.3.3 Antifolates
Antimalarial antifolates have been used extensively for treatment and 
prophylaxis for over 50 years (Nzila, 2006). As antifolates are a major part 
of this thesis they are discussed in depth in section 1.3.4.
1.3 P. falciparum Folate Pathway and 
Antimalarial Antifolates
The folate compound was discovered in the 1930s during work on 
anaemias. It was shown by Lucy Wills that a factor in yeast extract 
(Marmite) cured macrocytic anaemia of pregnancy (Hoffbrand and Weir, 
2001). In 1941 a similar factor was isolated from spinach and was named 
folic acid from the latin/o/mm meaning leaf (Mitchell et al., 1941). Folic 
acid was synthesised in pure crystalline form in 1945 (Angier et al., 1945)
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and was shown to consist of a pteridine moiety, para-aminobenzoic acid 
(pABA) and glutamic acid, with this compound also being known as 
pteroylglutamic acid (figure 1.7) (Nzila, 2006). It was soon noted that folic 
acid is not a naturally occurring folate, with natural folate differing from 
folic acid in three ways: (1) reduction of the pteridine rings to di- or 
tetrahydro forms at positions 7,8 and 5,6, (2) additional glutamate residues 
fonning polyglutamated derivatives and (3) additional single carbon units 
(methyl, formyl, methylene and methenyl) (Hoffbrand and Weir, 2001, 
Nzila, 2006). Higher animals, including humans, are unable to synthesise 
folate de novo and rely on dietary sources of pre-formed folate, whereas 
some microorganisms and plants are able to synthesise folates de novo. 
The P. falciparum malaria parasite is capable of both de novo biosynthesis 
and salvage of folate (Wang et ah, 2007). This difference in folate 
pathways between the malaria parasite and the human host is an attractive 
drug target and antimalarial antifolates have been used for over 50 years 
(Nzila, 2006).
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Figure 1.7. Structures of folic acid (1), pteridine (2), pABA (3) and glutamic 
acid (4).
1.3.1 De novo Folate Biosynthesis in P. falciparum
Unlike mammalian cells, P. falciparum is capable of de novo folate 
biosynthesis. The first evidence of the existence of this pathway in P. 
falciparum came from the susceptibility of the parasites to the antifolate 
sulphonamide and sulphone drugs which competitively interact with 
pABA and so inhibit the formation of folate derivitives in the parasite 
(Ferone, 1977). Further evidence came from the observation that the 
parasite is able to incorporate the radiolabelled folate precursors guanine
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triphosphate (GTP), pABA and glutamic acid into folate end products 
(Krungkrai et aL, 1989b). Folate biosynthesis has been extensively 
characterised in bacteria and the key genes in the pathway identified 
(Neidhart, 1996). Biochemical, genomic and molecular studies have also 
identified key folate pathway enzymes and genes in P. falciparum 
including GTP cyclohydrolase (Krungkrai et ai, 1985, Lee et aL, 2001), 
hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase 
(HPPPK-DHPS) (Triglia and Cowman, 1994), dihydropteroate synthase- 
folylpolyglutamate synthase (DHPS-FPGS) (Salcedo et ah, 2001) and 
dihydrofolate reductase-thymidylate synthase (DHFR-TS) (Bzik et aL, 
1987).
Biosynthesis of the pteridine moiety of the folate compounds starts with 
GTP which is subsequently converted to 7,8-dihydroneopterin triphosphate 
(DHNTP) (figure 1.8). This is catalysed by GTP cyclohydrolase which 
removes carbon 8 of the purine ring system forming DHNTP and formate. 
The next step in the P. falciparum pathway differs from that found in the 
conventional de novo folate biosynthesis pathway found in bacteria and 
plants (Dittrich et aL, 2008). In the conventional pathway DHNTP is 
converted to 6-hydroxymethyl-7,8-dihydropterin (HMDP) via a two step 
process, first the pyrophosphate group is removed then dihydroneopterin 
aldolase (DHNA) catalyses the cleavage of the lateral side chain releasing 
glycoaldehyde and producing HMDP (Benningham and Derrick, 2002).
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No candidate genes for DHNA have been found in Plasmodium but an 
unusual orthologue of 6-pyruvoyltetrahydopterin synthase (FTPS) has been 
found that could compensate for this (Dittrich et al., 2008). The P. 
falciparum FTPS (PfPTPS) enzyme converts DHNTP to 6-pyruvoyl- 
5,6,7,8-tetrahydopterin and HMDP. This HMDP is then converted to 6- 
hydroxymethyl-7, 8-dihydropterin pyrophosphate (DHPPP) in a reaction 
catalysed by 6-hydroxymethyl-7, 8-dihydropterin pyi'ophosphokinase 
(HPPPK) with the transfer of the pyrophosphate moiety from ATP 
(Bermingham and Derrick, 2002, Hyde, 2005).
The P. falciparum parasite is also capable of de novo biosynthesis of 
pABA (figure 1.8). The shikimate pathway is responsible for the 
production of chorismate, a pABA precursor, and this pathway has been 
shown to be present in P. falciparum (Keeling et ah, 1999, Gardner et al., 
2002, Triglia and Cowman, 1999b). Chorismate is converted to pABA, via 
4-amino-4-deoxychorismate (ADC), a reaction catalysed in P. falciparum 
by PABA synthase (a bipartite protein with domains homologous to 
Escherichia coli PabA and PabB) (Triglia and Cowman, 1999b). 
Dihydropteroate synthase (DHPS) condenses pABA (either from the de 
novo synthesis mentioned above or salvaged) and DHPPP to 
dihydropteroate. A glutamate residue is then attached to the carboxyl 
moiety of pABA in an ATP-dependent reaction catalysed by dihydrofolate 
synthase (DHFS) converting dihydropteroate to diliydrofolate (DHF). In a
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NADPH dependent reaction diliydrofolate reductase (DHFR) reduces DHF 
to the biologically active tetrahydrofolate (THF). The polyglutamation of 
synthesised THF or salvaged substituted THF cofactors is an MgATP 
dependent reaction catalysed by folylpolyglutamate synthase (FPGS) 
(Nzila et aL, 2005a),
1.3.2 Folate Salvage by P. falciparum
As well as de novo folate biosynthesis the malaria parasite is also capable 
of salvaging folate precursors, pre-formed folate and Ci substituted folate 
derivatives. Evidence of a need for pABA salvage by Plasmodium was first 
indicated in the 1960s when it was shown that P. berghei parasites had 
reduced growth when the mouse hosts were fed a pABA-deficient diet, 
with parasite growth returned to normal with the addition of pABA 
(Jacobs, 1964), This is further supported by the fact that induced folate 
deficiency in rhesus monkeys conferred protection against disease when 
injected with P. cynomolgy (Das et al, 1992). Experiments in vitro have 
also shown that P. falciparum is able to take up exogenous radiolabelled 
folic acid, folinic acid and pABA and convert it to polyglutamated folate 
end products (Krungkrai et al, 1989b, Wang et al, 2004). The transport of 
exogenous folate by P. falciparum has now been characterised and shown 
to be a specific energy-dependent, saturable process, inhibited by the
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classical anion transport inhibitors probenecid and furosemide (Wang et 
ai, 2007).
7,8-dihydroneopterin triphosphate
PfPTPS
shikimate
pathway
6-hydroxymethyl-7,8-dihydropterin
HPPPK
6-hydroxymethyl-7,8-dihydropterin pyrophospate
•C—» ADC—» pABA
7^ 8-dihyrdopteroate
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L-glutamine
7,8-dihydrofolate
pABA J 
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folate
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5,6,7,8-tetrahydrofolate
5,6,7, 8-tetrahydrofolate polyglutamates
_ Ci substituted THF- 
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Figure 1.8. P. falciparum de novo folate biosynthesis pathway and possible 
salvage routes. Enzymes are boxed in red and possible salvage is shown with 
broken arrows. Abbreviations: GTP, guanine triphosphate; GTPC, guanine 
triphospate cyclohydrolase I; PfPTPS, P. falciparum pyruvoyltetrahydropterin 
synthase; HPPPK, hydroxymethyldihydropterin pyrophosphokinase; DHPS, 
dihydropteroate synthase; DHFS, dihydrofolate synthase; DHFR, dihydrofolate 
reductase; FPGS, folylpolyglutamate synthase; C, chorismate; ADC, 4-amino-4- 
deoxychorismate; pABA, para-aminobenzoic acid; Paba S, PABA synthase. 
Modified from Hyde (2005), Nzila (2005a), Ochong (2008) and Dittrich et al 
(Dittrich et al., 2008).
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1.3.3 Role of Folates in P.falciparum
The biologically active THF derivatives are essential cofactors for one 
carbon metabolism. In P. falciparum they are essential for major 
biosynthetic pathways including the pyrimidine deoxythymidine-5’- 
monophosphate (dTMP) via the thymidylate cycle and the synthesis of 
methionine. The folate-dependent reactions in P. falciparum are 
summarised in figure 1.9. In mammalian cells THF derivatives are also 
essential in purine synthesis but the enzymes involved in this pathway are 
not found in Plasmodium and so it has been assumed that the parasite relies 
on purine salvage (Reyes et ai, 1982).
1.3.3.1 Thymidylate Cycle
5, 10-methylene tetrahydrofolate is the single carbon donor involved in 
converting 2’-deoxyuridine-5’-monophosphate (dUMP) to dTMP (Nzila et 
al.3 2005a). This reaction is catalysed by thymidylate synthase (TS) and the 
reduction of the methylene to a methyl group is accompanied with the 
oxidation of THF to DHF. This resulting DHF is recycled back into the 
folate pathway and reduced by DHFR to the biologically active THF 
(Nzila et aL, 2005a).
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5-MTHF SHMT
dTMP
MTHFR
dUMP
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Figure 1.9. Folate-dependent reactions in P. falciparum. Enzymes are boxed in 
red. Abbreviations: THF, tetrahydrofolate; SHMT, serine hydroxymethyl 
transferase; TS, thymidylate synthase; DHF, dihydrofolate; DHFR, 
dihydrofolate reductase; MTHFR, methylenetetrahydrofolate reductase; 5- 
MTHF, 5-methyltetrahydrofolate; MS, methionine synthase; Bi2, 
methylcobalamin. Modified from Krungkrai et al (1990).
1.3.3.2 Methionine Cycle
The folate pathway provides the one-carbon donor to methionine 
biosynthesis. 5-methyltetrahydrofolate (5-MTHF) is the methyl donor in 
the biosynthesis of methionine from homocysteine. This 5-MTHF is 
derived from 5, 10-methylenetetrahydrofolate in a reaction catalysed by 
methylenetetrahydrofolate reductase (MTHFR) (Nzila et al., 2005b). 
The cobalamin-dependent methionine synthase catalyses the conversion
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of homocysteine to methionine and results in the demethylation of 5- 
MTHF to THF. Both MTHFR and methionine synthase have been found 
in P. falciparum showing that the methionine can be synthesised by the 
parasite (Krungkrai et al., 1989a, Asawamahasakda and Yuthavong, 
1993). Methionine is required for protein synthesis and for the synthesis 
of S-adenosylmethionine (S-AdoMet) the methyl group donor for 
ubiquitous methylation of nucleic acids, proteins and lipids. Methionine 
is converted to (S-AdoMet) in an ATP-dependent reaction catalysed by 
methionine adenosyltransferase. The resulting S-AdoMet is an allosteric 
inhibitor of MTHFR providing feedback inhibition which is important 
as the MTHFR catalysed conversion of 5, 10-methyleneTHF to 5- 
MTHF is hreversible (Bailey, 2010).
1.3.4 Antimalarial Antifolates
Only two enzymes of the folate pathway have been used as phannalogical 
targets for malaria chemotherapy so far. These are DHPS and DHFR, with 
the sulpha drugs targeting DHPS and pyrimethamine, proguanil and 
cholorproguanil targeting DHFR (Nzila, 2006).
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1.3.4.1 Anti-DHFR Antimalarial Antifolates
1.3.4.1.1 Proguanil
The fest reported antifolate agent with antimalarial properties was 
proguanil. It was discovered during a research programme led by Imperial 
Chemical Industries (ICI) with the first report of its antimalarial properties 
in 1945 showing that it was more active than quinine on avian malarias 
(Nzila, 2006). Proguanil itself is a prodrug with the anti-DHFR activity 
coming from the cycloguanil (CCG) metabolite (figure 1.9). Proguanil has 
been used as prophylaxis and treatment with a prophylactic combination 
of proguanil and atovaquone now being marketed as Malarone® (Kain, 
2003).
1.3.4.1.2 Pyrimethamine
The antifolate property of pyrimethamine (PYR) was recognised as other 
drugs of the same class showed a structural similarity to proguanil (figure 
1.9) (Falco et ah, 1951). It was first introduced for routine human use in 
1952 and is one of the most widely used antimalarial antifolates so far, 
either used alone or in combination with sulphadoxine (SDX) (Hyde, 1990, 
Nzila, 2006).
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Figure 1.10. Structures of DHFR inhibitors proguanil (1), cycloguanil (2) and 
pyrimethamine (3).
1.3.4.1.3 Mode of Action of Anti-DHFR Antimalarial Antifolates
PYR and the active metabolite of proguanil, CCG, act on the folate 
pathway by competitively inhibiting DHFR enzyme (Hyde, 1990). It has 
been shown that PYR and CCG bind to the Plasmodium DHFR more 
strongly than the human DHFR allowing the drugs to selectively target the 
parasites (Ferone et al., 1969, Sirawarapom etaL, 1993). This disruption of 
the folate pathway prevents further folate-dependent reactions (as 
described in section 1.3.3) and so prevents DNA synthesis, methylation of 
proteins and nucleic acids and other essential pathways. Anti-DHFR drugs 
have the most marked effect against the late trophozoite and schizont 
stages of parasite development (Schellenberg and Coatney, 1961, 
McCormick et al., 1971, Janse et al., 1986, Banyal and Inselburg, 1986).
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This correlates with the fact that these drugs target the folate pathway as 
this stage of development is where DNA replication reaches a maximum 
(Hyde, 1990).
1.3.4.2 Anti-DHPS Antimalarial Antifolates 
1.3.4.2.1 Sulphadoxine
The bactericidal and antimalarial properties of the sulphonamides was 
discovered in the 1930s when sulphanilimide, a metabolite of prontosil 
dye, was observed to have an inhibitory effect (Diaz de Leon, 1937). 
Sulphadoxine (SDX) is often used in combination with PYR and the 
addition of the anti-DHFR synergizes the effect of SDX. This combination 
is commonly known as SP and marketed as Fansidar®.
1.3.4.2.2 Dapsone
Dapsone is a sulphone drug that was initially synthesised in 1908 in a 
search for molecules to produce azo dyes. Its microbial properties were 
noted in the 1930s and in the 1940s it was found to have antimalarial 
properties (Nzila, 2006). However, dapsone was not initially considered for 
antimalarial use due to worries about toxicity and the fact that there were 
other antimalarials already available (Nzila, 2006). Due to increasing 
worries over resistance to other available antimalarial drugs interest in
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dapsone has been renewed, with a combination of the DHFR inhibitor 
chlorproguanil and dapsone being marketed as Lapdap® (Watkins et al, 
1997, Winstanley et al., 1997). As with anti-DHFR and anti-DHPS 
combination SP, the Lapdap® combination is also synergistic. Dapsone is 
also used to treat leprosy (Britton and Lockwood, 2004) and pneumocystic 
pneumonia (Watson, 2002) and it is the most widely used anti-DHPS agent 
in human chemotherapy (Nzila, 2006).
1 2
Figure 1.11. Structures of the DHPS inhibitors sulphadoxine (1) and dapsone (2).
1.3.4.2.3 Mode of Action of Anti-DHPS Antimalarial Antifolates
SDX and dapsone act on the late erythrocytic stages of the parasite, with 
the mode of action being inhibition of DHPS (Sibley et al., 2001, Nzila, 
2006). These anti-DHPS drugs are structural analogues of pABA and 
interfere with the folate pathway by blocking pABA incorporation into 
dihydropteroate (Hyde, 2005). This mode of action has been confirmed by 
the fact that the addition of an exogenous supply of pABA can reverse the 
inhibitory effect of the anti-DHPS drugs (Wang et aL, 1997b).
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1.3.4.3 Mechanisms of Resistance to Antimalarial Antifolates
The combination of SDX and PYR (SP) has been used for almost 20 years 
as a first line treatment but drug resistance quickly emerged and is now 
drastically reducing the effectiveness of these drugs (Sibley et al., 2001). 
The understanding of mechanisms behind the rapid emergence of 
resistance to antimalarial antifolates is important as it can allow informed 
choices on how to overcome resistance or develop novel antimalarial 
antifolates. The mechanisms behind resistance to anti-DHFR and anti- 
DHPS drugs in P. falciparum have been shown to be mainly due to point 
mutations in the dhfr and dhps genes (Peterson et aL, 1988, Sibley et al., 
2001). PYR resistance first occurs with a mutation of serine to asparagine 
at codon 108 of the dhfr gene, which increases resistance approximately 
100-fold (Peterson et al., 1988, Sibley et al, 2001). Resistance increases 
with further mutations from asparagine to isoleucine at codon 51, cysteine 
to argmine at codon 59 and isoleucine to leucine at codon 164 (Peterson et 
al., 1988, Sibley et al., 2001, Nzila, 2006). Point mutations in the dhps 
domain of the dhps-hpppk gene have been shown to confer resistance to 
SDX (Nzila, 2006). Combinations of point mutations from serine to 
alanine or phenylalanine at codon 436, alanine to glycine at codon 437, 
lysine to glutamate at codon 540, alanine to glycine at codon 581 and 
alanine to serine or threonine at codon 613 have been shown to play a role 
in the development of resistance to anti-DHPS compounds (Triglia and 
Cowman, 1999a, Sibley et al., 2001, Nzila, 2006).
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1.4 Membrane Transport Pathways of P.
falciparum
The P. falciparum parasite has to cope with several different extracellular 
environments during its life cycle. The asexual stage in the RBC of the 
host is the phase that causes the clinical symptoms observed in malaria 
patients. This intracellular location allows the parasite to evade the host 
immune system but also means that it has to deal with surviving within a 
relatively inert cell with limited transport abilities. The parasite can obtain 
some nutrients from the digestion of haemoglobin but must rely on a 
supply of certain nutrients from the external milieu of the RBC (Divo et 
al., 1985). Unlike other eukaryotic cells the host RBC also has an 
unusually low Na+ concentration and high K+ concentration which poses 
further problems for the parasite (Kirk, 2001, Kirk, 2004, Biagini et aL, 
2005). In order to survive within this intracellular environment the parasite 
must have evolved membrane transport mechanisms to meet its nutritional 
requirements, to maintain its chemical composition and to allow 
elimination of waste metabolites from the parasite and the host cell (Kirk, 
2001).
The intraerthrocytic stages of the Plasmodium life cycle have three 
membranes separating them from the external environment (blood): the 
host RBC plasma membrane, the parasitophorous vacuole membrane
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(PVM) and the parasite plasma membrane (PPM). The parasite also 
contains several membrane bound intracellular organelles, including the 
nucleus, food vacuole, mitochondrion, apicoplast, Golgi apparatus and 
endoplasmic reticulum (Kirk, 2001, Staines et al, 2010). Therefore, the 
parasite must use a range of transport pathways to distribute solutes around 
the intracellular environment, as well as into and out of the cell. The 
transport proteins that the parasite uses to achieve this can be split into two 
groups: channels and transporters. Channels are integral membrane 
proteins that form hydrophilic pores spanning the lipid bilayer and provide 
a pathway for diffusion (Wolfersberger, 1994). They may be regulated by a 
range of physiological signals (for example, voltage and ligand gated 
channels) and allow passage of the appropriately sized and charged solutes 
down their electrochemical gradient (Kirk, 2004). Transporters (also 
known as carriers) are also integral membrane proteins but do not provide 
an open diffusion pathway, instead they transport solutes across a 
membrane by binding and undergoing a conformational change. The three 
mam classes of transporters are facilitative transporters (uniporters), 
primary active transporters (pumps) and secondary active transporters 
(symporters and antiporters) (Staines et al, 2010). Facilitative transporters 
are the simplest of the three as they facilitate the transport of substrates 
down their electrochemical gradient. The P. falciparum hexose transporter 
(PfHT) and the human RBC glucose transporter (GLUT1) are examples of 
facilitative transporters (see figure 1.12). Primary active transporters use
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energy derived from the hydrolysis of phosphodiester bonds in molecules 
like ATP and pyrophosphate in order to drive the active transport of 
solutes. In the RBC membrane there are several examples of primary 
active transporters (the plasma membrane Ca2+ pump and the Na+/K+ 
ATPase) and in the PPM there is a V-type H+ pump (figure 1.12). 
Secondary active transporters use energy derived from electrochemical 
gradients of solutes such as Na+ and H+ and couples the transport of one 
solute to the transport of another, either in the same direction (symporters) 
or in the opposite direction (antiporters) (Kirk, 2004, Staines et ah, 2010). 
Examples of secondary active transport include the H+ coupled lactate and 
pantothenate symporters in the PPM and the H+ coupled monocarboxylate 
transporter (MCT1) and the HCCb'/d' exchanger (band 3) in the RBC 
plasma membrane (figure 1.12) (Staines et al, 2010).
Initial annotation of the P. falciparum genome in 2002 identified only 54 
putative transport proteins and no obvious homologues of sodium, chloride 
or potassium ion channels (Gardner et al, 2002). A further analysis of the 
P, falciparum genome by Martin et al (2005) revealed a total of 109 
putative transport proteins, taking the number of putative transport genes to 
2.1% of all genes encoded for. This is a relatively low percentage 
compared to other eukaryotic genomes, for example 4.2% of the total 
proteins encoded by the Saccharomyces cerevisae genome are transport 
proteins and in Homo sapiens it is 3.4% (Martin et aL, 2005).
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1. Channels i 4. Transporters: secondary active
Figure 1.12. Schematic illustration of the classes of transport proteins and 
examples of parasite and host transport processes in Plasmodium infected 
RJBCs. The three membranes shown are the RBC plasma membrane (RBC PM), 
the parasitophorous vacuole membrane (PVM), and the parasite plasma 
membrane (PPM). 1. Channels: examples are the parasite-induced new 
permeation pathways (NPP) and the Gardos channel (Ca2~ activated K* channel) 
in the RBC PM. 2. Facilitative transporters: examples are the hexose 
transporters PfHT (in the PPM) and GLUT1 (in the RBC PM). 3. Primary active 
transporters: examples are a V-type H+ pump in the PPM, and the NaTKT 
ATPase and the plasma membrane Ca2' pump in the RBC PM. 4. Secondary 
active transport: examples are the FT coupled pantothenate (P') and lactate (L') 
symporters in the PPM, and the HCO.f/Cf exchanger (Band 3) and the FI+- 
coupled monocarboxylate symporter (MCT1, which is responsible for the efflux 
of lactate) in the RBC PM. Modified from Staines et al (2010).
Infection by the Plasmodium parasite causes changes to some of the host 
RBCs endogenous transport systems (Ginsburg and Stein, 1987, Sherman, 
1988, Cabantchik, 1989, Cabantchik, 1990, Gero and Kirk, 1994, Elford et 
al, 1995). For example, up to a two fold increase in activity of the host 
cells endogenous Na+/K+ ATPase has been observed in P. falciparum
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parasitised RBCs (Kirk et aL, 1991, Staines et aL, 2001). As the parasite 
develops within the host RBC the host cell membrane becomes more 
permeable to certain ions and small molecules (Kirk, 2004). An increased 
rate of transport has been demonstrated for certain solutes including 
monosaccharide sugars (Ginsburg et aL, 1985, Kirk et aL, 1994, Kirk et 
aL, 1996), peptides (Atamna and Ginsburg, 1997), nucleosides (Gero and 
Wood, 1991, Upston and Gero, 1995), small ammonium compounds 
(Staines et aL, 2000), monovalent inorganic ions (Cranmer et aL, 1995, 
Kirk et aL, 1994), various monocarboxylates (Cranmer et aL, 1995) and 
amino acids (Elford et aL, 1985, Ginsburg et aL, 1985, Kirk et aL, 1994). 
Some of the increase in uptake of low molecular weight solutes across the 
host RBC membrane has been attributed to the parasite-induced new 
permeation pathways (NPP) (Kirk, 2004). The contribution of the NPP to 
the uptake of particular nutrients depends on the relative rates of uptake by 
endogenous transporters compared to uptake via the NPP (Kirk and Saliba, 
2007). For example, although glucose is a substrate of the NPP the uptake 
of glucose across the RBC membrane in Plasmodium infected RBCs is 
mainly via an endogenous high capacity equilibrative hexose transporter 
(GLUT1), with negligible uptake via the NPP (Kirk et aL, 1996, Kirk and 
Saliba, 2007). The opposite is true for the essential nutrient pantothenate 
which relies exclusively on uptake across the RBC membrane via the NPP 
as the RBC lacks any endogenous transporter of pantothenate (Saliba et aL, 
1998). It is still unknown if the NPP consist of single or multiple channels
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or if they are parasite or host derived (Kirk et al., 1994, Alkhalil et aL, 
2004, Decherf et al, 2004, Biagini et al, 2005, Staines et al., 2006). 
Experiments using inhibitors and measuring uptake of various substrates 
have shown the NPP to be anion-selective although they do also allow 
transport of cationic and electroneutral solutes at a lower rate (Kirk et al, 
1994, Staines et al, 2005). Induction of the NPP appeal's to take place 10 
to 20 hours after invasion (Kirk, 2001, Staines etal, 2004).
Electrophysio logical studies of the PVM have indicated the presence of a 
high conductance channel that is permeable to a range of anions and 
cations and is open for more than 98 % of the time (Desai et al, 1993, 
Desai and Rosenberg, 1997). Another study that involved the use of 
streptolysin O to permeabilise the RBC membrane, but not the PVM, 
showed that a normally membrane impenneant biotin derivative gained 
access to parasitophorous vacuole proteins (Nyalwidhe et al, 2002). These 
findings suggest that the PVM allows free passage of low molecular 
weight nutrients, ions and metabolic wastes (Kirk, 2004).
The PPM is not freely permeable and maintains substantial ion gradients, 
with the movement of solutes across the PPM mediated via a range of 
transporters and channels (Kirk and Saliba, 2007). Transport across the 
PPM has been investigated for many substrates including nucleosides 
(Upston and Gero, 1995, Gero and Hall, 1997, Downie et al, 2006,
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Downie et al., 2008, Quashie et aL, 2008, Quashie et aL, 2010), glucose 
(Goodyer et al, 1997, Kirk et aL, 1996, Krishna et aL, 2000, Woodrow et 
aL, 2000, Landfear, 2010), choline (Biagini et aL, 2004, Lehane et aL, 
2004), pantothenic acid (Saliba and Kirk, 2001), inorganic phosphate 
(Saliba et aL, 2006), lactate and pyruvate (Kanaani and Ginsburg, 1991, 
Elliott et al., 2001), ATP/ADP (Kanaani and Ginsburg, 1989, Choi and 
Mikkelsen, 1990), and isoleucine (Martin and Kirk, 2007). The Xenopus 
laevis oocyte heterologous expression system has been a valuable tool in 
the expression and characterisation of Plasmodium encoded transporters. It 
has been used to characterise a nucleoside transporter designated either 
PfNTl (Carter et aL, 2000) or PfENTl (Parker et al., 2000), a hexose 
transporter designated PfHT (Krishna and Woodrow, 1999, Woodrow et 
al., 1999, Woodrow et al., 2000) a Ca2+ P-type ATPase designated PfATP4 
(Krishna et al., 2001b), and a Na+ :phosphate symporter designated PfPiT 
(Saliba et al., 2006). These functionally characterised transporters are 
described in more detail in section 1.4.1.
Few transporters responsible for the movement of solutes into and out of 
the membrane-bound organelles of the intraerythrocytic have been 
characterised. Several transporters have been identified on the digestive 
vacuole membrane including a thapsigargin (and cyclopiazonic acid)- 
sensitive Ca2+ pump (Biagini et al., 2003a), at least two discrete H+ pumps 
(a H+ -pyrophosphatase and a H+ -ATPase (Kirk and Saliba, 2007), and
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two integral membrane proteins PfCRTl (Fidock et al, 2000) and Pgh-1 
(Reed et al., 2000). Very few transporters involved in the movement of 
metabolites and nutrients have been identified in the membranes of other 
organelles. Using the presence of signal peptides to indicate the targeting 
of proteins to an organelle has allowed putative organelle associated 
transport proteins to be identified. Several putative apicoplast transporters 
have been identified in this way including ABC transporters, P -type 
ATPases, a putative amino acid transporter, and other putative transport 
proteins with unknown functions (Martin et al, 2005, Kirk and Saliba, 
2007). Signal peptides have also been used to identify nine transporters 
with putative mitochondrial targeting (Kirk and Saliba, 2007).
As well as transport pathways mediating the movement of nutrients into, 
out of and around the Plasmodium infected RBC the parasite also uses 
endocytosis to ingest the RBC cytosol (Kirk and Saliba, 2007). To do this 
the parasite uses the cytostome, a specialised mouth-like structure at the 
surface of the parasite. Double-membrane transport vesicles are formed 
from the cytostome with the inner membrane formed from the PVM and 
the outer from the PPM. These then move to the parasite’s digestive 
vacuole where they fuse and release their contents. Haemoglobin is the 
major component of the RBC cytoplasm and is broken down in the 
digestive vacuole and/or the transport vesicle (Hempelmann et al, 2003) 
by a range of proteases (McKerrow et al, 1993, Coombs et al, 2001, Kirk
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and Saliba, 2007). Peptides and amino acids resulting from the digestion of 
haemoglobin are though to be exported from the digestive vacuole 
(Kolakovich et al., 1997) with haemozoin crystallised from the residual 
haem groups in the digestive vacuole (Kirk and Saliba, 2007)
1.4.1 Currently Identified P. falciparum Membrane 
Transporters
1.4.1.1 P. falciparum Hexose Transporter (PfHT)
The expression of a facilitative glucose transporter on the PPM was 
suggested from studies of glucose uptake in parasitised RBCs (Kirk et ah, 
1996, Landfear, 2010). The presence of a glucose transporter encoded by 
the parasite was subsequently confirmed using the X. laevis oocyte 
heterologous expression system. X. laevis oocytes injected with mRNA 
from intraerythrocytic stages of P. falciparum showed a significant 
increase in uptake (7 fold) of radio labelled 2-deoxy-D-glucose compared to 
control oocytes injected with water (Penny et al., 1998). Comparative 
searches of a pre-launched version of the P. falciparum genome allowed 
the identification of the P. falciparum hexose transporter (PfHT) using the 
sequence of known glucose transporters, with PfHT sharing 29.8 % amino 
acid sequence identity with GLUT1 and 20-27 % amino acid sequence 
identity to other glucose transporters in eukaryotes and prokaryotes 
(Woodrow et al, 1999). This transporter is a member of the major
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facilitator superfamily (MFS). When expressed in X. laevis oocytes PfHT 
induced saturable, stereospecific and Na+-independent uptake of glucose 
(Km = 0.48 mM) and 2-deoxyglucose (Xm =1.31 mM) (Woodrow et ai, 
1999). PfHT showed a broad specificity for hexoses with uptake of both 
substrates inhibited by fructose, mannose, galactose, 6-deoxyglucose and 
3-0-methylglucose (Woodrow et al, 1999, Landfear, 2010). Cytochalasin 
B, a classical inhibitor of mammalian GLUTs, also inhibited glucose 
uptake by PfHT (Woodrow et al, 1999). PfHT mRNA expression was 
shown to be developmentally regulated using tandem competitive 
polymerase chain reaction (TC-PCR) with peak mRNA levels at the small 
ring stage and lowest in gametocytes (Woodrow et al, 1999). This pattern 
of expression is consistent with the differing levels of glucose utilisation by 
the maturing intraerythrocytic parasite (Krishna et al, 2001a). PfHT was 
shown to be localised to the PPM using confocal iimnunofluorescence 
microscopy (Woodrow et al, 1999).
Fructose has been shown to be an alternative to glucose as an energy 
source for the intraerythrocytic parasite and PfHT expressed in X. laevis 
oocytes is capable of transporting fructose as well as glucose (Woodrow et 
al, 2000). The substrate selectivity of PfHT was investigated in X. laevis 
oocytes with the mutation of the Q169 residue, located within the predicted 
amphipathic transmembrane helix 5, to an asparagine residue (Q169N). 
This resulted in transport of glucose similar to that observed for native
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PfHT but eliminated fructose transport, indicating that this single residue in 
helix 5 is involved in determining the substrate specificity of PfHT 
(Woodrow et al, 2000, Landfear, 2010). Genetic studies have shown PfHT 
to be essential for parasite growth as parasites were not viable when PfHT 
was knocked out unless the gene was complemented by an episomal 
construct (Slavic et al, 2010).
1.4.1.2 P. falciparum Nucleoside Transporters
Malaria parasites lack the enzymes required for synthesise of purines but 
do have the enzymes necessary for de novo synthesis of pyrimidines (Gero 
and O'Sullivan, 1990, de Koning et al, 2005, Downie et al, 2006). 
Therefore, the intraerythrocytic parasite must rely on salvaging purines 
from the external milieu (Divo et al., 1985). Purines have been shown to 
enter the parasitised RBC mainly via the human equilibrative nucleoside 
transporter (hENTl) and the human facilitative nucleobase transporter 
(liFNTl), both of which are endogenous transporters on the host RBC 
(Quashie et al, 2010).
As with the P. falciparum hexose transporter evidence for a purine 
transporter came from the use of the X. laevis oocyte heterologous 
expression system. X. laevis oocytes injected with mRNA from 
intraerythrocytic stages of P. falciparum showed increased transport of
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adenosine and hypoxanthine compared to water-injected control oocytes 
(Penny et al, 1998). Four members of the equilibrative nucleoside 
transporter (ENT) family have been found in the P. falciparum genome 
(Martin et al., 2005). One of these genes, designated PfNTl (Carter et al., 
2000) or PfENTl (Parker et al, 2000), was cloned and characterised using 
the X. laevis expression system by two groups at around the same time 
giving very different results. Expression of PfNTl in X laevis oocyte by 
Carter et al (2000) showed high affinity transport of adenosine (Km =13 
pM), which was inhibited by dipyridamole, but unable to transport 
nucleobases. This is in contrast to the findings by Parker et al. (2000) who 
reported PfENTl to have much a lower affinity for adenosine {Km = 320 
pM), which was not inhibited by dipyridamole, and was able to transport 
nucleobases. Despite these differing results it was clear that PfNTl is 
indeed a nucleoside transporter but that further studies were required to 
reconcile the results from these two studies (de Koning et al., 2005, 
Downie et al., 2006). Experiments using quantitative PCR showed that 
PfNTl is expressed throughout the intraerythrocytic stages of the parasite’s 
lifecycle and immune electron microscopy has shown it to be localised to 
the PPM (Rager et al., 2001). Further characterisation of PfNTl using the 
X. laevis oocyte expression system showed low affinity transport of 
adenosine {Km — 1.86 ± 0.28 mM) and thymidine (Km = 1.33 ± 0.17 mM) 
(Downie et al., 2006) and also low affinity transport of adenine (Km = 0.82 
mM) (Downie et al., 2008). Transport measurements by Downie et al
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(2006, 2008) with P. falciparum trophozoites isolated by saponin treatment 
showed similar kinetic characteristics for adenosine, thymidine and 
adenine transport and similar substrate specificity characteristics as 
observed for PfNTl in X. laevis oocytes above. These results led to the 
conclusion that PfNfTl is a high-capacity, low-affinity transporter that acts 
as a major route for the transport of nucleosides and nucleobases across the 
PPM (Downie et aL, 2006, Downie et aL, 2008, Kirk et aL, 2009). A 
separate study by Quashie et al (2008) on the purine uptake by P. 
falciparum trophozoites isolated by saponin treatment gave different 
results to those described above. In this study four purine transport 
activities were identified in intraerythrocytic parasites with parasite 
expression of (1) a high-affinity hypoxanthine transporter with a secondary 
capacity for purine nucleosides (PfNTl), (2) a separate high-affinity 
transporter for adenine, (3) a low-affinity transporter for adenosine and (4) 
a low-affinity, high-capacity adenine transporter (Quashie et al., 2008). 
These results show a similarity with purine salvage reported in other 
Plasmodium species and show purine uptake in P. falciparum to be closer 
to purine transport activity in other protozoa than the results from Downie 
et al. (2008, 2006) suggest (de Koning et ah, 2005). A subsequent attempt 
to reconcile these differing results has been made by Kirk et al. (2009) who 
suggested that Quashie et al (2008) may not have taken enough account of 
the effect of metabolism.
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The other three members of the ENT family encoded by P. falciparum 
(PfNT2, PfNT3 and PfNT4) have not yet been characterised. However, 
PfNT2 has been shown to be localised to the endoplasmic reticulum using 
confocal and immunoflourescence microscopy (Downie et al., 2010). 
PfNT2 is therefore the first intracellular purine permease to be found in 
apicomplexan parasites.
1.4.1.3 P. falciparum Ca2+ -ATPase (PfATP4)
The P. falciparum genome encodes six P-type ATPases (PfATPl-4, 
PfATP6 and PfXTP7). Immunoflourescence microscopy has shown that 
the P. falciparum Ca2+ -ATPase P£ATP4 is localised to the PPM of asexual 
stage parasites (Dyer et al, 1996). Analysis of the hydropathy profile of 
PfATP4 showed that it does not resemble that of SERCA 
(sarco/endoplasmic reticulum)-type ATPases or PMCA (plasma 
membrane)-type ATPases (Krishna et al., 2001b). Characterisation of 
P£ATP4 using the X. laevis oocyte expression system showed it had 
activity that is resistant to inhibition by ouabain (a Na+/K+ ATPase 
inhibitor) and thapsigargin (a selective SERCA inhibitor) but is inhibited 
by vanadate (a pentacoordinate phosphate analogue) and cyclopiazonic 
acid (a metabolite from Aspergillus penicillum that inhibits SERCA and 
PMR (yeast Golgi)-type pumps but not PMCA) (Krishna et al., 2001b). 
The same study also showed that the Ca2+ dependent activity of PfATP4 is
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stimulated by a broader range of [CA2+]fiee than the rabbit SERCA1 a or the 
avian SERCA1 pump. Analysis of the expression of PfATP4 throughout 
the parasite’s life cycle was earned out using quantitative PCR and showed 
that expression varied throughout the life cycle, with a five fold increased 
expression in meronts compared to ring stages (Krishna et ai, 2001b). 
These results have led to the conclusion that PfATP4 defines a novel 
subclass of Ca2+ -ATPases that are unique to apicomplexan parasites 
(Krishna et al^ 2001b).
1.4.2 P. falciparum Membrane Transport Pathways as Drug 
Targets
With the emergence and spread of resistance seriously threatening the 
usefulness of the currently available antimalarials it is vital to further 
understand the biology of the parasite in order to find new novel drug 
targets and to understand the mechanisms of resistance. Membrane 
transport pathways are a potential way of delivering drugs into the parasite 
and the transport proteins are potential targets themselves (Kirk, 2004, 
Staines et al, 2010, Biagini et al., 2005). The principle behind transporters 
as drug targets is to disrupt the uptake of one or more essential nutrients or 
to block the efflux of harmful metabolic waste products. Membrane 
transporters as a drug delivery strategy allow a route of entry for drugs that 
target essential cellular mechanisms, and it has been observed that carrier
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mediated uptake of drugs may be more common than traditionally thought 
(Dobson and Kell, 2008). Drugs targeting human membrane transporters 
are used to treat several diseases including congestive heart failure, blood 
pressure disorders, diabetes, and depression (Kirk, 2004), with 13 % of 
human protein drug targets for FDA approved oral drugs being transporters 
(Overington et aL, 2006). However, there are currently veiy few drugs for 
treating infectious diseases that are known to inhibit membrane transport 
processes (Kirk, 2004). The Trypanosoma brucei P2/TbATl aminopurine 
transporter is one of the best known examples of a protozoan transporter 
responsible for the delivery of a drug into a parasite (de Koning et al, 
2005, Staines et al., 2010). This transporter is responsible for the transport 
of adenosine and adenine but also canies melaminophenyl arsenicals 
including melarsoprol (Carter and FaMamb, 1993, Barrett and Fairlamb, 
1999, Stewart et al., 2005), and trypanocidal diamidines including 
diminazene and pentamidine (Barrett et al., 1995, Carter et at, 1995, De 
Koning et at, 2004), which are treatments for human African 
trypanosomiasis (Lanteri et at, 2006, Staines et at, 2010). The P. 
falciparum Ca SERCA pump PfATP6 is a proposed site of action of the 
antimalarial artemisinins, however there is no consensus over the exact 
mode of action of these drugs (Eckstein-Ludwig et at, 2003, O'Neill et at, 
2010).
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For a transport protein to be a suitable potential target it must be essential 
for the parasite’s survival, have no human orthologues that might be 
detrimentally targeted and it must be druggable. Draggability can be 
predicted if a target is a member of a family containing a clinically 
validated drag target or based on structural information (Staines et al, 
2010). Genetic and chemical validations are used in the selection of new 
drag targets. Chemical validation involves the identification of a 
compound that inhibits the targeted protein specifically (without affecting 
any host orthologues) and ideally works both in vitro and in vivo (Cowman 
and Crabb, 2007). Genetic validation will show if loss of gene function 
results in a non-viable parasites, indicating essentiality (Cowman and 
Crabb, 2007).
Currently only a few P. falciparum transporters have been validated as 
potential drug targets. The only potential target to be validated both 
chemically and genetically is the P. falciparum hexose transporter, PfHT 
(Slavic et al., 2011). 3-0 derivatives of glucose were shown to inhibit 
uptake of glucose by PfHT (when expressed inX laevis oocytes), with the 
glucose derivative 3 -0-((undec-10-en)-1 -yl)-D-glucose (known as 
compound 3361) inhibiting glucose uptake by PfHT with a Ki of -50 pM 
but poorly inhibiting glucose uptake by human GLUT1 (Ki ~3 mM) (Joet 
et al., 2003, Joet and Krishna, 2004, Landfear, 2010). Compound 3361 has 
also been shown to kill parasites in culture and in an in vivo animal model
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(P. berghei) (Joet et al., 2003, Staines et al., 2010). PfHT has been shown 
to be essential for parasite growth as loss of function, by knocking out the 
pfht gene, resulted in non-viable parasites with viability restored if the gene 
was episomally complemented (Slavic et al., 2010).
1.4.3 P. falciparum Membrane Transport Pathways as 
Antimalarial Resistance Mediation Targets
Membrane transport is also of importance regarding antimalarial resistance 
as transporters can be involved in mediating drug resistance. There are 
three main ways that transporters can mediate drug resistance: (1) by 
reducing the effective concentration of the drug at its target with the 
provision of an efflux pathway, (2) by mutation of the transporter that 
reduces drug affinity and effectiveness if the transporter is the target, and 
(3) by mutation of the transporter that reduces drug levels at the target if 
the transporter is a delivery route (Staines et al., 2010).
The P. falciparum chloroquine resistance transporter (PfCRT), a member 
of the drug/metabolite transporter (DMT) superfamily, is an example of the 
first mechanism and is a key determinant of resistance to chloroquine 
(Bray et al., 2005a). In resistant parasites with mutated PfCRT the 
transporter reduces the concentration of chloroquine in the food vacuole. 
This resistance is reversible with the calcium channel blocker verapamil.
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Attempts to reverse resistance to chloroquine with verapamil or other 
agents (including antipsychotic drugs, histamine receptor antagonists, and 
antidepressant agents) has been attempted but problems with side effects 
and toxicity at the needed concentrations has prevented further trials (van 
Schalkwyk et al, 2001, Henry et aL, 2006, Egan and Kaschula, 2007, 
Masseno et a/., 2009).
1.4.4 Amino Acid Transport
Amino acids form the building blocks of proteins and are important 
intermediates in metabohsm. They are necessary for a variety of cellular 
processes including nitrogen metabolism, energy generation, cell wall 
synthesis and intercellular communication (Saier, 2000a). Although the 
digestion of haemoglobin releases amino acids it has been shown that only 
up to 16 % of the amino acids released by haemoglobin digestion are used 
by the parasite (Kmgliak et al, 2002). Haemoglobin is also unable to 
supply the parasite with all amino acids as it contains no isoleucine and 
only low levels of methionine (Shennan, 1977). From in vitro growth 
experiments it has been shown that the parasite requires an exogenous 
supply of isoleucine, methionine, cysteine, glutamic acid, glutamine, 
proline and tyrosine to maintain nonnal growth (Divo et al, 1985). It has 
also been shown that the parasite is capable of taking up and incorporating 
into protein all 20 naturally occurring amino acids (Shennan, 1977, Elford
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et al., 1985, Kirk et al., 1994, Divo et aL, 1985). This evidence suggests 
that the parasite must have developed pathways to import amino acids, and 
transport can be assumed to be essential for parasite survival in the cases of 
isoleucine, methionine, cysteine, glutamic acid, glutamine, proline and 
tyrosine. Inhibition of the uptake of these amino acids could therefore be a 
good target for potential new antimalarial drugs.
In adult human RBCs there are a number of different amino acid transport 
systems with varying substrate specificities present at the plasma 
membrane (Barker and Ellory, 1990, Kirk, 2001). Apart from glutamate, 
all amino acids are transported across the RBC plasma membrane via one 
or more of these transporters (Elford et al, 1985). As glutamate is an 
essential amino acid for normal growth of the parasite the parasite must 
have a mechanism of transporting it through the parasitised RBC 
membrane. It has been shown that the parasite-induced NPP provide a 
major route of entry for most amino acids, including glutamate, but not the 
cationic amino acids arginine and lysine (Elford et al, 1985, Lauer et al, 
1997). The NPP show an apparent preference for hydrophobic neutral 
amino acids over similar sized hydrophilic neutral amino acids (Kirk et al, 
1994). Amino acid efflux from the infected RBC is also required to remove 
the unused amino acids released by haemoglobin digestion and this may be 
achieved via the NPP (Kirk, 2001, Staines et al., 2005). Without this 
expulsion of excess amino acids there would be substantial increase in the
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osmotic content of the infected RBC which would eventually lead to 
haemolysis. The relative contributions of the endogenous and parasite- 
induced transport pathways for the uptake of amino acids into infected 
RBCs are not yet known for all amino acids. The transport of isoleucine 
into trophozoite stage P, falciparum parasitised RBCs has been 
characterised and shown to be 5 fold higher than that observed in 
uninfected RBCs, with this transport attributable to parasite-induced NPP 
and not an increase in endogenous transport (Martin and Kirk, 2007). In a 
recent study, published at the end of this thesis’ work, it was shown that 
methionine is taken up by trophozoite stage P. falciparum parasitised 
RBCs at a rate 15 fold higher than uninfected RBCs (Cobbold et ah, 2011). 
As with isoleucxne this increase in transport was attributed to the NPP. 
These two studies also characterised the transport of isoleucine and 
methionine across the parasite plasma membrane. Isoleucine was shown to 
be taken up into the parasite via a high capacity saturable ATP, Na+ and H+ 
independent system (Martin and Kirk, 2007). Methionine was shown also 
shown to be taken up by the parasite via a saturable ATP, Na+ and H+ 
independent system that is also temperature dependent (Cobbold et ah, 
2011).
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1.4.5 Amino Acid Transporter Gene Families
Amino acid transport systems were initially characterised phenotypically 
with transport assigned to different systems according to characteristics 
such as ion dependence, substrate specificity and stereospecificity 
(Christensen, 1985, Barker and Ellory, 1990). Expression cloning and gene 
sequencing technology have given more information on transport proteins 
and the genes responsible. Gene sequencing has allowed transporters to be 
grouped into families based on the degree of similarity observed for their 
amino acid sequence. There are currently approximately thirty four 
transporter gene families that are recognised as transporters of amino acids 
and their- conjugates. These include one family of channel proteins, twenty 
eight families of secondary active transporters and five families of primary 
active transporters (Saier, 2000b, Saier, 2000a, Saier et al., 2009). The 
characteristics of these families are summarised in table 1.1.
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Table 1.1, Amino acid transporter gene families. Abbreviations: B, bacteria; A, 
archea; E> eukaryote; An, animal; Pi, plant; Y, yeast; F, fungi; TMS, 
transmembrane a-helical spanners. Modified from Saier (2000a), Busch and Saier 
(2002) and Saier et al. (2009).
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1.4.5.1 Families of Channel Proteins Capable of Transporting Amino 
Acids
The only family of channel proteins known to transport amino acids is the 
phospholemman (PLM) family (TC 1.A.27). They include mammalian 
phospholemmans, are found in heart muscle and other body tissues and 
are a major substrate for phosphorylation by protein kinase A and C (Kirk 
and Strange, 1998, Saier, 2000a). Expression in Xenopus oocytes induces a 
hyperpolarisation-activated chloride current (Moorman et al., 1992). The 
chloride-conductance inducer protein, Mat-8, is a PLM like protein that is 
expressed in human breast tumours (Monison et al., 1995). PLM channels 
are anion selective and permeable to chloride, taurine, glutamate, lactate, 
isethionate and gluconate (Kirk and Strange, 1998).
1.4.5.2 Families of Secondary Active Transporters Capable of 
Transporting Amino Acids
The majority of amino acid transporters are secondary active transporters, 
with twenty eight families having members that transport amino acids. 
These secondary active transporters function by proton motive force 
driven uptake or efflux, sodium-ion motive force driven uptake, by 
uniport or by solute-solute exchange (Saier, 2000a). Eight of the currently 
recognised secondary active transporters capable of transporting amino 
acids are found only in prokaryotes, two are found only in eukaryotes and
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the remaining nine are ubiquitous (Saier, 2000a, Saier, 2000b). The 
amino acid transporter gene families that fall into the category of 
secondary active transporters are discussed below.
1.4.5.2.1 The amino acid-polyamine-organocation (APC) superfamily
Ten families in the amino acid-polyamme-organocation (APC) 
superfamily (TC 2.A.3) include transporters that have been shown to 
transport amino acids. These are: the amino acid transporter (AAT) 
family (TC 2.A.3.1); the basic amino acxd/polyamine antiporter (APA) 
family (TC 2.A.3.2); the cationic amino acid transporter (CAT) family 
(TC 2.A.3.3); the amino acid/choline transporter (ACT) family (TC 
2.A.3.4); the ethanolamine transporter (EAT) family (TC 2.A.3.5); the 
archeal/bacterial transporter (ABT) family (TC 2.A.3.6); the glutamate:y- 
aminobutyrate (GABA) antiporter (GGA) family (TC 2.A.3.7); the L- 
Type amino acid transporter (LAT) family (TC 2.A.3.8); the spore 
gennination protein (SGP) family (TC 2.A.3.9); and the yeast amino acid 
transporter (YAT) family (TC 2.A.3.10). The APC superfamily includes 
members that function as solute:cation symporters and solute:solute 
antiporters (Jack et al., 2000, Saier, 2000a). There is a large size range 
between members with the larger proteins generally of eukaryotic origin 
and the smaller proteins generally of prokaryotic origin. The E. coli
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lysine permease, LysP (TC 2.A.3.1.2), is a lysine:H+ symporter in the 
APC superfamily (Steffes et aL, 1992, Ellis et ah, 1995).
1.4.5.2.2 The major facilitator superfamily (MFS)
The metabolite:H+ symporter (MHS) family (TC 2.A. 1.6) in the major 
facilitator superfamily (MFS, TC 2.A.1) includes transporters that have 
been shown to transport amino acids (Saier et al., 1999a, Saier, 2000a). 
The E. coli (proline/glycine-betaine):(H+/Na+) symporter, ProP (TC 
2. A. 1.6.4), is a member of the MHS family which transports proline and 
other osmoprotectants (Keates et ah, 2010).
1.4.5.2.3 The C4-dicarboxyIate uptake (Dcu) family
Members of the C4-dicarboxylate uptake (Dcu) family (TC 2.A.13) have 
been sequenced from Gram negative bacteria (Engel et al., 1994, Golby 
et aL, 1998, Saier, 2000a, Saier et al, 1999b). The C4-dicarboxylate 
uptake transporters DcuA (TC 2.A.13.1.1) and DcuB (TC 2.A.13.1.2) 
from E.coli are the best characterised transporters of the Dcu family. 
These proteins are antiporters for any two of aspartate, malate, fumarate 
and succinate.
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1.4.5.2.4 The betaine/carnitine/choline transporter (BCCT) family
The betaine/camitine/choline transporter (BCCT) family (TC 2.A.15) 
contains members from Gram negative and Gram positive bacteria (Saier 
et al., 1999b, Saier, 2000a). All members transport molecules with a 
quartemary ammonium group and are energised by proton motive force 
driven proton symport. One member of the BCCT family is the EctP is an 
ectosine/proline/glycine/betaine:Na+ symporter from Corynebacterium 
glutamicam (Peter et ah, 1998).
1.4.5.2.5 The proton-dependent oligopeptide transporter (POT) 
family
Transport proteins in the proton-dependent oligopeptide transporter 
(POT) family (TC 2.A. 17) are mainly peptide transporters but some 
members are known to transport nitrates and amino acids (Saier et al., 
1999b). Members of this family are proton sympoiters but there is 
variable substrate:H+ stoichiometry between members (Saier, 2000a). The 
BnNRTl;2 transporter from the plant Brassica napus belongs to the POT 
family and exhibits histidine and nitrate elicited currents when expressed 
mXenopus oocytes (Zhou et al., 1998).
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1.4.5.2.6 The amino acid/auxin permease (AAAP) family
Transporters of the amino acid/auxin permease (AAAP) family (TC 
2.A.18) have been shown to transport auxin, single amino acids or 
multiple amino acids, with some having broad substrate specificities for 
naturally occurring amino acids (Saier, 2000a). Six amino acid permeases 
in Arabidopsis thaliana (AAP1-6) belong to the AAAP family (Young et 
aL, 1999, Fischer et aL, 2002). The Arabidopsis thaliana general amino 
acid permease 1, AAP1 (TC 2.A.18.2.1) transports most neutral and 
acidic amino acids but not basic amino acids or aspartate (Hsu et aL, 
1993). AAP3 and AAP5 do transport basic amino acids but AAP6 is the 
only one to transport aspartate (Fischer et aL, 2002).
1.4.5.2.7 The solute:sodium symporter (SSS) family
There is broad substrate specificity between members of the 
solute:sodium symporter (SSS) family (TC 2.A.21) but they all catalyse 
solute transport via Na1’ symport (Saier, 2000a). An example of a member 
of the SSS family that transports amino acids is the E.coli proline:Na+ 
symporter, PutP (Nakao et aL, 1987, Jung et aL, 1998).
1.4.5.2.8 The neurotransmitter:sodium symporter (NSS) family
Members of the neurotransmitter:sodium symporter (NSS) family (TC 
2.A.22) use solute: Na+ symport to catalyse uptake of neurotransmitters,
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amino acids, osmolytes, taurine and creatine (Saier, 2000a). Two 
members of the NSS family in the brown rat, Rattus norvegicus, are the 
proline:Na+ symporter, NTPR (Fremeau et ai, 1992), and the glycine:Na+ 
symporter, GLYT1 (Guastella «/., 1992).
1.4.5.2.9 The dicarboxylate/amino acid:cation (H+ or Na’:) symporter 
(DAACS) family
The dicarboxylate/amino acid:cation (H+ or Na*) symporter (DAACS) 
family (TC 2.A.23) contams members that catalyse H+ or Na+ symport 
with (1) small, semipolar, neutral amino acids (alanine, cysteine, serine 
and threonine), (2) both neutral and acidic amino acids, (3) most 
zwitterionic or dibasic amino acids (Saier, 2000a). The 
glutamate/aspartate:H+ symporter, GltP, of E. coli is a member of the 
DAAC family (Wallace et al, 1990, Tolner et al.9 1992).
1.4.5.2.10 The alanine/glycine:cation symporter (AGCS) family
Members of the alanine/glycine:cation symporter (AGCS) family (TC 
2.A.25) are found in Gram positive and negative bacteria and transport 
alanine and/or glycine in symport with Na+ or H+ (Saier, 2000a). The 
alanine (or glycine):Na+ symporter of the marine bacterium Alteromonas 
haloplanktis, DagA, is a member of the AGCS family (MacLeod and 
MacLeod, 1992).
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1.4.5.2.11 The branched chain amino acid:cation symporter (LIVCS) 
family
The branched chain amino acidication symporter (LIVCS) family (TC 
2.A.26) includes members that transport the branched chain aliphatic 
amino acids leucine, isoleucine and valine via Na+ or H+ symport (Saier, 
2000a). The branched chain amino acid transporter:Na+ symporter, BraB, 
of Pseudomonas aeruginosa is a member of this family (Hoshino et al., 
1990).
1.4.5.2.12 The glutamate:Na+ symporter (ESS) family
The glutamate:Na+ symporter (ESS) family (TC 2.A.27) contains 
members found in bacteria that transport glutamate via Na+ symport 
(Saier, 2000b). One example from this family is the E. coli glutamate:Na+ 
symporter, GltS, which transports L- and D-glutamate, a- 
methylglutamate and homocyteate (Dobrowolski et aL, 2007).
1.4.5.2.13 The mitochondrial carrier (MC) family
Members of the mitochondrial earner (MC) family (TC 2.A.29) transport 
are only found in eukaryotes (Saier, 2000a). They are mostly found in 
mitochondria and many members are so lute: solute antiporters. The
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mitochondrial basic amino acid transporter (BAAC) of Neurospora 
crassa is a member of the MC family (Liu and Dunlap, 1996).
1.4.5.2.14 The hydroxy/aromatic amino acid permease (HAAAP) 
family
The hydroxy/aromatic amino acid permease (HAAAP) family (TC 2.A.42) 
are found in bacteria and includes aromatic and hydroxy amino acid:H+ 
sympoiters (Saier, 2000a). The tyrosine-specific pennease, TyrP, the high- 
affinity tryptophan-specific pennease, Mtr, and the low affinity tryptophan 
permease, TnaB, of E. coli are examples of this family that transport 
aromatic amino acids (Wookey and Pittard, 1988, Sarsero et al, 1991, 
Sarsero and Pittard, 1995). The serine permease, SdaC, and the threonine 
permease, TdcC, of E, coli are members of the HAAAP family that 
transport hydroxy amino acids (Goss et al, 1988, Shao et al, 1994).
1.4.5.2.15 The tripartite ATP-independent periplasmic transporter 
(TRAP-T) family
Members of the tripartite ATP-independent periplasmic (TRAP-T) family 
(TC 2.A.56) are generally heterotrimeric with three non-homologous, 
dissimilar subunits (Saier, 2000a). The Rhodobacter capsulatus DctMQP 
system is one of the best characterised members of this family, with all
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three proteins necessary for dicarboxylate uptake implying that the 
subunits function together (Saier, 2000a). DctM is a 12 TMS protein, DctQ 
is a 4 TMS integral membrane protein and DctP is a periplasmic integral 
membrane protein (Forward et al., 1997, Rabus et al., 1999).
1.4.5.2.16 The L-lysine exporter (LysE) family
The L-lysine exporter (LysE) family (TC 2.A.75) are found in bacteria and 
two members have been functionally characterised (Saier, 2000a). The two 
characterised members are the lysine/arginine exporter, LysE, of 
Corynebacterium ghitamicum (Vrljic et al, 1996, Vrljic et al, 1999) and 
the arginine exporter protein, ArgO, of E. coli (Nandineni and 
Gowrishankar, 2004). LysE provides the only route for L-lysine excretion 
horn C. ghitamicum and catalyses unidirectional efflux of L-lysine and 
other basic ammo acids (Saier, 2000a).
1.4.5.2.17 The resistance to homoserine/threonine (RlitB) family
Members of the resistance to homoserine/threordne (RlitB) family (TC 
2.A.76) are efflux pumps that may catalyse the efflux of threonine, 
homoserine and homoserine lactones (Zakataeva et al, 1999, Saier, 
2000a). One characterised member id this family is the 
homo serine/liomo serine lactone/(3-hydroxynorvaline efflux permease,
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RhtB, of E. coli which is likely to be a substrate:H+ antiporter (Zakataeva 
etal., 1999).
1.4.5.2.18 The branched chain amino acid exporter (LIV-E) family
The branched chain amino acid exporter (LIV-E) family (TC 2.A.78) are 
pairs of integral membrane proteins. The two-component permease, 
BmFE, of C glutamicum is a member of this family and has been shown to 
catalyse the efflux of methionine, isoleucine, leucine and valine 
(Kennerknecht et aL, 2002, Trotschel et aL, 2005). Another member is the 
branched chain amino acid efflux pump, AzlCD, of Bacillis subtilis 
(Belitsky et aL, 1997). This is another two-component permease (AzlC and 
AzlD) and is an efflux pump for branched chain amino acids.
1.4.5.2.19 The threonine/serine exporter (ThrE) family
One member of the threonine/serine exporter (ThrE) family (TC 2.A.79) 
has been functionally characterised to date. The tlii'eonine/serine exporter, 
ThrE, of C. glutamicum, catalyses the proton motive force driven efflux of 
threonine and serine (Simic et at, 2002, Eggeling and Salim, 2003).
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1.4.5,3 Families of Primary Active Transporters Capable of 
Transporting Amino Acids
The ATP-binding cassette (ABC) superfamily (TC 3.A.1) contains five 
families containing members that have been shown to transport amino 
acids (Saier, 2000a, Saier, 2000b, Saier et aL, 2009). These are: the polar 
amino acid uptake transporter (PAAT) family (TC 3.A. 1,3); the 
hydrophobic amino acid uptake transporter (HAAT) family (TC 3.A. 1.4); 
the peptide/opine/nickel uptake transporter (PepT) family (TC 3.A. 1.5); 
the quartemaiy amine transporter (QAT) family (TC 3.A. 1.12): and the 
taurine uptake transporter (TauT) family (TC 3.A. 1.17). Proteins in the 
ABC superfamily bind ATP and use the energy to drive transport of a 
range of molecules (Dean et aL, 2001).
The ABC superfamily includes members of both prokaryotic and 
eukaryotic origins and includes both uptake and efflux transporters 
(Saier, 2000b). The families with members known to transport amino 
acids are found in prokaryotes and are uptake permeases (Saier, 2000a). 
Two amino acid transporters in the ABC superfamily have been found in 
the filamentous cyanobacteria Anabaena sp\ the high-affinity basic amino 
acid uptake transporter, Bgt, belongs to the PAAT family (Pemil et aL, 
2008), and the neutral amino acid permease, N-I, belongs to the HAAT 
family (Picossi et aL, 2005).
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1,4.5.4 Amino Acid Transporter Genes in P. falciparum
No P. falciparum amino acid transporters have yet been identified at the 
molecular level and to date only six amino acid transporters have been 
putatively annotated in the P. falciparum genome (Martin et al., 2005). Of 
the six putative transporters currently annotated three show similarity to 
members of the amino acid/auxin permease (AAAP) family (PFF1430c, 
PFL0420w and PFL1515c) and the other three show similarity to 
members of the neurotransmitter:Na+ symporter (NSS) family 
(PFB0435c, PFE0775c and PF11_0334) (Martin et al, 2005). Despite the 
putative function of these genes being known no functional 
characterisation has yet been carried out.
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1.5 Aims of Thesis
The focus of the thesis is on transport and salvage in the Plasmodium 
falciparum malaria parasites. This work has been constructed on the 
following themes of interest:
1. A broad ranging study to identify and characterise potential P. 
falciparum amino acids transporters, with the functional 
characterisation of a gene-specific cDNA library of putative 
membrane transporters using the Xenopus laevis oocyte 
heterologous expression system carried out. The putatively 
annotated amino acid transporter PFF1430c has also been screened 
using this system to characterise its transport properties.
2. A targeted approach to characterise the properties of methionine 
uptake by P. falciparum infected RBCs and the free parasites.
3. A biochemical approach to understand the role of transport- 
mediated salvage of folate pathway substrates by detennining their 
effects on antifolate drugs in vitro in the presence and absence of a 
transport inhibitor, and also a targeted investigation of the substrate 
specificity of two likely P. falciparum folate transporters (PfFTl 
and PfFT2).
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CHAPTER 2
Materials and Methods
2.1 Culturing of P. falciparum parasites in 
vitro
Cultivation of P. falciparum was carried out following a modified 
version of the method described by Trager and Jensen (Trager and 
Jensen, 1976). P. falciparum parasites were kept in O positive human 
RBCs (2.8 % haematocrit; 1 ml washed erythrocytes in 35 ml culture) and 
culture medium, under an atmosphere of 3 % CO2, 4 % O2 and 93 % N2 in 
sterile 160 ml culture flasks (Nunc™ Rosklide, Denmark). The culture 
medium was replaced daily and the parasitaemia adjusted if required by the 
addition of washed O positive human RBCs. The cultures were maintained 
at 37 °C and all culture work was carried out under aseptic conditions in a 
laminar flow hood (class II biological safety cabinet, Nuaire). Cultures 
were examined using thin blood smears and the parasitaemia and growth 
stage assessed before the cultures were used for assays.
The strain of P. falciparum used throughout this work was 3D7, a strain 
sensitive to chloroquine and pyrimethamine, and moderately resistant to
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sulphadoxine originating from an airport malaria case at Schiphol Airport, 
The Netherlands.
2.1.1 Preparation of Red Blood Cells
Type O positive human blood from the National Blood Service blood bank 
at Speke, Liverpool was washed with wash medium containing either 
RPMI-1640 (Sigma, Poole, UK) supplemented with 0.02 mg/ml 
gentamycin (Sigma, Poole, UK) for the experiments requiring normal 
medium (with folate) or folate and pABA-free RPMI-1640 (HyClone, 
Thermo Scientific, UK) supplemented with 0.02 mg/ml gentamycin for 
the experiments requiring parasites to be cultured in the absence of 
folate and pABA. Wash steps were repeated three times when using 
wash medium with folate and pABA present and four times more when 
using folate and pABA-free wash medium. Washed blood was stored at 
4 °C and used for no longer than 6 days.
2.1.2 Preparation of Culture Media
Culture medium used for parasites grown in the presence of folate and 
pABA contained RPMI-1640 supplemented with 25 mM HEPES pH 7.4, 
0.25 % w/v Albumax II (GIBCO, Invitrogen), 36 pM hypoxanthine (Sigma, 
Poole, UK) and 0.02 mg/ml gentamycin. This culture medium was used for 
parasite cultures from which total RNA or genomic DNA was extracted
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and for the experiments described in chapter 4. Parasites used for 
experiments in the absence of folate and pABA were grown in folate and 
pABA-ffee but otherwise standard RPMI-1640 (HyClone, 
Thermo Scientific, UK) supplemented with 25 mM HEPES pH 7.4, 0.25 
% Albumax II, 36 pM hypoxanthine and 0.02 mg/ml gentamycin. Parasites 
were cultured in this folate and pABA-free medium for the experiments 
described in chapter 5. HEPES was used as buffer to prevent the 
acidification of the culture during parasite growth. A stock solution of 1 M 
HEPES was prepared in distilled water with the pH adjusted to 7.4 with 5 
M NaOH. This was filter sterilised and stored at 4 °C. Albumax II was 
used in place of the traditional serum as this is folate and pABA-fiee and a 
5 % w/v stock solution in distilled water was made. This was filter sterilised 
and stored at 4 °C for no longer than 30 days.
2.1.3 Examination of Parasites and Calculation of
Parasitaemia Using Giemsa Stained Slides
Parasite cultures were examined daily using giemsa stained thin blood 
smears. The thin blood smear was made from a drop of dense culture 
suspension (taken from the bottom of the flask) then fixed with methanol 
for 5 seconds and stained with 10 % giemsa for 10 minutes. The slide was 
then examined to check for the parasite stage using a light microscope with 
a 100 x oil immersion objective and the parasitaemia calculated (Zeiss,
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Germany). Parasitaexnia was calculated as the percentage of parasitised red 
blood cells out of the total number of red blood cells (with at least 500 cells 
in total counted).
2.1.4 Synchronisation of Parasite Cultures
In order to have synchronous cultures of parasites, cultures were 
synchronised using sterile 5 % D-sorbitol (Sigma, Poole, UK) in distilled 
water, following a modification of the procedure described by Lambros 
and Vanderberg (Lambros and Vanderberg, 1979). D-sorbitol removes 
trophozoites and schizont stages from the culture by selective osmotic lysis 
leaving a culture with mainly ring stage parasites. Synchronisation was 
earned out on mixed cultures or cultures with mainly ring stage parasites 
present. The cultures were centrifuged at 805 x g for 5 minutes and the 
supernatant removed. Five pellet volumes of 5 % D-sorbitol was added to 
the pellet, mixed thoroughly and kept for 20 minutes at room temperature. 
The suspension was centrifuged as before and the pellet washed once with 
an excess of the appropriate culture medium. The pellet was then 
resuspended in culture medium and transferred to a fresh culture flask, 
gassed and kept at 37 °C.
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2.1.5 Gassing of Parasite Cultures
The parasite cultures were kept under an atmosphere of 3 % CO2, 4 % O2 
and 93 % N2. This was achieved by using a pipette fitted with a 0.22 f.im 
filter (Millipore) to pass the gas into the culture flask. The flasks were 
flushed with gas for 1 minute then the lid was quickly and tightly replaced 
and the flasks returned to the 37 °C incubator.
2.1.6 Cryopreservation of Parasites
Parasites were cryopreserved for future use from ring stage cultures above 
5 % parasitaemia. Cultures were centrifuged at 805 x g for 5 minutes and 
the supernatant removed. One pellet volume of sterile cryopreservation 
solution (28 % glycerol; 72 % of 4.2 % w/v D-sorbitol in 0.9 % w/v NaCl) 
was added to the pellet and gently mixed. This suspension was then 
divided into 1 ml aliquots in sterile cryogenic vials (non-pyrogenic 
polypropylene, Coming Incorporated, Coming, USA). Vials were then 
stored under liquid nitrogen (Union Carbide, UK) in K series cryostorage 
tanks (JENCONS, Scientific LTD).
2.1.7 Retrieval of Cryopreserved Parasites
Vials of cryopreserved parasites were taken from the liquid nitrogen 
storage and allowed to thaw in the 37 °C incubator. Once thawed the
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contents were transferred to a 15 ml centrifuge tube (Greinerbio-one, 
Germany) and centrifuged at 805 x g for 5 minutes. The supernatant was 
removed and the pellet resuspended in an equal volume of sterile 3.5 % w/v 
NaCl and centrifuged as before. The supernatant was removed and the 
pellet washed once with culture medium (with folate and pABA). The 
resulting pellet was resuspended with 15 ml culture medium (with folate 
and pABA) and 0.5 ml washed red blood cells, then transferred to a 40 ml 
sterile culture flask (Nunc™ Roskhde, Denmark). This was gassed for 30 
seconds and then transferred to the 37 °C incubator.
2.2 Total RNA Extraction from P. falciparum 
Cultures
RNA was isolated from mixed and trophozoite stage P. falciparum 
infected erythrocytes with approximately 10 % parasitaemia. The culture 
was centrifuged at 805 x g for 5 minutes and the supernatant removed. The 
pellet was transferred to a 1.5 ml microcentrifrige tube and 1/10th pellet 
volume of 5 % w/v saponin in phosphate buffered saline (PBS, 137 mM 
NaCl, 2.7 mM KC1, 4.3 mM Na2HP04, 1.47 mM KH2PO4, at pH 7.4) was 
added to the pellet and mixed by inversion for under 1 minute until a bright 
red supernatant appeared. This was centrifuged immediately at 17000 x g 
for 1 minute in a bench top microcentrifuge (Heraeus Freco 17, Thermo
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Scientific) and the supernatant discarded. One ml of Trizol (Invitrogen) 
was added and the pellet was resuspended thoroughly by pipetting. This 
suspension was left for 5 minutes at room temperature then 200 pi of 
chloroform was added, mixed by vortexing and then centrifuged at 17000 x 
g for 15 minutes at 4 °C. The upper aqueous phase was carefully removed, 
taking care not to contaminate it with the DNA containing interphase, and 
transferred into a fresh 1.5 ml micro centrifuge tube. Five hundred pi of 
high quality isopropanol was added and left at room temperature for 10 
minutes. The sample was then centrifuged at 17000 x g for 10 minutes at 4 
°C. The supernatant was discarded and the pellet washed by adding 750 pi 
of 70 % ethanol and centrifuging at 17000 x g for 5 minutes at 4 °C. The 
pellet was dried then resuspended in diethylpyrocarbonate (DEPC) treated 
water, the volume depending on the size of the pellet (small pellets 
resuspended in 20 pi and larger pellets in 50 pi). The concentration was 
determined using a NanoDrop Nd-1000 UV/Vis 1 pi Spectrophotometer 
(Labtech International, UK) at 260 nm and samples with an A260:A280 of 
over 1.7 deemed to be of suitable purity. The RNA was then aliquoted and 
stored at -80 °C. All water, solutions, micro centrifuge tubes and pipette 
tips used for RNA extraction were RNase-free and DNase-free.
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2.3 cDNA Synthesis from Total P. falciparum
RNA
cDNA was produced from isolated P. falciparum RNA by reverse 
transcription. Contaminating genomic DNA was degraded before cDNA 
synthesis by incubating total RNA with 1 pi Turbo DNase (Ambion, UK) 
and incubated at 37 °C for 30 minutes to degrade any contaminating DNA. 
The sample was then heat inactivated at 65 °C for 20 minutes. The 
ThennoScript™ RT-PCR System (Invitrogen) was used for cDNA 
synthesis, with 2 pg of isolated RNA, 2 pi random hexamers, 2 pi dNTPs 
and 5.074 pi DEPC freated water incubated at 65 °C for 5 minutes. This 
mix was then added to 4 pi 5 X buffer, 1 pi 0.1 M DTT, 1 pi DEPC treated 
water, 1 pi RNaseOUT, and 1 pi Thermo Script RT (reverse transcriptase) 
and incubated overnight at 37 °C. The reaction was terminated by heating 
to 85 °C for 5 minutes. The RNA template was removed by adding 2 U 
RNase H and incubating at 37 °C for 20 minutes. The cDNA was stored in 
aliquots at -20 °C (for use within one month) or -80 °C for longer term 
storage.
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2.4 Genomic DNA Extraction from P.
falciparum Cultures
Genomic DNA was isolated from mixed and trophozoite stage P. 
falciparum infected erythrocytes with approximately 10% parasitaemia. 
The culture was centrifuged at 805 x g for 5 minutes and the supernatant 
removed. Five pellet volumes of ice-cold 0.05 % w/v saponin in PBS (137 
mM NaCl, 2.7 mM KC1, 4.3 mM Na2HP04, 1.47 mM KH2PO4, at pH 7.4) 
was added to the pellet, mixed and left on ice for 10 minutes then 
centrifuged at 2000 x g for 5 minutes. The supernatant was discarded and 
the pellet washed twice with PBS. After the second wash the pellet was 
resuspended in 1/100th of the original culture volume of TE buffer (10 mM 
Tris-Cl, pH 7.5 and 1 mM EDTA) and transferred to a 1.5 ml 
microcentrifuge tube. Proteinase K and SDS were added to respective final 
concentrations of 20 pg/ml and 0.5 % and mixed slowly by inversion. This 
mix was then incubated at 56 - 65 °C for 2 hours. An equal volume of 
phenohchloroform/isoamyl alcohol (25 : 24 : 1, v/v/v) to the current mix 
was added and mixed thoroughly by inversion until a mixture of organic 
and aqueous phases occurred. This was then centrifuged at 17000 x g at 4 
°C for 5 minutes and the resulting upper aqueous phase transferred into a 
fresh 1.5 ml micro centrifrige tube. This was followed by two more 
phenoVchloro form extractions carried out in the same way. One tenth 
volume of 3 M sodium acetate and 2.5 volumes of 99 % ethanol were then
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added to the final aqueous phase and chilled at -20 °C overnight. After 
chilling the mix was centrifuged at 17000 x g for 10 minutes and the 
supernatant discarded. The pellet was ah dried then resuspended in DEPC 
treated water, the volume depending on the size of the pellet (small pellets 
resuspended in 20 pi and larger pellets in 50 pi). The concentration was 
read using a NanoDrop Nd-1000 UV/Vis 1 pi Spectrophotometer (Labtech 
International, UK) at 260 nm and samples with an A260:A280 of over 1.8 
deemed to be of suitable purity. The DNA was then aliquoted and stored at 
-80°C. All water, solutions, micro centrifuge tubes and pipette tips used for 
genomic DNA extraction were DNase and RNase-free.
2.5 Agarose Gel Electrophoresis
Agarose gel electrophoresis was used for the separation and identification 
of DNA fragments from restriction digests and PCR amplifications. 
Agarose gels were prepared with 1 % agarose in TBE buffer (89 mM Tris, 
89 mM Boric acid, 2 mM EDTA pH 8) and TBE was used as the running 
buffer. Before loading, samples were mixed with loading buffer II 
(Ambion) and the Tracklt™ 1Kb plus DNA ladder (Invitrogen) was used as 
a molecular weight marker. Electrophoresis was performed at 90 V for 1 
hour and the gel incubated in a solution of 0.5 pg/ml ethidium bromide for 
20 minutes. The bands were analysed for the expected DNA fragment size
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using Gene Genius Bio-imaging Gel Documentation System (Syngene, 
Synoptics, Ltd. Cambridge, U.K.).
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CHAPTER 3
Xenopus laevis Oocyte Screening of Putative P. 
falciparum Amino Acid Transporters
3.1 Introduction
Malaria parasites spend a large part of then lifespan within the host’s RBC 
and so they must evolve appropriate transport networks to acquire vital 
nutrients that are not present, or that are in limited supply, within these 
cells (see section 1.4 for more details on Plasmodium membrane transport). 
It is important to identify and characterise these transport pathways and the 
transport proteins responsible to further understand the biology of the 
malaria parasite and as they may be potential antimalarial 
chemotherapeutic targets. Transporters can be targeted either as way of 
delivering drugs into the parasite or by targeting the transport proteins 
directly as described in section 1.4.2 (Biagini et ah, 2005, Kirk, 2004). 
Evidence has shown that the intraerythrocytic malaria parasite cannot meet 
its demand for amino acids by the digestion of haemoglobin alone (as 
discussed in section 1.4.4). The parasite also requires an exogenous supply 
of isoleucine, methionine, cysteine, glutamic acid, glutamine, proline and 
tyrosine for normal growth in vitro, suggesting that the parasite must have
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transport pathways to import them (Divo et al, 1985). The presence of 
amino acid transport pathways in the parasite is also supported by the fact 
that the parasite is able to take up and incorporate all 20 naturally occurring 
amino acids into protein (Sherman, 1977, Elford et ah, 1985, Kirk et al, 
1994, Divo etal, 1985).
To date only six amino acid transporters have been putatively annotated in 
the P. falciparum genome (Martin et al., 2005). Three of the six 
transporters currently annotated as amino acid transporters show similarity 
to members of the amino acid/auxin permease (AAAP) family 
(PFF1430c, PFL0420w and PFL1515c) and the other three show 
similarity to members of the neurotransmitter:Na+ symporter (NSS) 
family (PFB0435c, PFE0775c and PF11_0334) (Martin et al, 2005). The 
characteristics of these two families of amino acid transporter genes, as 
well as other families of amino acid transporter genes, are discussed in 
section 1.4.5. Despite the putative function being known for these six 
proteins no functional characterisation has previously been carried out 
and so this is addressed in this chapter.
As there is a possibility that there are more amino acid transporters than the 
six described above a gene-specific cDNA library was constructed. This 
was constructed by Dr Enrique Salcedo Sora before the start of the work 
described in this thesis. Genes with three or more transmembrane domains
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and lacking signal peptides were selected, suggesting that they may code 
for plasma membrane bound proteins. One hundred and fifteen genes were 
identified in this way and forty eight cloned (by Invitrogen) for functional 
characterisation. These forty eight genes were not chosen specifically out 
of the one hundred and fifteen but because the remaining sixty seven genes 
were unable to be cloned.
The functional characterisation of these forty eight genes and the six 
putatively annotated genes was important in order to provide the 
confirmatory data needed to support their role in amino acid transport. 
The Xenopus laevis oocyte expression system was chosen as a 
heterologous expression system to investigate the roles of these genes in 
amino acid transport. This is a well characterised system and was chosen 
as it would have been difficult to ascertain the role of individual genes by 
investigating transport in the intact parasite due to the complex nature of 
different transport routes within the parasite. The X. laevis oocyte 
expression system has been used extensively in the past for expression of 
membrane transporters and has several important and attractive features: 
they normally produce faithful and efficient translation of exogenous 
RNA; display the correct orientation of the encoded protein; and the 
oocytes themselves are large and easily handled. This model has been 
used for the expression of foreign genetic material since the 1970s, with 
initial work on the model carried out by Gurdon and colleagues (Gurdon
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et al., 1971). To date it has also been used to study P. falciparum 
transport activity with the hexose transporter, the chloroquine resistance 
transporter, nucleoside transporters and the Ca2+ dependent ATPase 
transport systems being studied (Joet et ah, 2003, Martin et aL, 2009, 
Downie et al., 2007, Downie et al., 2006, Krishna et al., 2001b). It has 
also been used previously for the characterisation of amino acid 
transporters (Closs et al., 1997). The AT-rich nature of the P. falciparum 
genome can cause problems with expression of P. falciparum proteins in 
heterologous systems but it does not seem to cause as much of a problem 
in X. laevis oocytes as it does in other systems (Krishna et al., 2001a, 
Kirk et al., 2005). There are a number of potential drawbacks to the X. 
laevis oocyte expression system including: the misfolding or degradation 
of the protein; inefficient translation or degradation of the mRNA; the 
protein not being targeted to the oocyte plasma membrane; the protein 
may be part of a heteromeric complex and not function alone (for 
example members of the TRAP-T family and ABC superfamily); 
endogenous X. laevis proteins may interact with expressed foreign 
proteins and so affect their functional properties; and the protein may not 
be active as a transporter because of problems in posttranslational 
modifications (Wagner et al, 2000b, Kirk et al, 2005).
Yeast is another potential eukaryotic system for expressing Plasmodium 
proteins. However, the AT bias of the P. falciparum genome can cause
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problems with expression in yeast (Kirk et ah, 2005). Codon optimisation 
can be used to reduce the AT content and therefore improve expression in 
yeast, but as the cDNA library was already under construction without 
codon optimisation this would have introduced a further step if yeast was 
to be used as the expression system. Manipulation of gene expression in 
the parasite itself is also a potential method of investigating the function 
of transport proteins. Knock-out experiments can establish gene function 
but may be problematic if the transporter is essential for parasite survival. 
If there is a known substrate and it can be transported via another uptake 
route then increased concentrations of the substrate can be added in order 
to allow parasite survival, or if there is no alternative uptake route then 
relevant downstream metabolites can be provided instead as long as they 
can be taken up by the parasite (Kirk et al., 2005). Mutation of 
transporters can also be used to investigate specific amino acid 
substitutions. For the number of genes being investigated genetic 
manipulation would have been too time consuming for the time-frame of 
this thesis. This is, however, a worthwhile approach as it would allow 
validation of the gene function and the essentiality of the genes to be 
investigated.
After a number of rounds of PCR, only one of the six putatively 
annotated genes was successfully amplified (PFF1430c, the putative 
amino acid transporter of the AAAP family). This chapter describes the
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screening and characterisation of this gene as well as the forty eight 
strong gene-specific cDNA library. The uptake of the substrates 
methionine, isoleucine, leucine, glutamic acid, taurine, pantothenic acid 
and choline by proteins encoded by the cDNA library or PFF1430c was 
measured. Methionine, isoleucine, glutamic acid, and the vitamin 
pantothenic acid were used as these have been shown to be essential for 
parasite growth in vitro. Leucine was used as it has been shown to be a 
substrate for the P. falciparum isoleucine transporter (Martin and Kirk, 
2007) so it would be interesting to investigate if any gene was responsible 
for transport of both leucine and iso leucine.
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3.2 Materials and Methods
3.2.1 Chemicals
Radio labelled reagents: [methyl-3H] choline chloride, 81Ci/mmol 
(Ainersham); [3’, 5’, 7, 9-3H] folic acid (American Radiolabeled 
Chemicals, Inc.); L-[2, 3, 4-3H] glutamic acid, 50Ci/mmol (American 
Radiolabeled Chemicals, Inc.); L-[4, 5-3H] isoleucine, 60Ci/mmol 
(American Radiolabeled Chemicals, Inc.); L-[4, 5- H] leucine,
166Ci/mmol (GE Healthcare, UK); L-[methyl-3H] methionine, 83Ci/mmol 
(GE Healthcare, UK); D-[2, 3-3H] pantothenic acid, 50Ci/mmol (American
•5
Radiolabeled Chemicals, Inc.); [2- H] taurine, 20Ci/mmol (American 
Radiolabeled Chemicals, Inc.); and L-[2,3,4-3H] glutamine, 44Ci/mmol 
(American Radiolabeled Chemicals, Inc.).
3.2.2 Bioinformatics
Potential integral membrane proteins were identified by bioinfonnatic 
methods. This identification was carried out by Dr Enrique Salcedo Sora 
before the stall of this project. The HMMTOP transmembrane topology 
prediction server (http://www.enzim.hu/hmmtop/index.html) (Tusnady and 
Simon, 2001) and the TMHMM server
(http://www.cbs.dtu.dk/services/TMHMM/) were used to select genes with 
more than 3 transmembrane domains. Only non-organellar proteins,
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identified as lacking signal peptides, were chosen, suggesting that they 
may code for plasma membrane bound proteins. One hundred and fifteen 
genes were identified in this way.
As well as this screening, six putative P. falciparum amino acid 
transporters have been previously identified through homology (Martin et 
«/., 2005). These are PFF1430c, PFL0420w, PFL1515c, PFB0435c, 
PFE0775c and PF11_0334. PFF1430c, PFL0420w and PFL1515c are 
similar to members of the amino acid/auxin permease (AAAP) family 
and PFB0435c, PFE0775c and PF11_0334 are similar to members of the 
neurotransmitter:Na+ symporter (NSS) family (Martin et aL, 2005).
3.2.3 Gene Specific cDNA Library
A gene-specific cDNA library of 48 clones was produced by Invitrogen 
from the 115 genes identified as potential integral membrane proteins 
above (table 3.1). These 48 genes were not chosen specifically out of the 
115 identified but because the remaining 67 genes were unable to be 
cloned. Genes were cloned from cDNA (generated from total 3D7 P, 
falciparum RNA) into the pDEST47 vector and propagated in Escherichia 
coli. The genes were provided as glycerol stocks and stored at -80 °C.
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Table 3.1. Table of gene-specific cDNA library. Similar known proteins identified 
using blastp (Altschul et al., 1997, Altschul et ah, 2005).
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3.2.3.X Plasmid Preparation from cDNA Library Glycerol Stocks
Overnight cultures were set up as follows; 50 ml LB medium, 100 jag/ml 
Ampicillin, and 20pi of transformed E, coli glycerol stock (from gene- 
specific DNA library). Either cultures from individual clones or groups of 
8 clones together were set up (see table 1 for group assignments). In the 
case of group 1 the overnight culture also included human reduced folate 
earner 1 (hRFCljpKSM, provided by Dr Enrique Salcedo Sora). Flasks 
were incubated in a shaking incubator at 37 °C overnight. Twenty five 
ODeoo units of culture were centrifuged, in 15 ml or 50 ml tubes as 
required, at 4000 ipm for 10 minutes. The supernatant was discarded and 
the plasmid extracted and purified using the commercially available 
QIAprep spin miniprep kit (QIAGEN) following the kit protocol. The 
concentration of DNA was determined using a NanoDrop Nd-1000 
UV/Vis Ipl Specfrophotometer (Labtech International, UK) at 260 nm 
(with the purity measured as the ratio of absorbance at 260 and 280 nm,
A260/280)-
3.2.3.2 Linearisation of Plasmid DNA
DNA was linearised by adding 20 units of Xbal (New England Biolabs) 
restriction enzyme to 45 pi plasmid DNA, 1 X end concentration buffer 2 
and 1 X end concentration BSA, and incubating at 37 °C for 1 hour. After 1 
hour a further 1 pi restriction enzyme was added and incubated at 37 °C for
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another hour. The mix was heat inactivated at 65 °C for 20 minutes, then
treated with 8 |.l1 5% SDS, 8 (.il 2.5 mg/ml Proteinase K and 11.5 (j.1 DEPC 
treated water and incubated at 50 °C for 30 minutes. The DNA was cleaned 
by phenol/chloroform extraction as follows: 120 \x\ DEPC treated water 
was added to the linearisation mix to make up to 200 pi total volume then 
200 pi phenoVchloroform/isoamyl alcohol (25 : 24 : 1, v/v/v) was added 
and mixed by inversion. This was then centrifuged at 17000 x g for 1 
minute in a bench top microcentrifuge to separate the aqueous and organic 
phase. The aqueous phase was taken into a fresh 1.5 ml microcentrifuge 
tube and the phenol/chloroform extraction was repeated. Commercially 
available Wizard SV Gel and PCR Clean-up System (Promega) was used 
to purify the linearised DNA following the kit protocol. The DNA was 
eluted in DEPC treated water and the concentration was determined using 
a NanoDrop Nd-1000 UV/Vis Ipl Spectrophotometer (Labtech 
International, UK) at 260 nm (with the purity measured as the ratio of 
absorbance at 260 and 280 nm, A26o/2so)- DNA was analysed on 1 % 
agarose gel (as detailed in section 2.4) and stored at -20 °C.
3.2.3.3 Heterologous cRNA Synthesis
For X laevis oocyte expression it is simpler to use capped complimentary 
RNA (cRNA) than cDNA as it is much easier to inject the cRNA into the 
cytoplasm of the oocyte than to inject cDNA into the nucleus. cRNA was
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transcribed from the linearised cDNA (produced as described in section 
3.2.3.2) using the commercially available mMessage mMachine High 
Yield RNA Transcription Kit T7 (Ambion) following the manufacturer’s 
instructions. Briefly, this included 1 pg linearised DNA, 1 X NTP/CAP, 1 
X reaction mix, 2 pi enzyme mix and nuclease-free water to a total volume 
of 20 pi, incubated at 37 °C for 6 hours. In order to remove the template 
DNA from the in vitro transcription products 1 pi of TURBO DNase was 
added to the reaction mix and incubated at 37 °C for 15 minutes. RNA was 
recovered by lithium chloride precipitation by adding 30 pi nuclease-free 
water and 30 pi lithium chloride precipitation solution (mMessage 
mMachine High Yield RNA Transcription Kit T7, Ambion) and incubating 
overnight at -20 °C. After incubation the precipitation mix was centrifuged 
at 17000 x g at 4 °C for 10 minutes, washed once with 70 % v/v ethanol 
and the pellet dried in the laminar flow hood. The pellet was resuspended 
in 15 pi nuclease-free water and concentration was read using a NanoDrop 
Nd-1000 UV/Vis Ipl Spectrophotometer (Labtech International, UK) at 
260 nm (with the purity measured as the ratio of absorbance at 260 and 280 
mn, A260/280)* The cRNA was analysed on 1 % agarose gel as described in 
section 2.4 with the samples prepared up to 10 pi with nuclease-free water 
with 2 pi formaldehyde (to denature the cRNA) and 3 pi gel loading buffer 
II also added. The cRNA concentration was adjusted to 1 pg/pl, split into 5 
pi aliquots in 1.5 ml nuclease free micro centrifuge tubes and stored at -80 
°C.
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3.2.4 Cloning of PFF1430c, PFL0420w, PFLISISc,
PFB0435c, PFE0775c? PF11_0334
3.2.4.1, PCR Amplification of PFF1430c, PFL0420w, PFLISISc, 
PFB0435c, PFE0775c, PF11_0334
Amplification of PFF1430c, PFL0420w, PFL1515c, PFB0435c,
PFE0775c, and PF11_0334 was attempted using the PCR method. Primers 
were designed based on the published sequences of these genes and are 
shown in table 3.2. An initial amplification reaction was set up with the 
end concentration of the following reagents: 2 X amplification buffer, 2 X 
PCRX enhancer solution, 2.3 mM MgSCfi, 0.2 mM dNTPs mix, 1 unit 
Platinum® Pfx DNA Polymerase (Invitrogen), 2 pM of the forward and 
reverse primer (Invitrogen), 4 pi template 3D7 cDNA (produced following 
the protocol described in section 2.3) and DEPC-H2O to a total volume of 
21.4 pi. PCR amplifications were all earned out using the Biometra-T- 
Personal-Thermal-Cycler (Anachem, Luton, UK) and the initial 
amplification attempt used the following cycling conditions: initial 
denaturation (94 °C for 4 minutes), 40 cycles of denaturation (94 °C for 15 
seconds), annealing (53 °C for 30 seconds) and extension (72 °C for 2 
minutes) and a final extension (72 °C for 10 minutes). Primers for PfCRT 
(provided by Dr Enrique Salcedo Sora) were used as a positive control for 
the PCR reactions. The size and integrity of the PCR products was 
visualised on a 1 % w/v agarose gel as described in section 2.5.
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Primer Name Sequence (S'to 3')
PFF 1430c Forward Primer AT AT AAG CTT AT G AATAAA A AG TAJG G
PFF1430C Reverse Primer ATATG A ATT CTT ATA A A ATT A A ATTT AAG G
PFL0420w Forward Primer ATATAAGCTTATGAGTATATGCATATC
PFL0420w Reverse Primer ATATG AATTCTTA ATATATA AAATCATA AAG G
PFL1515c Forward Primer ATATAAG CTTAT G AAT CT A A A AT G G
PFLISISc Reverse Primer AT AT G AATT CTT AACCA AAT AAT AAAI CAG
PFB0435c Forward Primer ATATAAG CTTATG CT ACA AAAGTTAAG
PFB0435c Reverse Primer ATATGAATTCTCATATTTTACTTTTAGTAG
PFE0775c Forward Primer ATATAAGCTTATGTCGAGGGAAACATC
PFE0775C Reverse Primer ATATG AATTCCTACATATTTATAAATTCAC
PF11 0334 Forward Primer ATATAAG CTTATG G G AACACCTG
PF11 0334 Reverse Primer AT AT G AATT CTT AAT AG G A A ATATG AGC
Table 3.2. Primer combinations used to amplify PFF 1430c, PFL0420w, 
PFL1515c, PFB0435c, PFE0775c andPFll_0334.
Optimisation of the PCR was carried out as the initial PCR did not 
successfully amplify any of the six genes of interest. Firstly, several 
attempts at PCR using the same mix of reagents, with new batches of 
cDNA from freshly extracted RNA, and only increasing the extension time 
to 5 minutes were tried but were also unsuccessful. A gradient PCR was 
used to attempt to amplify PFF1430c using 2 different reaction mixes, 
again with a new batch of cDNA from freshly extracted RNA. Mix one 
included 1 X amplification buffer, 1.5 mM MgS04, 0.2 mM dNTPs mix, 1
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unit Platinum® Pfx DNA Polymerase (Invitrogen), 1.6 jaM of the forward 
and reverse primer, 1 pi template 3D7 cDNA and DEPC-H2O to a total 
volume of 25 pi. Mix two was the same but also included 1 X PCRX 
enhancer solution. The following cycling conditions were used for the 
gradient PCR: initial denaturation (94 °C for 2 minutes), 40 cycles of 
denaturation (94 °C for 15 seconds), annealing (75 °C, 73.3 °C, 70.3 °C, 
65.8 °C, 59.5 °C, 55 °C, 51.9 °C, or 50 °C for 30 seconds) and extension 
(72 °C for 2 minutes) and a final extension (72 °C for 10 minutes).
As the gradient PCR did not successfully amplify PFF1430c amplification 
of PFL0420w was attempted using genomic DNA as a template, as this 
gene has no introns. Three different reaction mixes were used with three 
different DNA polymerases. The first mix used Platinum® Pfx DNA 
Polymerase and consisted of the following reagents: 2 X amplification 
buffer, 2 X PCRX enhancer solution, 2.5 mM MgS04, 0.2 mM dNTPs mix, 
1 unit Platinum® Pfx DNA Polymerase (Invitrogen), 2 pM of the forward 
and reverse primer, 2 pi template 3D7 genomic DNA (produced as 
described in section 2.4) and DEPC-H2O to a total volume of 20 pi. Mix 
two used Platinum® taq DNA Polymerase and consisted of the following 
reagents: 1 X amplification buffer, 1.5 mM MgCh, 0.2 mM dNTPs mix, 1 
unit Platinum® taq DNA Polymerase (Invitrogen), 0.2 pM of the forward 
and reverse primer, 2 pi template 3D7 genomic DNA and DEPC-H2O to a 
total volume of 20 pi. Mix three used Platinum® taq DNA Polymerase
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High Fidelity and consisted of the following reagents: 1 X amplification 
buffer, 2 inM MgS04, 0.2 mM dNTPs mix, 1 unit Platinum® taq DNA 
Polymerase High Fidelity (Invitrogen), 0.2 pM of the forward and reverse 
primer, 2 pi template 3D7 genomic DNA and DEPC-H2O to a total volume 
of 20 pi. The following PCR cycling conditions were used for all mixes: 
initial denaturation (94 °C for 2 minutes), 40 cycles of denaturation (94 °C 
for 15 seconds), annealing (55 °C for 30 seconds) and extension (68 °C for 
2 minutes) and a final extension (68 °C for 10 minutes). PFL0420w was 
found to he successfully amplified using mix two with Platinum® taq DNA 
Polymerase and so this could be used for further cloning work.
Touchdown PCR was used in a final attempt to amplify PFF1430c, 
PFL0420w, PFL1515c, PFB0435c, PFE0775c and PF11_0334 horn 
cDNA. An amplification reaction was set up with the end concentration of 
the following reagents: 1 X amplification buffer, 2.3 mM MgSCU, 0.25 
mM dNTPs mix, 2.5 units Platinum® taq DNA Polymerase High Fidelity 
(Invitrogen), 2 pM of the forward and reverse primer (Invitrogen), 2 pi 
template 3D7 cDNA and DEPC-H2O to a total volume of 21 pi. The 
following cycling conditions were used for this touchdown PCR: initial 
denaturation (94 °C for 2 minutes), 40 cycles of denaturation (94 °C for 15 
seconds), annealing (63 °C for 30 seconds, dropping by 0.5 °C for each 
cycle) and extension (68 °C for 4 minutes) and a final extension (68 °C for
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10 minutes). PFF1430c was successfully amplified using this method and 
was used for cloning.
3.2.4.2 Deoxyadenosine (dA)-Tailing
As the PFF1430c was amplified using a proofreading enzyme the fragment 
lacked 3’ A-overhangs that are necessary for cloning and so these were 
recreated by dA-tailing. The reaction mixture contained the following 
ingredients at the final concentration; IX Taq buffer, 2.5mM MgCF, 
O.lmM dATP, 2.5 units Taq DNA polymerase (Promega) and PCR 
product. The reaction was incubated at 68 °C for 1 hour. The product was 
then purified using the commercially available Wizard SV Gel and PCR 
Clean-Up System (Promega) and eluted with 20 pi DEPC-H2O.
3.2.4.3 TOPO® Cloning
The ligation reaction was canied out using the commercially available 
TOPO® TA cloning kit (Invitrogen). A molar ratio of 3:1 (insert DNA : 
vector DNA) was used. For ligation of PFF1430c and the pCR II TOPO® 
vector the reaction was set up as follows: 4 pi dA-tailed PCR product, 1 pi 
pCR II TOPO® vector and 1 pi salt solution. The ligation reaction mix of 
PFL0420w and the pCR II TOPO® vector was set up as follows; 6 pi PCR 
product, 1 pi pCR II TOPO® vector and 1 pi salt solution. Both reactions
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were incubated for 30 minutes at room temperature then used directly for 
transformation.
3.2.4.4 Transformation Into One Shot® TOPIO competent E. coli cells
The ligation mix was transferred directly into a vial of One Shot® TOPIO 
competent cells and incubated on ice for 30 minutes followed by a 45 
second heat-shock at 42°C. The vial was immediately transferred to ice and 
250 pi of room temperature SOC medium was added then transferred to a 
shaking incubator for 1 hour at 37 °C. Forty pi 40 mg/ml X-gal and was 
added to the mix and spread out onto pre-wanned 100 pg/ml ampicillin 
treated LB agar plates. The plates were incubated at 37 °C overnight.
3.2.4.S Plasmid Preparation and Clone Selection
Individual white colonies from LB agar plates were picked and cultured 
overnight in 5 ml LB medium, containing 100 pg/ml ampicillin, at 37 °C 
and shaking at 200 rpm. The plasmids were prepared hum this culture 
using the commercially available QIAGEN QIAprep miniprep kit 
following the kit protocol. A restriction digest was performed on the eluted 
DNA to check for the presence of the insert. The restriction digest 
reactions were set up as follows: 1 pg plasmid DNA, 1 X EcoRI buffer 
(Promega), 1 X BSA, 10 units of EcoRI restriction enzyme (Promega) with 
DEPC treated water to a total volume of 20 pi. The reaction was incubated
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for one horn* at 37 °C after which the size and integrity of the digested 
DNA was checked on a 1 % w/v agarose gel electrophoresis (as detailed in 
section 2.5). This confirmed the presence of ligated PFF1430c_pCR®II- 
TOPO® but provided no confirmation of successful ligation of PFL0420w_ 
pCR®n-TOPO®
The orientation of the PFF1430c insert in the pCR®II-TOPO® vector was 
detennined using another restriction digest. This digest was set up as for 
the previous digest but using EcoRV restriction enzyme (New England 
Biolabs) and buffer 3 (New England Biolabs) and the presence of the 
correctly orientated insert was detennined by 1 % w/v agarose gel 
electrophoresis.
3.2.4.6 Subcloning PFF1430c from pCR®II-TOPO® into the KSM 
pBluescript vector
The pKSM vector (originally provided by Dr Bill Joiner, University of 
Pennsylvania, USA) is a derivative of pBluescript in which the insertion 
site is flanked by the 5’- and 3’-untranslated regions of the Xenopus [3- 
globin gene to enhance the expression of heterologous cRNAs in the 
oocytes. Using DNA from colonies showing the PFF1430c insert in the 
correct orientation, PFF1430c was released from the PCRIITOPO® vector 
using the Xhol and BamHl restriction enzymes (New England Bio labs).
107
This restriction digest reaction was set up as follows: 18 pg plasmid DNA, 
1 X buffer 3 (New England Biolabs), 1 X BSA, 200 units of Xhol 
restriction enzyme (New England Biolabs), 200 units BamHI restriction 
enzyme (New England Biolabs) and DEPC treated water to a total volume 
of 100 pi. The reaction was incubated for four hours at 37 °C, after which 
the DNA was cleaned to remove enzyme using the commercially available 
QIAamp PCR Purification kit (QIAGEN) following the kit protocol and 
eluted from the column with 30 pi DEPC treated water. The eluted DNA 
was then checked for the presence of the correctly sized excised insert by 1 
% w/v agarose gel electrophoresis as described in section 2.5. The pKSM 
vector was digested from hRECl_pKSM (provided by Dr Enrique Salcedo 
Sora) using the same restriction enzymes and reaction mix as for 
PFF1430cjpCR®II-TOPO®. The digested DNA was cleaned using the 
commercially available QIAamp PCR Purification kit (QIAGEN) 
following the kit protocol and eluted from the column with 30 pi DEPC 
treated water. This was also checked for the presence of the coiTectly sized 
cut vector by 1 % w/v agarose gel electrophoresis. The excised PFF1430c 
fragment and cut pKSM vector were excised from agarose gel and 
extracted using the commercially available Wizard SV Gel and PCR 
Clean-Up System (Promega) following the manufacturer’s instructions and 
eluted from the membrane with 30 pi DEPC treated water.
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Ligations of PFF1430c into pKSM were carried out at molar ratios of 2:1 
or 4:1 (insert DNA : vector DNA) and the reaction set up as follows: 200 
ng or 400 ng PFF 1430c DNA and 200 ng pKSM DNA with T4 DNA 
ligase buffer at 1 X final concentration and 3 units of T4 DNA ligase. The 
reaction was incubated for 2 hours at room temperature for the 2:1 molar 
ratio reaction or overnight at 4 °C for the 4:1 molar ratio reaction then used 
directly for transfonnation. The ligase mix was added directly to a vial of 
One Shot® TOP 10 competent cells and the transfonnation carried out as 
described in section 3.2.4.4, with the exception of no addition of X-gal 
when plating out. No colonies were observed after the initial ligation and 
transformation attempt so the same procedure was repeated with a 2:1 
molar ratio and ligation for 2 hours at room temperature, but this time 
using new T4 ligase, T4 ligase buffer and One Shot® TOP 10 competent 
cells. This time one colony was observed and plasmids were prepared from 
this colony as described in section 3.2.4.5. Digestion with EcoRI as 
described in section 3.2.4.5 was carried out but no correctly sized insert for 
PFF1430c was observed when observed on 1 % agarose gel.
A different approach was then taken to attempt to successfully subclone 
PFF1430c into pKSM. Both PFF1430c_pCR®II-TOPO® and hRFC_pKSM 
were digested using Xhol and Spel (restriction sites in pCR®II-TOPO® 
vector and internal sites in the 5’- and 3’-untranslated regions of the pKSM 
vector). The digest reaction was set up as follows: 25 jig plasmid DNA, 1
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X buffer 2 (New England Biolabs), 1 X BSA, 200 units of Xhol restriction 
enzyme (New England Biolabs), 200 units Spel restriction enzyme (New 
England Bio labs) and DEPC treated water to a total volume of 100 pi The 
reaction was incubated at 37 °C for 4 hours and heat inactivated at 65 °C 
for 20 minutes. A different procedure for cleaning up the digested DNA 
was also followed. The digested PFF1430c_pCR®IlTOPO® and 
hRFCjpKSM were treated with proteinase k (250 pg/ml end 
concentration) and SDS (1 % end concentration) at 50 °C for 30 minutes. 
This was followed by a phenol/chloroform extraction with the proteinase K 
treated digest mixes made up to 200 pi with DEPC heated water and 200 
pi phenohchloroform/isoamyl alcohol (25 : 24 : 1, v/v/v) added and mixed 
by inversion. The mixes were then centrifuged at 17000 x g for 1 minute 
and the aqueous phases transferred to new 1.5 ml microcentrifuge tubes. 
The phenol/chloroform extraction was repeated once more and the DNA 
recovered using an overnight ethanol precipitation at -20 °C with the 
folio whig reagents used: 1/10th volume 3 M sodium acetate (pH 5.2) and 4 
volumes of ice-cold absolute ethanol. After incubation the mixes were 
centrifuged at 17000 x g at 4 °C for 10 minutes, washed once with 70 % 
7v ethanol and the pellet dried in the laminar flow hood. The dried pellets 
were resuspended in 30pl DEPC treated water and loaded onto a 1 % 
agarose gel, made and run as described in section 2.5. The excised 
PFF1430c fragment and cut pKSM vector were observed to be the correct 
size and were excised from agarose gel and extracted using the
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commercially available Wizard SV Gel and PCR Clean-Up System 
(Promega) following the manufacturer’s instructions and eluted from the 
membrane with 15 pi DEPC treated water.
Ligations of PFF1430c into pKSM using insert and vector horn the Xhol 
and Spel digests of PFF1430c_pCR®II-TOPO® and hRFCljpKSM were 
carried out at molar rations of 3:1 and 6:1 (insert DNA : vector DNA) and 
the reaction set up as follows: 300 ng or 600ng PFF1430c DNA and 200 ng 
pKSM DNA with T4 DNA ligase buffer at 1 X final concentration and 3 
units of T4 DNA ligase. The reaction was incubated for 2 hours at room 
temperature for then used directly for transformation as described for the 
previous ligation and transfonnation attempt. Four colonies were obtained 
(1 from the 3:1 molar ratio and 3 from the 6:1 molar ratio) and plasmids 
prepared from these as described in section 3.2.4.5. Digestion of the DNA 
from the colonies with Xhol and Spel (1 pg DNA, 1 X buffer 2, 1 X BSA, 
20 units of Xhol and Spel made up to 20 pi with DEPC treated water) was 
carried out at 37 °C for 1 hour. The reaction was then heat inactivated at 65 
°C for 20 minutes and analysed on a 1 % agarose gel. No band 
corresponding to the size of PFF1430c was observed so further work on 
these colonies was discontinued.
A further step to try and achieve successful ligation and transfonnation was 
attempted by treating the digested vector with Antarctic phophatase to
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prevent self ligation. After a fresh digestion of PFF143 Oc jiCR®II-TOPO® 
and hRFCjpKSM using Xhol and Spel, carried out in same way as 
previously described in this section, the digested hRFCl_pKSM was 
treated with Antarctic phosphatase. This would help to prevent self ligation 
of the vector by dephosphorylation of the 5’-cohesive ends. The heat 
inactivated digestion reaction was incubated with 25 units of Antarctic 
phosphatase (New England Biolabs) and 1 X Antarctic phosphatase buffer 
(New England Bio labs) at 37 °C for 15 minutes then heat inactivated at 65 
°C for 5 minutes. Further clean-up of the digested PFF1430c_pCR®II- 
TOPO® and Antarctic phosphatise treated hRFC_pKSM was carried out 
using proteinase K treatment, phenol/chloroform extraction and ethanol 
precipitation as described for the previous digest. The commercially 
available Wizard SV Gel and PCR Clean-Up System (Promega) was used 
(following the kit protocol) to excise and extract the PFF1430c fragment 
and cut pKSM vector from a 1 % agarose gel. A sample of the pKSM 
DNA eluted from the spin column of this kit was also run on a 1 % agarose 
gel and showed as a clear compact band at the expected size (3.2 kb).
Ligations of PFF1430c into pKSM using the vector treated with Antarctic 
phosphatase were carried out in the same way as the previous ligation and 
transformation attempt (with 3:1 and 6:1 molar rations of insert DNA : 
vector DNA). However, this was also unsuccessful with no colonies 
observed after overnight culture of the transformations on LB agar plates.
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After these unsuccessful rounds of ligation and transformation attempts it 
was decided to use a synthesised gene for further work on PFF1430c as 
several other researchers in the group had also had difficulty subcloning 
successfully into the pKSM vector and the codon-optimised synthesised 
genes were ordered together.
3.2.4.T Synthesis of Optimised PFF1430c
After multiple unsuccessful attempts at subcloning PFF1430c into the 
KSM pBluescript vector a codon-optimised PFF1430c flanked by the 5!- 
and 3s-untranslated regions of the Xenopus P-globin gene was designed 
and synthesised (synthesised by GenScript Corp., Piscataway, NJ).
3.2.4.8 Plasmid Preparation, Linearisation and cRNA Transcription of 
Optimised PFF1430c
Carried out as described for the gene-specific DNA library in sections 
3.2.3.1 to 3.2.3.3, with the exception of using the mMessage mMachine 
High Yield RNA Transcription Kit Sp6 (Ambion) mstead of the TV kit.
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3.2.5 X. Laevis Oocyte Expression System
3.2.5.1 Animal Husbandry
Healthy wild laboratory conditioned sexually mature female X. laevis frogs 
were obtained in batches of 20 from Xenopus Express (Haute-Loire, 
France). The frogs were kept in specially designed Premier tanks 
(measuring 118 cm x 50 cm x 50 cm) filled 2/3rd full with non-chlorinated 
water. The tanks were housed in an aquarium within the School of 
Biological Sciences at the University of Liverpool which was kept at a 
constant 18 °C. Feeding with pellet food specifically for amphibians was 
earned out 3 tunes a week along with a water change with any uneaten 
food and other debris removed by siphoning. The tank was thoroughly 
cleaned once a week. The frogs were examined frequently for any sign of 
disease or damage, with special attention for any sign of red leg (an 
infectious disease affecting the underneath of the thighs).
3.2.S.2 Preparation and Selection of Oocytes
For each experiment one frog was selected and euthanised by submersion 
in 1 litre euthanising dose of ice-cold ethyl 3-aminobenzoic acid ethyl ester 
methanesulfonate salt (MS222, Sigma), 5g/L in distilled water, pH 7.4 for 
at least 40 minutes. The euthanised frog was washed thoroughly to remove 
the anaesthetic solution, and placed on a clean tray lined with absorbent 
tissue for the surgical removal of oocytes. The forceps and scissors used
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for the removal of the ovary sacs were sterilised with 70 % ethanol. Using 
scissors, a lateral cut through the outer layer of skin across the lower 
abdomen was made with 2 flaps created by making an upwards cut at the 
midline. The skin was parted to expose the internal body wall which was 
cut in the same way as the outer skin, taking care not to sever the artery 
running along the midline under the body wall. Ovary sacs were then 
removed from the abdomen of the flog using forceps and the sacs opened 
up to allow separation of the oocytes.
Two methods for isolating individual oocytes were used. The first method 
isolated single denuded oocytes from the ovaries enzymatically with 
collagenase treatment (1 mg/ml, Sigma, Poole, UK) in Barths solution 
minus calcium (containing 88 mM NaCl, 1 mM KC1, 2.4 mM NaHCOs, 
0.82 mM MgS04.7H20, 15 mM HEPES adjusted to pH 7.6 with NaOH) 
for 2 hours, shaking at 60rpm on a flat bed shaker, at room temperature. 
This was followed by thorough washing with Barths solution minus 
calcium and finally with Barths solution with calcium (as Barths minus 
calcium with 0.3mM CaN03.6H20 added). Oocytes were then kept at 18 
°C for 1 to 2 hours to allow the oocytes to rest. Healthy looking (with 
animal and vegetal poles sharply contrasting), moiphologically intact stage 
V-VI oocytes were selected and kept in petri dishes filled with Barths 
solution with calcium supplemented with penicillin and streptomycin at 18
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°C overnight to allow another selection of the healthiest looking oocytes 
before injection.
The second method used a platinum loop to pull individual oocytes from 
the ovary sacs, with healthy oocytes selected and kept overnight as for the 
previous method. When using this method injected oocytes were treated 
with collagenase (as above) for 20 minutes, shaking at 60 rpm on a flat bed 
shaker, at room temperature after injection and incubation, and prior to the 
uptake assays being carried out.
3.2.S.3 Microinjection of Oocytes
Needles for injection of cRNA into oocytes were made from R-series 
borosilicate glass capillaries (World Precision Instruments) using the PUL- 
1 Micropipette Puller (World Precision Instruments). Briefly, this involved 
heating the centre point of the capillary until it reached melting point then 
using the Micropipette Puller to pull the two ends apart, and so creating 
two needles with long fine points. The needle was then loaded onto the 
KITE micromanipulator (World Precision Instruments) and the end 
trimmed off to allow sample to be loaded as the Micropipette Puller creates 
needles with sealed ends. A stereomicroscope was used to visualise the 
needle cutting and injection process due to small size of the needle and 
oocytes being injected. A PV830 Pneumatic PicoPump (World Precision
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Instruments) and DA7C vacuum pump (Charles Austen Pumps) were 
linked to the KITE micromanipulator to provide regulated positive and 
negative pressure to allow uptake of sample and injection of a specified 
volume of cRNA or water. The appropriate volume of cRNA (or DEPC 
treated water as negative control) for the experiment being carried out was 
loaded into the needle by suction from a droplet placed on film on the stage 
of the stereomicroscope. The drop size was checked and the size adjusted 
to approximately 50 nl (therefore approximately 50 ng 1 ng/nl cRNA per 
drop).
One final selection of the healthiest oocytes from the isolation on the 
previous day was carried out before injection in order to improve the 
chances of oocyte survival and expression of the injected cRNA. Not all 
injected oocytes survive the 4 day incubation period so approximately 
double the number of oocytes required for the planned uptake experiment 
were injected (as 10 oocytes were required per condition or time point 
approximately 20 were injected for each). The selected oocytes were then 
aligned onto a groove on a plastic rack and injected with approximately 50 
nl (~50 ng) of cRNA or approximately 50 nl of DEPC freated water for the 
negative control.
After injection the injected oocytes were fransferred to petri dishes 
containing Barths solution with calcium supplemented with penicillin and
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streptomycin. Each cRNA (or group cRNA) injected oocytes and water- 
injected negative control oocytes were kept in separate dishes but the same 
number of oocytes were kept in each and the same batch of Barths solution 
with calcium (supplemented with penicillin and streptomycin) was used for 
all oocytes. Injected oocytes were incubated for 4 days to allow expression 
of the injected cRNA. Throughout this incubation period the oocytes were 
kept at a constant 18 °C in an incubator kept in the cold room, as this 
allowed a more accurate maintenance of temperature. This temperature 
was used as it has been found to be the optimal temperature for 
maintenance of A! laevis oocytes (Sigel and Minier, 2005). This is because 
fi’ogs are cold blooded animals so oocytes will die at higher temperatures. 
The Barths solution with calcium supplemented with penicillin and 
streptomycin was changed daily, and the same batch was used for all 
oocytes. Any dead or dying oocytes were removed to prevent 
contamination of the solution. At the end of the incubation period the 
oocytes were used for uptake studies.
3.2.5.4 Radiolabelled Transport Assays
Uptake assays were performed at room temperature (21 °C) and carried out 
in Ringers buffer pH 7.4 (106 mM NaCl, 24 mM NaHCOs, 5.4 mM KC1, 
1.2 mM CaCl2, 1 mM Na2HP04, 25 mM HEPES). Room temperature was 
used as all literature examined appeared to use around 21 °C and this was
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the standard procedure used within the group (Penny et ah, 1998, Carter et 
al.3 2000, Parker et al, 2000, Woodrow et ah, 2000, Joet et ah, 2003, 
Downie et ah, 2006, Downie et ah, 2008). Using tills temperature, rather 
than 37 °C, will affect the Un:ax but should not affect the Km of transport. 
The consequences of using this temperature are discussed in the critical 
assessment section of this chapter (section 3.4.1).
Assays were carried out using a final specific activity of 2 gCi/ml and the 
concentrations of substrates as follows: choline chloride 30.47 nM, 
glutamic acid 40 nM, isoleucine 33.34 nM, leucine 12.05 nM, methionine 
24.1 nM, pantothenic acid 40 nM, taurine 100 nM and folic acid 30nM), 
plus or minus unlabelled substrate. For each cRNA and substrate 10 
oocytes were incubated with the radiolabelled amino acid for 45 minutes. 
For the tune course experiments 10 oocytes were used for each time point. 
After incubation oocytes were washed in 4 consecutive baths of ice-cold 
Barths solution with calcium and placed in individual 1.5 ml 
microcentrifuge tubes. 1ml of scintillation fluid (Ultima Gold, Coming) 
was added to each tube, and the uptake measured using liquid scintillation 
counting ([3-counter, Wallac). Figure 3.1 shows a diagram of the X. laevis 
oocyte expression system and the preparation of the cRNA.
The initial group screening consisted of one round of experiments, with ten 
replicates of each data point measurement within each experiment. This
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screening was broken down into several parts. Groups 1 to 3 were 
investigated fust, due to the glycerol stocks of the individual genes in these 
groups arriving first, with the uptake of isoleucine, methionine, glutamic 
acid and folic acid measured on the same day, using oocytes horn the same 
hog that were injected on the same day and kept under identical 
conditions. Uptake of taurine, pantothenic acid, choline chloride and 
leucine was measured in a subsequent independent experiment, using 
oocytes horn the same hog that were injected on the same day and kept 
under identical conditions. Groups 4 to 6 were investigated in the same 
way as groups 1 to 3.
The screening of the individual genes in group 1 consisted of three to six 
independent experiments for each substrate tested, with ten replicates of 
each data point measurement within each experiment. In each experiment 
oocytes horn one hog were used. All subsequent experiments were carried 
out once, with ten replicates of each data point measurement within each 
experiment, using oocytes horn one hog per experiment.
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DNA library PFF1430c
Radiolabelled Transport Assay
Figure 3.1 Schematic illustration of theX laevis oocyte expression system.
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3.2.6 Statistical Analysis of Results
Non-parametric tests were used as the distribution of values within each 
group could not be detemoined to be Gaussian. Therefore the Mann- 
Whitney U test was used to establish whether there was a significant 
difference between the groups. Bonferroni correction of p values was 
earned out where multiple comparisons were made to reduce the chances 
of type I errors occurring. Significance was counted with p values of <0.05.
122
3.3 Results
3.3.1 Functional characterisation of the gene-specific cDNA 
Library
3.3.1.1 Screening of Grouped Gene Specific cDNA Libraiy
The gene-specific DNA libraiy of 48 genes was divided into 6 groups of 8 
genes for initial screening using the X. laevis oocyte expression system (see 
table 3.1 for group allocations) with the human reduced folate earner, 
hRFCl, added to group 1 as a positive control. Water-injected control 
oocytes, treated in the same way as cRNA injected oocytes, were included 
in the experiment to allow any endogenous transport by the oocytes to be 
accounted for. The uptake of methionine, isoleucine, leucine, glutamic 
acid, taurine, pantothenic acid and choline chloride for each cRNA group 
and water-injected control oocytes was measured after 45 minutes. These 
substrates were chosen due to the need for supplementation with them for 
parasite growth in vitro and so increasing the likelihood that the parasite 
will transport these substrates (Divo et al, 1985, Geary et al., 1985). The 
uptake of folic acid by oocytes injected with group 1 cRNA (with hRFCl 
present) and water-injected control oocytes was also measured after 45 
minutes. Uptake of a substrate was counted when there was significantly 
increased uptake by the group cRNA injected oocytes compared to the 
water-injected controls or else if a high number of positive oocytes (those
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oocytes in cRNA injected groups taking up obviously more than the mean 
water-injected control value) were observed even if significance between 
group and water control was lacking. This method was used as the 
variability between the 10 oocytes within a group was sometimes high 
making it difficult to prove any statistical difference between the cRNA 
injected oocytes and the water control oocytes.
The uptake of methionine by oocytes injected with group 1 cRNA was 
significantly higher than the water-injected oocytes, with a p value of 0.001 
(figure 3.2). Group 1 cRNA injected oocytes also appeared to take up more 
isoleucine than the water-injected controls, however this was not 
significant. Leucine was also taken up by group 1 cRNA injected oocytes 
more than the water-injected controls (p = 0.004). Group 4 cRNA injected 
oocytes showed a higher uptake of glutamic acid than the water-injected 
oocytes (p = 0.03). Group 4 cRNA injected oocytes also appeared to take 
up more methionine than the water-injected controls, however this was not 
significant. Group 1 and group 4 cRNA injected oocytes showed higher 
uptake of taurine than the water-injected oocytes, with respective p values 
of 0.008 and 0.0072. Pantothenic acid appeared to be taken up more by 
group 4 and group 6 cRNA injected oocytes than the water-injected control 
oocytes, with p values of 0.0005 and 0.001. No groups showed 
significantly more uptake of choline chloride than the water-injected 
controls oocytes. Folic acid was taken up by group 1 cRNA injected
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oocytes significantly more than by the water-injected control oocytes with 
a p value of 0.0003, suggesting that the injected cRNA was successfully 
expressed on the oocyte plasma membrane.
From these results it was decided to further investigate individual genes in 
groups 1, 4 and 6 as these showed the most uptake beyond that of the 
water-injected control oocytes.
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Figure 3.2. Uptake of radiolabelled methionine, isoleucine and leucine (A), 
glutamic acid, taurine and pantothenic acid (B), and choline chloride and folic 
acid (C) in water-injected and group 1 to 6 cRNA injected oocytes. Uptake was 
measured over 45 minutes in Ringers pH 7.4. Data shown is the central median 
line, with the box representing the central 50 % of data and the whiskers showing 
the data range, from 10 individual oocytes per data point (from the same frog for 
each data point). Significance values between water-injected and group cRNA 
injected oocytes were calculated using the Mann-Whitney U test and are 
Bonferroni corrected (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).
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3.3.1.2 Screening of Individual Genes from Group 1
The initial screening of grouped cRNA showed group 1 to take up 
methionine, iso leucine and taurine above the level of water-injected control 
oocytes (figure 3.2), so the individual genes in this group were further 
investigated using the X. laevis oocyte expression system. The 8 genes 
from the cDNA library in group 1 (table 3.1) were individually linearised 
and cRNA was synthesised in vitro from the linearised cDNA. In order to 
characterise these genes X. laevis oocytes were microinjected with the 
cRNA from individual genes and assayed for the uptake of radiolabelled 
methionine, isoleucine and taurine. There was no obvious increase in 
uptake of isoleucine or taurine by any of the oocytes injected with 
individual gene cRNA compared to water-injected oocytes (figure 3.3). 
Although there was no significant increase in uptake of methionine 
compared to water-injected oocytes there was an increased number of 
positive oocytes for those injected with gene 41 (MALI3P 1.210) and gene 
49 (PF11_0384) cRNA (figure 3.3).
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Figure 3.3. Uptake of radiolabelled methionine, isoleucine, and taurine in water 
and group 1 individual cRNA injected oocytes. Uptake was measured over 45 
minutes in Ringers pH 7.4. Data points shown are the averages from 3 to 6 
independent experiments (with each independent experiment carried out using 
oocytes from one frog), each with 10 oocytes per data point, and the median line 
shown.
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In order to further investigate the potential methionine transport by genes 
41 (MAL13P1.210) and 49 (PF11_0384) the effect of 0.2 mM unlabelled 
methionine on the uptake of [3H] methionine over 45 minutes was 
examined. The results (figure 3.4) showed no significant inhibitory effect 
by the unlabelled methionine, with no significant decrease in the uptake of 
methionine with the addition of unlabelled methionine observed for either 
41 (MAL13P1.210) or 49 (PF11_0384). Neither gene showed an increase 
in uptake of methionine compared to the water-injected oocytes. These 
results suggest that there may be no specific uptake of methionine by either 
gene. However, as only one concentration of unlabelled methionine was 
used it is not possible to conclude that there is no specific uptake as the 
concentration used may have been too low to measure any inhibition. The 
results presented in the following chapter showed that methionine uptake 
by free P falciparum trophozoites has a Km value of 1.13 ±0.16 mM and 
that there was no significant inhibition of methionine uptake with the 
addition of 2 mM of unlabelled methionine. Therefore, the concentration of 
unlabelled methionine added here was likely to be too low (far below the 
Km value and, therefore, the K\ value) to measure inhibition of transport by 
a P. falciparum encoded protein. As gene 49 (PF11_0384) showed very 
little uptake compared to the water-injected oocytes it was concluded that it 
was unlikely to be a transporter of methionine, and so work on this gene 
was stopped. However, as accumulation of methionine by gene 49 injected 
oocytes was significantly lower than the water-injected controls (p = 0.001)
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there is a possibility that this gene is involved in the efflux of methionine 
from the oocyte, and in doing so cancels out the oocytes endogenous 
methionine uptake transporters. This is interesting as Plasmodium parasites 
must release large quantities of the amino acids generated from 
haemoglobin digestion, although in the case of methionine only small 
quantities are found in haemoglobin. However, six previous experiments 
had shown accumulation of methionine by gene 49 injected oocytes to be 
slightly, but not significantly, higher than the control so it was decided not 
to further investigate possible methionine efflux by gene 49.
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Figure 3.4. Uptake of radiolabelled methionine with and without 0.2 mM 
unlabelled methionine in water and gene 41 and 49 cRNA injected oocytes. 
Uptake was measured over 45 minutes in Ringers pH 7.4. Data shown is the 
central median line, with the box representing the central 50 % of data and the 
whiskers showing the data range, from 10 individual oocytes per data point (from 
the same frog). Significance values shown are between water-injected and other 
results. P values were calculated using the Mann-Whitney U test and are 
Bonferroni corrected (* = p < 0.05, ** = p < 0.01).
There was a decrease in the uptake of methionine by water-injected 
oocytes when unlabelled methionine was added (p = 0.025) (figure 3.4). 
One potential reason for the inhibition of [ H] methionine uptake by 
unlabelled methionine in the water-injected control oocytes is that there is 
an endogenous low-capacity high-affinity transporter which has reached
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saturation at the concentrations used. As this endogenous transport could 
have been masking any methionine transport by gene 41 (MAL13P1.210) 
a time course experiment was carried out to find out if there was a time 
point where the transport of methionine by gene 41 (MAL13P1.210) was 
significantly higher than uptake by the water-injected oocytes. Uptake of 
methionine by gene 41 (MAL13P1.210) cRNA and water-injected oocytes 
was measured at 10, 20, 30, 45 and 60 minutes (figure 3.5). There was no 
significant increase in uptake of methionine by gene 41 (MALI3P1.210) 
cRNA injected oocytes compared to water-injected oocytes at any time 
point, and so work on this gene was discontinued.
Time (min)
■ Water 
* 41
Figure 3.5. Time course uptake of radiolabelled methionine in water-injected and 
gene 41 cRNA injected oocytes. Data shown is the median ± standard error from 
10 individual oocytes for each time point (from the same frog).
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3.3.1.3 Screening of Individual Genes from Group 4
The results from the initial screening of grouped cRNA showed group 4 to 
take up glutamic acid, taurine and pantothenic acid above the level of 
water-injected control oocytes (figure 3.2), so the individual genes in this 
group were further investigated using the X. laevis oocyte expression 
system. The genes in group 4 (table 3.1) were individually linearised and 
cRNA synthesised in vitro. In order to characterise these genes X. laevis 
oocytes were microinjected with the cRNA from individual genes and 
assayed for the uptake of radiolabelled glutamic acid, taurine and 
pantothenic acid. The uptake of taurine and pantothenic acid was higher in 
gene 98 (PF10_0317) cRNA injected oocytes than in water-injected 
oocytes, with p values of 0.0021 and 0.0007 respectively (figure 3.6). Gene 
95 (PF10_0276) cRNA injected oocytes showed a lower accumulation of 
glutamic acid than water-injected oocytes. This is interesting as 
Plasmodium parasites must release large quantities of the amino acids 
generated from haemoglobin digestion, therefore, amino acid efflux 
transporters are physiologically important. Gene 93 (PFI0800c) cRNA 
injected oocytes showed more uptake of glutamic acid than water-injected 
oocytes, p = 0.004 (figure 3.6). However, the uptake of glutamic acid by 
gene 93 (PFI0800c) and the efflux of glutamic acid by gene 95 
(PF10_0276) were not further investigated due to time constraints.
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Figure 3.6. Uptake of radiolabelled glutamic acid, taurine and pantothenic acid in 
water-injected and individual group 4 cRNA injected oocytes. Uptake was 
measured over 45 minutes in Ringers pH 7.4. Data shown is the central median 
line, with the box representing the central 50 % of data and the whiskers showing 
the data range, from 10 individual oocytes per data point (from the same frog). 
Significance values between water-injected and cRNA injected oocytes were 
calculated using the Mann-Whitney U test and are Bonferroni corrected (** = p <
0.01, *** = p <0.001).
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The uptake of taurine and pantothenic acid by gene 98 (PF10_0317) was 
further investigated by examining the effect of the addition of 0.2 mM 
unlabelled taurine and pantothenic acid on [3H] taurine and [3H] 
pantothenic acid over 45 minutes. The effect of botli unlabelled taurine and 
pantothenic acid on [3H] taurine and [3H] pantothenic acid was investigated 
in order to see if these substrates are transported via the same route; as 
inhibition of the radio labelled substrate would be inhibited by the addition 
of either of the unlabelled substrates if they do use the same route of 
uptake. Unlike the previous experiment these results showed no increase in 
uptake of [3H] taurine or [3H] pantothenic acid by gene 98 (PF10_0317) 
cRNA injected oocytes compared to water-injected controls (figure 3.7). 
There does appear to be specific uptake of pantothenic acid by water- 
mjected oocytes as the addition of 0.2 mM unlabelled pantothenic acid 
significantly reduced the uptake of [ H] pantothenic acid (figure 3.7). One 
potential reason for the inhibition of [3H] pantothenic acid uptake by 
unlabelled pantothenic acid in the water-injected control oocytes is that 
there is an endogenous low-capacity high-affinity transporter which has 
reached saturation at the concentrations used. The results also showed no 
significant inhibitory effect on taurine uptake by unlabelled taurine for 
either gene 98 cRNA injected oocytes or water-injected oocytes. However, 
as only one concentration of unlabelled taurine was used it is not possible 
to conclude that there is no specific uptake as the concentration used may 
have been too low to measure any inhibition. Unlabelled taurine at 200 pM
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is likely to be well below the predicted Km and Ki (the inhibition constant, 
the inhibitor concentration required to produce half maximal inhibition) 
values of taurine transport. This would mean that competitive inhibition of 
taurine transport would not be observed with a decrease in accumulation of 
[3H] taurine, even if specific transport was occurring. In this case the 
competitive inhibitor is the same as the substrate being investigated, so the 
Ki value is likely to be similar to the Xm value (Van Winkle, 1999).
Due to the fact that there appeared to be no specific uptake of either 
substrate by gene 98 (PF10_0317) it was decided not to carry out any 
further studies into this gene. This decision was taken as the two results 
(figures 3.6 and 3.7) did not show consistent uptake of pantothenic acid or 
taurine by gene 98 (PF10_0317) and also due to tune constraints. 
However, further experiments are necessary before it is possible to be 
confident that this gene does not encode a transporter for these substrates, 
especially as there was no proof of heterologous expression in these 
experiments.
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Figure 3.7. Uptake of radiolabelled pantothenic acid (A) and taurine (B) plus 
competition with 0.2mM unlabelled pantothenic acid (Cold P) and taurine (Cold 
T) in water-injected and gene 98 cRNA injected oocytes. Uptake was measured 
over 45 minutes in Ringers pH 7.4. Data shown is the central median line, with 
the box representing the central 50 % of data and the whiskers showing the data 
range, from 10 individual oocytes per data point (from the same frog). 
Significance values between water-injected and cRNA injected oocytes were 
calculated using the Mann-Whitney U test and are Bonferroni corrected (** = p <
0.01, *** = p <0.001).
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3.3.1.4 Screening of Individual Genes from Group 6
The results from the initial screening of grouped cRNA showed oocytes 
injected with group 6 cRNA to take up pantothenic acid above the level of 
water-injected control oocytes (figure 3.2), so the individual genes in this 
group were further investigated using the X laevis oocyte expression 
system. The genes in group 4 (table 3.1) were individually linearised and 
cRNA synthesised in vitro from the linearised cDNA. In order to 
characterise these genes for pantothenic acid transport X. laevis oocytes 
were micro injected with the cRNA from individual genes and assayed for 
the uptake of radiolabelled pantothenic acid for 45 minutes. No uptake was 
observed for any of the genes and due to time constraints no investigation 
into the uptake of taurine was carried out (figure 3.8).
Pantothenic Acid
tP <?> oP*
Figure 3.8. Uptake of radiolabelled pantothenic acid in water-injected and 
group 6 individual cRNA injected oocytes. Uptake was measured over 45 
minutes in Ringers pH 7.4. Data shown is the central median line, with the 
box representing the central 50 % of data and the whiskers showing the data 
range, from 10 individual oocytes per data point (from the same frog).
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3.3.2 Cloning of PFF1430c, PFL0420w, PFL1515c,
PFB0435c, PFE0775c, PF11_0334
The initial PCR of PFF1430c, PFL0420w, PFL1515c, PFB0435c, 
PFE0775c and PFF 0334 from cDNA was carried out using Platinum'' Pfx 
DNA Polymerase (Invitrogen) and using the cycling conditions given in 
section 3.2.4.1. cDNA synthesised from RNA isolated from mixed stage 
cultures was used as gene expression has been shown to vary slightly 
between these genes (Martin et ai, 2005). This initial amplification attempt 
did not show any bands of the correct size for the six genes of interest but 
did a band was observed for the PfCRT control (figure 3.9).
Figure 3.9. Agarose gel visualisation of PCR products from the initial PCR 
reaction.
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In order to achieve amplification several methods were attempted to 
optimise the PCR reaction. The extension time was increased in order to 
improve amplifaction and gradient PCR (with and without PCRX enhancer) 
was carried out but both of these were unsuccessful in amplifying any of 
the six genes of interest. As PFL0420w does not contain any exons an 
attempt at amplifying it using genomic DNA with three different 
polymerases was carried out. This resulted in a band of the correct size 
after amplification with Platinum" taq DNA Polymerase (Invitrogen) when 
visualised by agarose gel electrophoresis (figure 3.10).
Figure 3.10. Agarose gel visualisation of PCR products from amplification of 
PFL0420w or PfCRT with Platinum* Pfx DNA Polymerase, Platinum* taq DNA 
Polymerase or Platinum* taq DNA Polymerase High Fidelity.
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Touchdown PCR was used in a final attempt to amplify PFF1430c, 
PFL0420w, PFL1515c, PFB0435c, PFE0775c and PF11 0334 from 
cDNA. This was successful for PFF 1430c with a band of the correct size 
visualised by agarose gel electrophoresis (figure 3.11).
3000 bp —
2000 bp— 
1650 bp —
1000 bp—
Figure 3.11. Agarose gel visualisation of PCR products from touchdown PCR.
PFF 1430c was amplified using a proofreading enzyme so the resulting 
PCR product lacked 3’ A-overhangs necessary for cloning so these were 
recreated by dA-tailing of the PCR product. The resulting dA-tailed 
PFF 1430c and the PFL0420w amplified from genomic DNA were ligated
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into the pCR II TOPO® vector and transformed into One Shot® TOP 10 
competent cells. Overnight cultures from individual white colonies on LB 
agar plates were made and the plasmids prepared from these cultures. A 
restriction digest with EcoRI was used to check for the presence of insert 
and agarose gel electrophoresis of the digest product showed that 
PFF1430cjpCR®II-TOPO® had been successfully ligated but that 
PFL0420w_ pCR®II-TOPO® had not been. Another restriction digest, this 
time using EcoRV, was used to determine the orientation of the PFF 1430c 
insert in the pCR®II-TOPO® vector. Visualisation by agarose gel 
electrophoresis showed that the orientation was correct and so this was 
used for subcloning into the pKSM Xejwpus optimised vector.
Five rounds of subcloning were attempted with varying molar ratios, 
different ligation conditions and using a different combination of 
restriction enzymes to digest the pKSM vector and PFF1430cjpCR®II- 
TOPO®. As none of these resulted in successful ligation it was decided to 
use a synthesised gene for further work on PFF1430c, and a codon- 
optimised PFF 1430c flanked by the 5’- and 3’-untranslated regions of the 
Xenopus p-globin gene was synthesised (GenScript Corp., Piscataway, NJ). 
Several other people in the group also had difficulty subcloning 
successfully into the pKSM vector and the codon-optimised synthesised 
genes were ordered together.
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3.3.3 Functional characterisation of PFF1430c
PFF1430c has been designated a putative amino acid transporter but has 
not yet been functionally characterised (Martin et al., 2005). Subcloning of 
this gene into the optimal vector for X. laevis expression, KSM 
pBluescript, was unsuccessful. To address this problem a codon-optimised 
PFF 1430c flanked by the 5’- and 35-untranslated regions of the Xenopus (3- 
globin gene was synthesised and functionally characterised (GenScript, 
USA). In order to characterise tins gene X. laevis oocytes were 
microinjected with in vitro transcribed cRNA from the cloned plasmid 
insert of PFF1430c and assayed for the uptake of radiolabelled methionine, 
isoleucine, leucine, glutamic acid, taurine and pantothenic acid. PFF1430c 
cRNA injected oocytes showed no increase in uptake of methionine, 
isoleucine, leucine, glutamic acid, taurine and pantothenic acid compared 
to water-injected oocytes (figure 3.12).
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Methionine Isoleuclne
Leucine Gutamlc Acid
Taurine Pantothenic Acid
Figure 3.12 Uptake of radiolabelled methionine, isoleucine, leucine, glutamic 
acid, taurine, pantothenic acid and choline chloride in water-injected and 
PFF1430c cRNA injected oocytes. Uptake was measured over 45 minutes in 
Ringers pH 7.4. Data shown is the central median line, with the box 
representing the central 50 % of data and the whiskers showing the data range, 
from 10 individual oocytes per data point, (from the same frog).
As PFF 1430c shows some homology to system N amino acid transporters 
the uptake of glutamine was assayed, as this is the classical substrate for 
system N (Barker and Ellory, 1990). A time course experiment was used in 
order to be able to identify if there was any time dependent uptake and also
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so that the time point where the greatest potential difference between 
PFF 1430c cRNA injected oocytes and water-injected oocytes could be 
identified. There was no increase in uptake of glutamine by PFF 1430c 
cRNA injected oocytes compared to the water-injected oocytes over all 
time points (figure 3.13).
Glutamine Time Course
Time (min)
■ Water 
* PFF1430C
Figure 3.13. Time course uptake of radiolabelled glutamine in water-injected 
and gene PFF 1430c cRNA injected oocytes. Data shown is the median ± 
standard error from 10 individual oocytes per time point (from the same frog).
The lack of uptake of any of the amino acids tested with PFF 1430c is 
surprising as this gene shows homology to the AAAP family of amino acid 
transporters and similarity to system N amino acid transporters.
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3.4 Discussion
Amino acid transport is important to the malaria parasite as it has been 
shown in vitro that the presence of certain amino acids is required for 
growth (Divo et aL, 1985). Currently there are only six genes annotated as 
putative amino acid transporters in the P. falciparum genome, and none of 
these have yet been functionally characterised (Martin et al, 2005). As it is 
possible that there are more, as yet undiscovered, P. falciparum amino acid 
transporters a gene-specific DNA library of forty eight genes was created. 
Genes were chosen based on having more than three trans-membrane 
domains and lacking signal peptides. In this chapter the gene-specific DNA 
library and PFF1430c (one of the putatively annotated amino acid 
transporters) were functionally characterised for amnio acid transport using 
the X. laevis oocyte expression system. The original intention was also to 
characterise the other five putatively annotated amino acid transporters 
(PFL0420w, PFL1515c, PFB0435c, PFE0775c and PF11_0334). 
However, attempts to amplify these genes were not successful and so no 
further work was earned out on them.
The X. laevis oocyte expression system was chosen over other 
heterologous expression systems as it is a well characterised eukaryotic 
system, normally produces faithful and efficient translation of exogenous 
RNA and it has previously been used successfully to study several P.
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falciparum transporter proteins (Joet et aL, 2003, Martin et al., 2009, 
Downie et aL, 2007, Downie et al, 2006, Krishna et al., 2001b). Initial 
screening of the gene-specific DNA library was carried out with the genes 
collected into groups of 8. Tills allowed more rapid identification of any 
potential transporters and saved time. Genes in groups that showed 
evidence of transport were then studied individually. From the initial 
grouped screening there was evidence of transport of methionine, 
isoleucine, taurine, glutamic acid and pantothenic acid. However, when the 
individual genes were studied no genes responsible for this transport were 
definitively identified. Characterisation of the PFF1430c gene showed no 
evidence of transport of glutamic acid, glutamine, isoleucine, leucine, 
methionine, taurine, pantothenic acid or choline chloride.
The lack of any conclusive evidence of amino acid transport by the genes 
in the gene-specific cDNA library or the putative amino acid transporter 
PFF1430c could be due to several factors. One could be that simply none 
of the genes in the cDNA library or PFF1430c are transporters of the 
amino acids tested; however there are too many other factors to conclude 
that this is the case. The fact that very low substrate concentrations were 
used erroneously may not have allowed detectable uptake by scintillation 
counting even if any of the proteins expressed are amino acid transporters. 
This problem is discussed further in the critical assessment section below. 
Only one round of expression was canied out for the group screening, and
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along with the multiple comparisons carried out this could have resulted in 
false positive results. Multiple comparisons increase the familywise error 
rate and, therefore, increase the chance of type I errors occurring. This 
would mean that it is possible that in some cases the null hypothesis could 
be erroneously rejected (i.e. the uptake of substrate by cDNA injected 
oocytes was falsely identified as being significantly different to uptake by 
water-injected control oocytes). The Bonferroni correction was used 
throughout this chapter where multiple comparisons were made in order to 
correct for this error.
Another potential reason for transport being observed in the group stage 
but not from individual gene expression is that transport activity could 
have been dependent on the presence of co-factors or heterodimers within 
the groups. An example of this is the heteromeric system L transporter unit 
which is composed of a heavy (4F2hc) and light chain (LAT1) heterodimer 
(Wagner et al., 2000a, Broer et al., 1998, Ritchie and Taylor, 2001). Amino 
acid transporters in the TRAP-T family and ABC superfamily are also 
composed of multiple subunits (Saier, 2000a).
There are limitations within the X. laevis oocyte expression system 
including variation in oocyte quality between different frogs, which could 
affect the reproducibility of results, and the potential for endogenous 
transporters to mask any transport activity of the inserted protein (Taylor et
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aL, 1996). The characteristics of endogenous X laevis oocyte transport of 
folic acid, leucine glutamic acid and glutamine are shown in table 3.3 as 
these are the only substrates used in this study for which detailed 
characterisation has been carried out. Leucine, glutamic acid and glutamine 
are all transported via a Na+ dependent system (Belle et al., 1976, Taylor et 
al., 1989, Steffgen et al., 1991, Marciani et al., 1998). The transport of 
glutamine appears to be via the Na+ dependent system B0,+ and this is the 
only well documented amino acid transporter definitely found in X. laevis 
oocytes (Taylor et al, 1989, Van Winkle, 1993). In X. laevis oocytes 
system B0,+ appears to transport a broad range of zwitterionic and cationic 
amino acids (Van Winkle, 1993). Glutamine transport has been shown to 
be inhibited by BCH and a range of amino acids including alanine (table 
3.2) (Taylor et al, 1989). The addition of these to the glutamine transport 
assays might have allowed reduction of the endogenous transport 
background. This was not used in the experiments carried out in this 
chapter but would have been a very useful addition.
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Substrate /<m inX. laevis oocytes Characteristics
Folic Acid 42 ± 7 nM (Lo ef al, 1991) Na* independent, highly pH dependent 
(severely inhibited below pH 6.5)
Inhibited by anion transport inhibitors 4,4'- 
diisothiocyanatostilbene-2,2'-disulfonate 
(DIDS) and 4-acetamido-4'- 
isothiocyanostilbene-2,2'-disulfonate (SIDS) 
(Loetal.,1991)
Leucine 57 + 21 nM (Marciani eta/., 1998) Na* dependent
Partially inhibited by ouabain, an inhibitor of 
membrane ATP-ases (Belle etaf., 1976)
Glutamic Acid Two saturable components, one low 
affinity (Km 9 mM) and one high 
affinity (Km 0.35 pM) (Steffgen et al,, 
1991)
Na+ dependent (Steffgen et al,. 1991)
Glutamine 0.12 + 0.02 mM (Taylor et a/., 1989) Na+ dependent
Inhibited by L-alanine, D-alanine, L- 
asparagine and L-arginine (~60 % inhibition 
at 1 mM); L-histidine, L-valine and L-glycine 
(25-40 % inhibition at 1 mM); L-serine, L- 
lysine, L-phenylalanine and L-glutamate (40- 
55 % inhibition at 10 mM); BCH (50 % 
inhibition at 10 mM) (Taylor et al., 1989)
Table 3.3. Substrates used in this study for winch the transport characteristics mX. 
laevis oocytes are known.
3.4.1 Critical Assessment
To address the failure of the cloning efforts, one step RT-PCR, using gene- 
specific primers, could have been attempted. The reason for performing 
reverse transcription using random hexamers was to increase versatility as 
the resulting cDNA could then be used for multiple PCRs. Carrying out
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two step RT-PCR also allowed optimisation of the two steps without 
compromising one for the other. Using random hexamers to prime the 
reverse transcription could, however, have resulted in the generation of a 
very small amount of cDNA of the genes of interest which would have 
made amplification of these genes by PCR difficult. This potential problem 
could have been remedied by using gene-specific primers.
Subcloning into the pKSM X. laevis vector has been found to be 
problematic by various other researchers in our group. A possible way 
around these problems would have been to use an alternative X. laevis 
expression vector as used by other groups, for example the pBSTA plasmid 
(Very and Gaymard, 1995) and the pXBG plasmid (Preston et al,, 1992, 
Francis et al., 2000). A codon-opthnised synthesised PFF1430c, flanked by 
the 5’- and 3’-untranslated regions of the X. laevis (3-globin gene, was 
created instead of hying a different vector in order to save time.
Ideally, codon optimisation would have been carried out for all genes 
rather than just for PFF 1430c. The reason it was not carried out for the 
cDNA library was an issue of cost as the cDNA library was already in the 
process of being created when this project began. For PFF1430c creating a 
codon-optimised synthesised gene was deemed to be worth the expense as 
it is amiotated as a potential amino acid transporter (Martin et al., 2005) 
and was created during the course of this project. Xenopus 3’ and 5’ (3-
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globin UTR flanking sequences were added to the codon-optimised 
synthesised PFF1430c as it was simple to do so at the time (no subcloning 
would be required) and previous studies have shown that they increase 
expression (Woodrow et al., 2000). Ideally these flanking sequences would 
have been incorporated into the genes in the cDNA library but the time it 
would have taken to subclone all 48 genes into the pKSM vector with the 
Xenopus flanking sequences would have made it veiy difficult to carry out 
in the time flame of this thesis. This is a weakness in the methodology used 
as Woodrow et al., (2000) noted that when Xenopus (3-globin UTR 
flanking sequences were added to the P. falciparum hexose transporter 
(PfHT) ORF uptake of glucose was increased compared to PfHT ORF 
alone.
The temperature used for the radiolabelled uptake assays carried out in this 
chapter was 21 °C. Tins temperature was chosen mstead of 37 °C for 
practical reasons, as it was much simpler to use room temperature (which 
was measured to be consistently 21 °C). Temperature is an important factor 
affecting transporters and enzymes, however it usually only affects the 
Umax but not the Km of transport. The Km gives important information on 
the affinity of the transporter for the substrate, with a relatively high Km 
signifying low affinity and a relatively low Km signifying high affinity. 
The Umax gives less infonnation on the nature of the transport, but is useful 
if the transport is to be modelled. Temperature changes can affect the lipid
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environment in which transporters reside, as the lipid bilayers that make up 
cell membranes undergo phase transitions with changes in temperature. 
Therefore, this can have an indirect effect on membrane transporters 
(Carmthers and Melchoir, 1988). In order to comprehensively characterise 
a transporter, reaction parameters need to be investigated at a range of 
temperatures. This can yield information on the way the transporter 
operates at different temperatures which can give insights into the nature of 
the transporter. Results gathered Rom experiments earned out over a range 
of temperatures can be plotted on an Arrhenius plot. This is a plot of the 
logarithmic value of the rate constant, K, versus the inverse temperature, 
1/T, which results in a negatively sloped line that is equal to the negative 
activation energy divided by the gas constant, R. The activation energy 
(Ea), the minimum energy required before a reaction can occur, can then be 
calculated and this can give infonnation on the nature of the transporter 
being investigated. Channels typically have Ea values of 4 to 8 kcal.mol'1 
(Hille, 1978, Maurel et aL, 1994, Chraibi and Horisberger, 2002) and 
earners typically have Ea values of 9 to 40 kcalmol'1 (Loo et aL, 1999, 
Zhang and Kaback, 2000, Derbyshire et al, 2008, Martin et ah, 2008), 
Transport by a carrier typically results in a high Ea as the canier protein 
must undergo a conformational change to translocate the substrate across 
the membrane. The lower Ea for transport via a channel is due to the fact 
that channel proteins do not undergo as extensive conformational changes 
as canier proteins and are less temperature dependent. This technique has
155
been utilised to analyse whether the chloroquine resistance conferring form 
of PfCRT (PfCRTCQR) behaves like a channel or carrier when expressed in 
X. laevis oocytes (Summers and Martin, 2010). PfCRTc<^R was shown to 
have an Ea of 41.3 kcalmof1 for transport of chloroquine, suggesting that a 
substantial conformational change occurs during the translocation of 
chloroquine and supporting the theory that PfCRT is a carrier. If any 
definite uptake had been observed by the genes in the cDNA library, or 
PFF1430c, then further characterisation on the temperature dependence of 
transport would have been extremely useftd for determining the nature of 
transport.
A major problem with the experimental work described in this chapter is 
that very low concentrations of substrates were used erroneously in the 
uptake experiments. This error was not realised in time to repeat the 
experiments in this chapter but the following work in this thesis does make 
use of physiological concentmtions of substrates. The substrate 
concentrations used, compared to the concentrations found in human 
plasma are shown in table 3.4, and in all cases except folic acid the 
concentrations used in this study are much lower. This may have resulted 
in uptake that was insufficient to be detected by scintillation counting and 
so makes it difficult to draw any conclusions. Radiolabelled uptake assays 
should have been earned out using concentrations of substrates close to or 
just below the expected Km values. The use of only one, relatively low,
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concentration of unlabelled substrate (0.2 inM) in the inhibition 
expemnents may also have been too low to measure inhibition of transport 
by a P. falciparum encoded protein, as this concentration may be well 
below the Km and K\ values for the transport activity under investigation. 
This limitation would result in a lack of inhibition being noted: the low 
concentrations used would mean no competitive effect between the 
radiolabelled and imlabelled substrates would be observed by a decrease in 
accumulation of the radiolabelled substrate. If any P. falciparum encoded 
protein investigated does transport the substrates tested, inhibition by 
unlabelled substrate would only be observed when the substrate 
concentration becomes high enough to allow competition between the 
radiolabelled and unlabelled substrate to be observed. This would correlate 
with the results obtained in the next chapter where it was observed that 
inhibition of radiolabelled methionine uptake by the free P. falciparum 
parasite was only achieved when 10 mM unlabelled methionine was added. 
This should have been further investigated by repeating the uptake 
experiments with higher concentrations of unlabelled substrates as this 
would have allowed saturation to be reached. The inhibition of 
radiolabelled methionine uptake by unlabelled methionine in the water- 
injected control oocytes could be explained by the presence of an 
endogenous low-capacity high-affinity transporter which has reached 
saturation at the concentrations used.
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Substrate
Concentration 
Used In This 
Study
Physiological 
Range in 
Human Plasma Km in Plasmodium or other organism
Folic Acid 30 nM 0.5 nM X. Laevis oocytes - 42 ± 7 nM (Lo etal., 
1991)
Methionine 24.1 nM 16 - 30 tiM P. falciparum trophozoites (free) - 
1.132 ± 0.16 mM (from this thesis, chapter 
4)
1.6 ± 0.3 mM (Cobbold ef a/., 2010)
Isoleucine 33.34 nM 42-100 pM Human RBCs-10 ± 1 mM
P. falciparum trophozoites (free) - 0.93 ± 
0.26 pM (Martin and Kirk, 2006)
Leucine 12.05 nM 66-170 pM Human RBCs -12.9 mM (Young at al., 
1980)
Glutamic Acid 40 nM 18-98|JM Leishmania amazonensis - 0.59 ± 0.04 
mM (Paesefa/., 2008)
Glutamine 45.46 nM 390-650 ji M Human RBCs - 25 ± 3.5 pM (Eliory et al., 
1983)
Taurine 100 nM 45 -130 pM Anguilla japonica (eel) RBCs - 22.6 ± 2.3 
mM (Fincham atal., 1987)
Pantothenic Acid 40 nM 1.57-2.66 pM P. falciparum trophozoites (free) - 22.6 ± 
2.3 mM (Saliba and Kirk, 2001)
Choline Chloride 30.47 nM 10 - 20 gM P. falciparum trophozoites (free) - 25 ±
3.5 [aM (Biagini etal., 2004)
Table 3.4. Substrates concentrations used in this study, their concentrations in 
human plasma and the Km of transport in Plasmodium or other cells.
An issue in the experimental design of the group screening experiments is 
that they were broken down into sections. This was done by first 
investigating groups 1 to 3 then groups 4 to 6, and splitting the uptake 
experiments into two (with one experiment for isoleucine, methionine, 
glutamic acid and folic acid, and another for taurine, pantothenic acid,
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choline chloride and leucine). The reasons why groups 1 to 6 were 
investigated first were because the glycerol stocks of the individual genes 
in these groups arrived first and it was decided that it was simpler to start 
with a more manageable number of groups of cRNA. However, this means 
that variability between oocytes from different frogs and any slight 
changes in the assay conditions could have confounded the results. 
Carrying out the group screening all in one experiment would, however, 
have been veiy difficult due to the number of oocytes to be injected and the 
large number of oocytes to process during the transport assays. A better 
option would have been to wait until the glycerol stocks for all the 
individual genes in the cDNA library had arrived before starting the 
screening. This would have allowed all the groups to be investigated for a 
substrate at the same time, minimising any confounding factors.
The positive control used in the group screening stage was the human 
reduced folate carrier 1 (liRFCl). This did show significantly increased 
uptake of folic acid compared to water-injected controls and so provided 
proof that the expression system was working. However, the same 
problems are found with this result as the other results in the group 
screening stage; specifically that this experiment was only earned out once 
so there is a potential for statistically spurious results to be generated. 
Inclusion of a positive control in subsequent experiments would have also 
been extremely useful and should have been included. Ideally a known
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amino acid transporter would have been included as a positive control but 
hRFCl was available within our group at the time so it was used instead. 
Using an amino acid transporter as a positive control would have provided 
an opportunity for the problem with using very low substrate 
concentrations to be noticed early enough to have tune to correct the error. 
There are low physiological concentrations of folic acid in human plasma 
(0.5 nM) and as the concentration of [3H] folic acid used in this experiment 
was 30 nM it did not show up the issue with substrate concentrations.
In this study the expression of proteins resulting from the injection of 
cRNA was not checked. To have assurance that the proteins were being 
expressed in the X laevis oocytes the expression should have been checked 
using specific antibodies and visualised with Western blotting or 
fluorescence microscopy, or by RT-PCR on oocytes after injection and 
incubation. This was planned to be carried out if reproducible transport 
was observed for any gene, but if it had been carried out at the start it 
would have identified any problems with the expression. Using one of 
these techniques to test expression of just one or two proteins would have 
given some proof that the expression system was working and should have 
been carried out.
Further repeats of most of the experiments in this chapter are required to 
confirm the results found, as only the screening of the individual genes in
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group 1 was repeated more than once. This is a major flaw as it is difficult 
to draw conclusions based on the reliability of individual experiments. 
However, any repeats of the radiolabelled transport assays would only be 
useful if they took into account the problem of using too low substrate 
concentrations and incorporated robust controls. Further work to 
investigate the uptake of taurine and pantothenic acid by gene 98 
(PF10_0137), the uptake of glutamic acid by gene 93 (PPFIOSOOc), and the 
efflux of glutamic acid by gene 95 (PF10_0276) is also required. Gene 98 
(PF10_0137) significantly increased uptake of taurine and pantothenic acid 
in one experiment (figure 3.6) but no increase in uptake was observed in 
the following experiment (figure 3.7). As these results did not show 
consistent uptake of these substrates by oocytes injected with the cRNA of 
this gene it was decided not to continue working on this gene due to time 
constraints. The lack of further work on gene 93 (PFFIOSOOc) and gene 95 
(PF10 0276) was also due to time constraints. However, a more critical 
approach to the X. laevis oocyte work should have been taken: correct 
substrate concentrations used, a positive control included and the 
expression of the heterologous proteins checked. This would have given 
more credibility to the results obtained and allowed more reliable 
identification of any transporters for the substrates tested.
The intraerythrocytic P. falciparum parasite digests up to 65 % of the host 
cell’s haemoglobin, but only up to 16 % of the amino acids released from
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this degradation are utilised by the parasite (Krugliak et al, 2002). This 
means that the parasite must mediate the disposal of waste amino acids 
generated by haemoglobin digestion. In this study the potential for some of 
the genes in the gene-specific cDNA library to encode amino acid efflux 
transporters was not investigated. These should have been further studied 
as amino acid efflux transporters are physiologically important and could 
be potential drug targets.
A problem with the gene-specific cDNA library used in this study is that 
only twenty of the forty eight genes have six or more trans-membrane 
domains. Only three amino acid transporter gene families, out of seventeen 
found in eukaryotes, have fewer than ten trans-membrane domains (Saier, 
2000b). These are the MHS, LysE and PLM families. The characteristics 
of these and other amino acid transporter gene families are discussed in 
section 1.4.5. This indicates that the work carried out on the cDNA library 
would have been better focused to the twenty genes with six or more trans­
membrane domains.
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CHAPTER 4
Methionine Transport in the P. falciparum
Parasite
4.1 Introduction
The use of the X. laevis oocyte expression system in the previous chapter 
did not lead to the functional characterisation of any P, falciparum amino 
acid transporters. A more targeted approach was, therefore, taken to study 
methionine transport by the P. falciparum parasite. Methionine is required 
for protein synthesis as well as for the ubiquitous methylation of proteins, 
nucleic acids and lipids. In the malaria parasite there is a functioning 
methionine synthase, allowing homocysteine to be converted to methionine 
with the addition of a methyl group from the folate product 5-MTHF 
(Krungkrai et al, 1989a, Asawamahasakda and Yuthavong, 1993). 
Through this process the methionine cycle is linked to the folate pathway, 
as the demethylation of 5-MTHF produces THF, which is recycled back 
through the folate one-carbon metabolism enzymes (see section 1.3.3 for 
more details). Despite the presence of a functioning methionine synthase 
an exogenous source of methionine has been shown to be necessary for 
parasite growth, as discussed in section 1.4.4 (Divo et al., 1985). The 
characterisation of the transporter(s) responsible for the uptake of
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exogenous methionine may provide useful information for the 
identification of new drug targets, as inhibition of methionine influx could 
potentially starve the parasite of an essential amino acid.
The membrane transport of methionine into human RBCs is known to be 
facilitated by the Na+ independent system L (Winter and Christensen, 
1964, Rosenberg, 1982, Barker and Ellory, 1990, Tunnicliff, 1994). Until 
very recently the transport of only one amino acid, isoleucine, had been 
characterised in P, falciparum parasites (Martin and Kirk, 2007). In this 
chapter the methionine transport in P. falciparum parasites has been 
characterised. The objectives of the work earned out in this chapter were to 
discern any changes in methionine transport by RBCs when infected with 
P. falciparum parasites, to characterise the kinetics of methionine transport 
by flee P. falciparum parasites and to further characterise this transport 
using transport inhibitors and inhibition with other amino acids.
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4.2 Materials and Methods
4.2.1 Parasite Cultivation
The P. falciparum clone 3D7, originating from an airport malaria case 
at Schiphol, the Netherlands, was used for all experiments described in 
this chapter. Cultivation was carried out following the modified method 
of Trager and Jensen as described in section 2.1 (Trager and Jensen, 
1976).
4.2.2 Transport Assays In P. falciparum Parasitised Red 
Blood Cells
4.2.2.1 Magnetic Separation of Trophozoite Stage P. falciparum 
Infected Red Blood Cells
Cultures of trophozoite stage P. falciparum infected RBCs at 
approximately 5 % parasitaemia or above were used. Trophozoites were 
concentrated to 40 % parasitaemia using a VarioMACS magnetic 
separation unit (Miltenyi Bio tec, Germany). The parasite cultures were 
centrifuged at 805 x g for 5 minutes, the supernatant discarded and the 
pellet resuspended in solution 1 (2 % BSA and 20 mM glucose in PBS). 
The resuspended pellet was then passed through the VarioMACS column 
attached to the magnetic separation unit and washed thoroughly with 
solution 1. The bound trophozoites were eluted with solution 1 and washed
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3 times with Ringers buffer pH 7.4 (106 mM NaCl, 24M m NaHCOs, 5.4 
mM KC1,1.2 mM CaCl2, 1 mM Na2HP045 0.8 mM MgCb, 25 mM HEPES 
and 10 mM glucose). The cell density was then estimated using an 
Improved Neubauer haemo cytometer.
4.2.2.2 Methionine Uptake in P. falciparum Infected Red Blood Cells 
and Uninfected Red Blood Cells
Trophozoite stage P. falciparum infected RBCs at 40 % parasitaemia (from 
magnetic separation) or uninfected RBCs, that had been maintained in 
culture under the same conditions as the infected RBCs, were suspended is 
Ringers buffer pH 7.4 (as previously described) at a concentration of 
approximately 1 x 10s cells/ml. An appropriate volume of radiolabelled 
substrate solution was made with Ringers buffer pH 7.4 (as above) 
supplemented with 34 pM unlabelled methionine and L-[methyl- H] 
Methionine (GE Healthcare, UK) at a specific activity of 20 pCi/ml. The 
prepared cell suspensions and substrate solution were kept at 21 °C and the 
uptakes carried out at this temperature. The uptake was started with the 
mixing of an equal volume of the cell suspension with the radiolabelled 
substrate solution (giving a final concentration of 17 pM unlabelled 
methionine, the approximate physiological concentration in adult human 
plasma, and a final activity of [3H] methionine of 10 pCi/ml). For time 
courses, at predetermined intervals 200 pi aliquots of the mixed cell and
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substrate suspension were transferred to 1.5 ml microcentrifuge tubes 
containing 300 pi Dow Corning oil with 1ml ice-cold Ringers buffer pH 
7.4 (as previously described) supplemented with 1.7 mM unlabelled 
methionine layered on top (in order to stop the transport immediately). The 
tubes were then immediately centrifuged at 17000 x g for 1 minute to pass 
the cells through the oil layer. The supernatant layer above the oil was 
removed by aspiration, the walls of the tube washed 3 times under flowing 
water and the oil layer removed by aspiration. The cell pellet was dissolved 
by adding 100 pi boiling distilled water and mixing. This was transferred 
to a 6 ml scintillation vial and 5 ml scintillation fluid (Optima Gold, 
Coining) added. The radioactivity was measured using p-scintillation 
counter (Packard). All points in each uptake were earned out in triplicate.
As 40 % parasitaemia was used for the uptake experiments using P. 
falciparum infected RBCs the uptake was adjusted to 100 % parasitaemia. 
This was earned out by removing the uptake by the uninfected cells (based 
on data from time courses using uninfected cells) then adjusting to 100 % 
parasitaemia.
Each experiment was carried out three times, with thine replicates of each 
data point measurement within each experiment.
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4.2.3 Transport Assays in Free P. falciparum Parasites
4.2.3.1 Free P. falciparum Trophozoites Isolated by Saponin Lysis
P. falciparum trophozoites were isolated from the host RBC by saponin 
lysis. Treatment with saponin permeabilises the host RBC and 
parasitophorous vacuole membranes, leaving the parasite plasma 
membrane intact (Saliba and Kirk, 1999).
Cultures of trophozoite stage P. falciparum infected RBCs at above 5 % 
parasitaemia were used for free parasite generation by saponin lysis. 
Cultures were centrifuged at 805 x g for 5 minutes and the infected RBC 
pellet washed once with Ringers buffer pH 7.4 (as previously described). 
Five pellet volumes of 0.15 % saponin in PBS was added to the pellet and 
gently mixed until red blood cell lysis was observed. This was then 
centrifuged at 2000 x g, 4 °C for 5 minutes, the supernatant carefully 
removed and the pellet washed and resuspended four times in Ringers 
buffer pH 7.4 (as previously described) to remove all traces of saponin. 
The cell density was then estimated using an Improved Neubauer 
haemocytometer and the success of the saponin lysis checked by wet 
smear. Briefly, a drop of the washed, saponin treated, suspension was 
placed on a microscope slide, a cover slip placed over the drop and 
examined using a light microscope with a 100 x oil immersion objective. 
For the experiments where methylation and/or protein synthesis inhibitors
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were used 20 mM cyclo leucine and/or 40 [iM cycloheximide were added 
to the cell suspensions at this stage and incubated for 30 minutes at 21 °C.
4.2.3.2 Methionine Uptake in Free P. falciparum Parasites
All of the [3H] methionine uptake experiments in free P. falciparum 
parasites were canied out at 21 °C. For time course assays the uptake was 
started with the mixing of an equal volume of the cell suspension with the 
radiolabelled substrate solution (20 p.Ci/ml [ H] methionine and 34 pM 
unlabelled methionine in Ringers buffer pH 7.4, as previously described). 
At predetermined intervals 200 pi aliquots of the mixed cell and substrate 
suspension were transferred to 1.5 ml microcentrifuge tubes containing 1 
ml ice-cold Ringers buffer pH 7.4 (as previously described) supplemented 
with 1.7 mM unlabelled methionine (in order to stop the transport 
immediately). The tubes were then immediately centrifuged at 17000 x g, 4 
°C for 1 minute to sediment the cells. The supernatant was removed by 
aspiration and the walls of the tube washed with 1ml ice-cold Ringers 
buffer pH 7.4 (as previously described) supplemented with 1.7 mM 
unlabelled methionine. The cell pellet was dissolved by adding 100 pi 
boiling distilled water and mixing. This was transferred to a 6 ml 
scintillation vial and 5 ml scintillation fluid (Optima Gold, Corning) added.
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For single time point experiments where uptake over 30 seconds was 
measured the uptake was started by the addition of 100 pi cell suspension 
to 100 pi radiolabelled substrate solution in individual 1.5 ml 
microcentrifiige tubes. After 30 seconds the uptake was tenninated by the 
addition of 1 ml ice-cold Ringers buffer pH 7.4 (as previously described) 
supplemented with 1.7 mM unlabelled methionine (in order to stop the 
transport immediately). The tubes were then immediately centrifuged at 
17000 x g for 1 minute to sediment the cells. The cell pellets were then 
treated the same way as in the time course experiments. The radioactivity 
was measured using (3-scintillation counter (Packard).
In the experiments where transport inhibitors were used these were added 
to the substrate solution prior to mixing with the cell suspension to start the 
uptake (so double the required end concentration added). The system L 
inhibitor 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid (BCH) 
(Christensen et al., 1969) was used at end concentrations of 2 mM and 20 
mM and the system y+ inhibitor N-ethylmaleimide (NEM) (Soriano- 
Garcia et al, 1998) was used at end concentrations of 0.1 mM and 1 mM. 
NEM is, however, a generally unspecific inhibitor as it is reactive towards 
all sulfhydryl groups.
For the experiments investigating inhibition by other amino acids the 
uptakes were earned out over 30 seconds as described above, but with the
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addition of 0.4 inM, 4 mM or 20 mM appropriate unlabelled amino acid to 
the radiolabelled substrate solution (giving end concentrations of 0.2 mM, 
2 mM or 10 mM when mixed with the cell suspension to start the uptake). 
An electronic metronome was used for uptakes with time points of 30 
seconds or less to improve accuracy of the timing. All points in each 
uptake were carried out in triplicate.
Each experiment was carried out three times, with the exception of the 
experiment investigating inhibition by 10 mM of other amino acids where 
only one experiment was earned out. Each individual experiment consisted 
of three replicates of each data point measurement.
4.2.4 Statistical Analysis of Results
Non-parametric tests were used as the distribution of values within each 
group could not be determined to be Gaussian. The Mann-Whitney U test 
was used to establish whether there was a significant difference between 
the groups. Bonferroni correction of p values was carried out where 
multiple comparisons were made to reduce the chances of type I errors 
occurring. Significance was counted with p values <0.05.
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4.3 Results
4.3.1 Uptake of Methionine by P. falciparum Parasitised 
Human Red Blood Cells
Time courses of the uptake of methionine into trophozoite stage P. 
falciparum infected and uninfected RBCs were carried out at 21 °C in the 
presence of the approximately physiological concentration of methionine 
(17 pM) and the absence of all other amino acids (figure 4.1), This 
temperature was used as it was simpler to carry out for an initial study. The 
influx of methionine into P. falciparum infected RBCs was not higher than 
that observed for uninfected RBCs. The initial rate of influx was calculated 
from the linear phase of uptake (inset, figure 4.1), which was shown to be 
significantly linear with r2 values of 0.65 for infected RBCs and 0.78 for 
uninfected RBCs (calculated using Graphpad Prism). No significant 
difference was observed between the initial rate of influx of methionine 
into uninfected RBCs and that of infected RBCs, with respective rates of 
991 ± 208 finol/106 cells/minute and 608 ±301 fmol/106 cells/minute 
(mean from three independent experiments on different days, each in 
triplicate, ± standard error, with significance values calculated using the 
Mann-Whitney U test). Due to the lack of parasite-induced change in 
methionine influx in RBCs it was decided to focus further mainly on 
methionine transport in free P. falciparum parasites.
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Figure 4.1. Uptake of methionine by P. falciparum infected and uninfected 
RBCs at 21 °C. Measured in Ringers pH 7.4 in the presence of 17 pM 
methionine and the absence of other amino acids. Empty blue squares denote 
uptake by P. falciparum infected RBCs and solid red triangles denote uptake 
into uninfected RBCs. The inset graph shows the initial linear element of 
uptake. Values are represented as mean from three independent experiments 
carried out on different days, with each data point in triplicate, ± standard error.
4.3.2 Uptake of Methionine by free P. falciparum parasites
The transport of methionine by free P. falciparum parasites was measured 
using trophozoite stage parasites isolated from the host RBCs using the 
saponin lysis technique, which frees the parasite from the RBC and 
parasitophorous vacuole membrane. Time courses of methionine uptake 
were carried out at 21 °C in the presence of the approximately
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physiological concentration of methionine (17 pM) and the absence of all 
other amino acids. To make sure only the true transport of methionine was 
being measured, and not the knock on effect of further methionine 
metabolism, the effects of a methionine adenosyltransferase inhibitor 
(cycloleucine) and a protein synthesis inhibitor (cycloheximide) were 
examined. Figure 4.2 shows the time courses for the uptake of methionine 
into free P, falciparum parasites in the absence of inhibitor, or in the 
presence of 20 mM cycloleucine or 40 pM cycloheximide. The initial rate 
of influx was calculated from the linear phase of uptake (inset, figure 4.2), 
which was shown to be significantly linear and with r2 values of 0.81 for 
uninhibited parasites, 0.82 for parasites with 20 mM cycloleucine and 0.89 
for parasites with 40 pM cycloheximide (calculated using Graphpad 
Prism). The initial rate of influx of methionine into the free parasites was 
248 ± 86 finol/106 cells/minute for the uninhibited pamsites, 220 ±38 
finol/106 cells/minute for parasites with 20 mM cyclo leucine and 210 ± 32 
finol/106 cells/minute for the parasites with 40 pM cycloheximide, with no 
significant difference between the uninhibited parasites and either inhibitor 
(mean from three independent experiments on different days, each in 
triplicate, ± standard error, with significance values calculated using the 
Mann-Whitney U test). The effect of inhibiting methylation or protein 
synthesis was only noticeable after 1 minute, but to make sure that only 
true transport of methionine was measured, and not the effect of
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methylation or protein synthesis, both cycloleucine and cycloheximide 
were included as a precaution in further experiments.
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Figure 4.2. Uptake of methionine by free P. falciparum trophozoites at 21°C. 
Measured in Ringers pH 7.4 in the presence of 17 pM methionine and the 
absence of other amino acids. Time courses shown in the absence of inhibitors 
(denoted by solid black squares), with methionine adenosyltransferase 
inhibition (20 mM cycloleucine, denoted by empty red triangles) or protein 
synthesis inhibition (40 pM cycloheximide, denoted by empty green circles). 
The inset graph shows the initial linear element of uptake. Values are 
represented as mean from three independent experiments carried out on 
different days, with each data point in triplicate, ± standard error.
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4.3.2.2 The Kinetics of Methionine Transport
The kinetics of methionine transport in free trophozoite stage P. falciparum 
parasites was investigated by measuring the uptake of [3H] methionine at 
21 °C over 30 seconds. A range of methionine concentrations were used, 
from 120.5 nM to 10.6 mM. Figure 4.3 shows the concentration 
dependence of the uptake of methionine and shows that methionine uptake 
was saturable and conforming to Michaelis-Menten kinetics. The 
(Michaelis constant, the substrate concentration that gives the half maximal 
rate of uptake) of methionine uptake was determined to be 1.13 ± 0.16 mM 
with a Fmax (maximum rate of uptake) of 3200 ± 120 pmol/106 cells/hour.
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Figure 4.3. The uptake of increasing concentrations of methionine by free 
trophozoite stage P. falciparum parasites at 21 °C. Uptake was measured over 
30 seconds in Ringers pH 7.4 with a range of concentrations of methionine 
(120.5 nM to 10.6 mM) and methionine adenosyltransferase and protein 
synthesis inhibitors added (20 mM cycloleucine and 40 pM cycloheximide). 
Values are represented as mean from three independent experiments carried out 
on different days, with each data point in triplicate, ± standard error. The curve 
was drawn using the equation: methionine uptake = Fmax [met]/(ATm + [met]), 
with Km = 1.13 ± 0.16 mM and Vmax = 3200 ± 120 pmol/106 cells/hour.
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4.3.2.3 The Effect of Transport Inhibition
In order to investigate the nature of the methionine transport over the P. 
falciparum plasma membrane uptake experiments were carried out with 
the addition of inhibitors of known amino acid transport systems. 2- 
aminobicyclo[2.2.1]heptane-2-carboxylic acid (BCH) is an inhibitor of 
system L amino acid transport, a system that is responsible for transport of 
neutral amino acids in mammalian cells (Christensen et ah, 1969). The 
effect of BCH on the uptake of [3H] methionine over 30 seconds at 21 °C 
is shown in figure 4.4. No significant decrease in uptake was observed with 
the addition of 2 mM and 20 mM BCH using the Mann-Whitney U test, 
but a drop in uptake without a dose response can be observed from figure 
4.4.
N-ethylmaleimide (NEM) is an inhibitor of system y+ amino acid transport 
(Soriano-Garcia et aL, 1998) but will also bind to, and inactivate, any 
integral plasma membrane protein with a free sulfhydryl group. The 
addition of even just 0.1 mM NEM reduces the uptake to background 
levels (figure 4.5). The incomplete inhibition by BCH and lack of dose 
response suggests that there may be more than one transporter responsible 
for the uptake of methionine. BCH is a more specific inhibitor than NEM 
and could, therefore, be targeting a particular transport route. If more than 
one methionine transporter is present and BCH is only targeting one of 
these then even increasing the concentration of BCH will not reduce the
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transport occurring via alternate transporters. NEM is generally an 
unspecific inhibitor and so may target more than one transport route.
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Figure 4.4. Methionine uptake by free trophozoite stage parasites with the 
addition of 2 mM or 20 mM 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid 
(BCH), at 21 °C over 30 seconds. Measured in Ringers pH 7.4 in the presence 
of 17 pM methionine and the absence of other amino acids. Methionine 
adenosyltransferase and protein synthesis inhibitors were also added (20 mM 
cycloleucine and 40 pM cycloheximide). Values are represented as mean from 
three independent experiments carried out on different days, with each data 
point in triplicate, ± standard error.
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Figure 4.5. Methionine uptake by free trophozoite stage parasites with the 
addition of 0.1 mM or 1 mM N-ethylmaleimide (NEM), at 21 °C over 30 
seconds. Measured in Ringers pH 7.4 in the presence of 17 pM methionine and 
the absence of other amino acids. Methionine adenosyltransferase and protein 
synthesis inhibitors were also added (20 mM cycloleucine and 40 pM 
cycloheximide). Values are represented as mean from three independent 
experiments earned out on different days, with each data point in triplicate, ± 
standard error. Significance values between control and parasites treated with 
NEM were calculated using the Mann-Whitney U test, are Bonferroni corrected, 
and shown as *** representing a p value < 0.001.
4.3.2.4 Inhibition by other Amino Acids
The ability of 0.2 mM, 2 mM or 10 mM unlabelled naturally occurring 
amino acids and taurine (only 0.2 mM and 2 mM unlabelled glutamate, 
tryptophan and arginine were used) to inhibit the influx of [ H] methionine 
was investigated (figure 4.6). Cysteine was the only amino acid to inhibit 
the influx of [3H] methionine at all the concentrations used with the influx 
of [3H] methionine completely reduced when 10 mM unlabelled cysteine
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nadded. No other unlabelled amino acids appeared to reduce [ H] 
methionine influx when 0.2 mM or 2 mM was added. Unlabelled lysine 
and histidine caused non significant inhibition of [3H] methionine influx 
when 10 mM was used. The addition of unlabelled methionine did not 
inhibit [3H] methionine influx when 0.2 mM or 2 mM was added, only 
showing inhibition when 10 mM was added, although this was not 
significant. No significant inhibition of [3H] methionine influx was 
observed by D-methiorune but further experiments would have to be 
carried out in order to make any conclusions on the stereo specificity of 
methionine transport. The inhibition observed here cannot be assumed to 
be competitive as further experiments would need to be canied out to 
allow the nature of inhibition to be analysed.
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Figure 4.6. Inhibition of [?H] methionine influx into free trophozoite stage P. 
falciparum parasites by unlabelled amino acids. Influx is shown as a percentage 
of the influx measured in the absence of unlabelled amino acids (control). 
Measurements were carried out at 21 °C over 30 seconds in Ringers pH 7.4 in 
the presence of methionine adenosyltransferase and protein synthesis inhibitors 
(20 mM cycloleucine and 40 pM cycloheximide). The influx of [?H] methionine 
was measured in combination with 0.2 mM, 2 mM or 10 mM unlabelled amino 
acids (with the exception of glutamate, tryptophan and arginine where only 0.2 
mM and 2 mM were used). White bars show 0.2 mM unlabelled amino acid, 
dashed bars show 2 mM unlabelled amino acid and black bars show 10 mM 
unlabelled amino acid. For 0.2 mM and 2 mM amino acids values are 
represented as mean from three independent experiments carried out on 
different days, with each data point in triplicate, ± standard error. For 10 mM 
values are the mean from one experiment, with each data point in triplicate, ± 
standard error.
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4.4 Discussion
In this chapter the methionine transport in intact P. falciparum parasitised 
RBCs and free P, falciparum parasites has been investigated. In adult 
human RBCs methionine is taken up via the saturable system L (Barker 
and Ellory, 1990). Previous studies have shown that RBCs infected with 
the malaria parasite, P. falciparum, to have an increased permeability to 
amino acids (Elford et al, 1985), and the increase in uptake of iso leucine 
by parasitised RBCs has been well characterised (Martin and Kirk, 2007). 
In the study earned out here, RBCs infected with the 3D7 strain of P. 
falciparum did not show significantly increased uptake of methionine 
compared to uninfected RBCs. A characterisation of the transport of 
methionine by P. falciparum strain FAF6 infected RBCs and isolated 
parasites has recently been published by Cobbold et al (2011). This study 
found methionine to be taken up by RBCs infected with P. falciparum 
parasites 15 fold faster than uninfected RBCs. This increase in transport 
was attributed to the parasite-induced NPP, with transport rates decreasing 
to that of uninfected RBCs with the addition of an anion transport inhibitor, 
flirosemide, which inhibits the NPP. There are a number of differences 
between the study described in this chapter and that earned out by Cobbold 
et al (2011). For example: different strains of P. falciparum were used in 
each study; different temperatures were used for the influx assays (21 °C 
was used in this study and 37°C was used by Cobbold et al)\ and the
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reaction medium in the study by Cobbold et al was supplemented with the 
full range of amino acids at approximately physiological concentrations, 
whereas the reaction medium used in this study was not supplemented with 
any amino acids other than the physiological concentration of methionine. 
However, the lack of increase in methionine uptake by P. falciparum 
infected RBCs observed in this study is highly unusual compared to other 
nutrients. Isoleucine has been shown to be taken up 5 fold faster in 
parasitised RBCs compared to uninfected RBCs (Martin and Kirk, 2007), 
glutamine uptake has been shown to be increased up to 100 fold (Elford et 
ah, 1985) and glucose uptake has been shown to be increased 40 to 100 
fold (Woodrow et ah, 2000, Kirk, 2001). In order to conclude that there is 
definitely no increase in methionine uptake by parasitised RBCs more 
experiments would have to be carried out and a control included of a 
substrate known to be transported at a greater rate in parasitised RBCs.
Methionine uptake in various vertebrate cells and other organisms has 
previously been characterised. As well as the ubiquitous Na+-independent 
system L, the sodium dependent system A has been characterised and 
found to be responsible for methionine transport in many vertebrate cell 
types, except for RBCs and reticulocytes (Barker and Ellory, 1990). 
Systems B0+ and b0+ are Na+-dependent systems shown to transport 
methionine in blastocytes. All of these systems are also responsible for the 
transport of a wide range of neutral ammo acids as well as methionine
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(Barker and Ellory, 1990). In the yeast Saccharomyces cerevisae three 
distinct methionine transport systems have been found, with one high 
affinity, high specificity methionine pennease, named Mupl, with a Km of 
12 pM (Isnard et al., 1996). In the procyclic and blood stream forms of the 
kinetoplastid parasite Trypanosoma brucei brucei methionine is taken up 
by a relatively high affinity carrier, with a Km of 30 pM (Hasne and 
Barrett, 2000). Methionine transport in T. brucei procyclic forms was 
shown to be weakly inhibited by leucine, phenylalanine, tryptophan and 
D,L-homocysteine, with blood stream forms also inhibited by D- 
methionine, isoleucine and glycine.
Transport of methionine into the free P, falciparum parasite was shown to 
be a saturable process, with a Km of 1.13 ± 0.16 mM. This is similar to that 
found in the study by Cobbold et al (2011) who found a Km of 1.6 ± 0.3 
mM. Compared to the methionine transport characterised in other systems, 
for example the Mupl methionine permease in S. cerevisae and T. brucei 
methionine transport, the transport into free P, falciparum trophozoites is 
relatively low affinity. Methionine transport into free P. falciparum 
trophozoites was inhibited approximately 50 % by BCH, a specific system 
L transport inhibitor (Christensen et al, 1969). There is a lack of dose 
response with BCH inhibition which suggests that there may be more than 
one transporter responsible for the uptake of methionine and so transport 
via the BCH inhibited pathway may be via a system L like transport
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system. NEM, an inhibitor of system y+ (Soriano-Garcia et aL, 1998), 
completely inhibited transport of methionine into the free parasites. 
However, as NEM binds covalently and without specificity to accessible 
sulfhydryl residues in proteins it is difficult to know if this is only 
inhibiting transport via a system like the vertebrate system y+ or another 
pathway (Janick et aL, 1977).
From influx assays earned out with the addition of unlabelled amino acids 
it was observed that methionine influx into the free parasites was inhibited 
most effectively by cysteine. Transport also appeared to be inhibited by 
lysine and histidine but only when 10 mM unlabelled amino acid was used. 
This pattern of inhibition is different to that found by Cobbold et al (2011), 
who found inhibition by a wide range of neutral amino acids, including 
cysteine, and no significant competition by either acidic or basic amino 
acids. The inhibition of methionine uptake by lysine is interesting when 
combined with the inhibition observed with the system y+ inhibitor NEM 
as lysine is one of the main substrates of this system. Although system y+ 
is predominantly a cationic amino acid transporter it has been shown to 
transport neutral amnio acids when Na+ is present, as it was in the reaction 
medium used in transport assays in this chapter. However, no definite 
conclusions about the contribution of a system y+ like transport system can 
be made based on the results from NEM inhibition as NEM is a very 
unspecific inhibitor.
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In conclusion, the results from this chapter show that methionine is taken 
up by the P. falciparum parasite via one or more saturable systems, with 
one component showing similarity to the vertebrate systems L.
4.4.1 Critical Assessment
The “free” P. falciparum parasites referred to in this work were isolated 
horn infected human RBCs using saponin lysis. This is a relatively simple 
technique where saponin, a plant-derived detergent, interacts with 
cholesterol in the cell membrane and disrupts the integrity of these 
membranes (Ansorge et aL, 1996). The technique has been widely used 
since its introduction by Christophers and Fulton (1939). Treatment of 
malaria-parasitised RBCs with saponin does not completely remove the 
RBC membrane surrounding the intracellular parasite, instead it forms 
pores in the RBC membrane allowing it to be permeable to solutes as large 
as soluble proteins (e.g. haemoglobin) (Kirk, 2001). Treatment with 
saponin also appears to penneabilise the PVM without damaging the PPM 
(Ansorge et al, 1997). Studies have shown that the PPM can maintain a 
large, inwardly negative, membrane potential (Allen and Kirk, 2004) and 
generate and maintain ionic gradients (Saliba and Kirk, 1999) after 
treatment with saponin for permeabilisation purposes. These attributes 
allowed saponin lysis to be deemed suitable for use in the experiments 
described in tins chapter, despite the fact that the pamsites still reside in
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the, permeabilised, ghosts of the RBC membrane. It is possible to culture 
Plasmodium parasites axenically, but the yields are low with only 
approximately 1 % of harvested merozoites developing into trophozoites 
(Trager et ai, 1992, Trager et al., 1996). This means that for experiments 
using isolated (“free”) pamsites it is still necessary to use parasites isolated 
from host RBCs in order to obtain large enough yields. As well as saponin 
there are other methods that can be used to isolate parasites from infected 
RBCs. These include: digitonin, another plant-derived detergent that also 
penneabilises the RBC membrane (Desai et al., 1993); Sendai virus, which 
induces fusion of erythrocytes and leaves the parasite intact within freely 
permeable erythrocyte ghosts (Kanaani and Ginsburg, 1988, Kanaani and 
Ginsburg, 1989); complement-mediated immune lysis (Trager et al, 
1990); streptolysin O, a bacterial protein that permeabilises the RBC 
membrane but not the PVM (Ansorge et al, 1996, Ansorge et al., 1997); 
isoosmotic lysis with sorbitol (Hoppe et al., 1992); and nitrogen cavitation 
followed by free flow electrophoresis (Heidrich et al., 1986). However, 
saponin lysis still remams the most widely used method for obtaining 
isolated Plasmodium parasites from the host RBC. Its ease of use, 
permeabilisation of both RBC membrane and PVM whilst leaving the 
PPM intact, and the fact that the technique was already established within 
the group, led to the decision to use saponin lysis as the method of 
obtaining “free” parasites in this chapter.
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The methionine uptake experiments were earned out at 21 °C as initial 
experiments at this temperature showed uptake to be rapid. Increasing the 
temperature to 37 °C would have increased the initial rate of uptake and 
made it more difficult to accurately carry out the short time courses 
required, so 21 0C was continued to be used. There is also precedent for 
transport assays to be carried out at non-physiological temperatures 
(Biagini et al., 2004, Downie et al., 2006, Martin and Kirk, 2007). Using 
21 °C instead of 37 °C will affect the Vma}l but should not affect the Km of 
transport. As discussed in section 3.4.1, the Km of transport gives important 
infonnation on the affinity of the transporter for the substrate while the 
Kmax gives less information on the nature of the transport, but is useful if 
the transport is to be modelled. In order to comprehensively characterise 
the transport of methionine by infected and uninfected RBCs and free 
parasites, reaction parameters need to be investigated at a range of 
temperatures. This allows the Ea to be determined (from an Arrhenius plot, 
as described in section 3.4.1) winch can give further infonnation on 
whether transport is channel or carrier mediated. Cobbold et al (2011) 
showed methionine uptake by free P. falciparum parasites to be 
temperature dependent, however only two temperatures were used to 
investigate this (4 °C and 22 °C) and the Ea was not detennined.
The transport assays were terminated with the addition of ice-cold buffer 
containing 1.7 mM unlabelled methionine. This should have been much
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higher considering that the A^m of methionine transport in free parasites was 
1.13 ± 0.16 mM and the addition of 2 mM unlabelled methionine does not 
reduce methionine uptake. It was initially assumed that using 100 fold 
increased concentration of unlabelled methionine from the physiological 
concentration (17 pM) would be sufficient for the stop solution. A time 
course experiment carried out on ice, using ice-cold 1.7 mM methionine 
stop solution, showed only background uptake (figure 4.7). This 
experiment was only carried out once (in triplicate) so cannot be 
completely relied on, but it may negate this problem slightly as the 
temperature reduction and physical dilution of the substrate could be 
assumed to be sufficient for inhibiting further transport of [3H] methionine.
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Figure 4.7. Uptake of methionine by free P. falciparum trophozoites on ice. 
Measured in Ringers pH 7.4 in the presence of 17 pM methionine and the 
absence of other amino acids. Values are represented as mean from one 
experiment, with each data point in triplicate, ± standard error.
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Conclusions on the nature of the inhibition of methionine uptake by 
cysteine, lysine, histidine, taurine, BCH and NEM cannot be drawn from 
the current data. The inhibition by other amino acids is not necessarily 
competitive. In order to find out if the inhibition is competitive more 
comprehensive experiments would have to have been carried out, using 
several concentrations of methionine and a wider range of concentrations 
of potentially inhibiting amino acids. The results from these would have 
allowed further analysis of the nature of the inhibition using a Dixon plot. 
The Dixon plot is a graph of the reciprocal of the initial velocity, 1/V, 
against the concentration of inhibitor which produces a set of intersecting 
lines representing substrate concentration. A competitive inhibitor graphed 
using a Dixon plot would have lines converging above the x axis whereas a 
non-competitive inhibitor would have lines converging on the x axis. 
Competitive inhibition would also cause an increase in the Km. with the 
addition of inhibitor, but no change in the F1Iiax. Non-competitive inhibition 
would cause a decrease in the Fmax with the addition of inhibitor, but no 
change in the Km.
A control of a substrate known to be transported at a greater rate in 
parasitised RBCs and with known transport kinetics in free parasites 
should have been included in order to give the results more reliability. This 
would have been especially useful with the experiments comparing uptake
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of methionine by P. falciparum infected and uninfected RBCs as these, 
surprisingly, showed no increased uptake by parasitised RBCs.
191
CHAPTER 5
Antagonism of the Natural Folate Precursor 
para-Aminobenzoic Acid on the Action of 
Anticancer and Antimalarial Antifolates
5.1 Introduction
After investigating methionine transport in the P. falciparum infected 
RBC and free trophozoites (chapter 4) it was decided to investigate the 
transport-mediated salvage of folate pathway substrates. The folate 
pathway provides the one-carbon donor to methionine biosynthesis with 
5-methyltetrahydrofolate (5-MTHF) the methyl donor in the 
biosynthesis of methionine from homocysteine (see section 1.3 for the 
folate pathway and methionine cycle). Antifolates have been effective 
antimalarial drugs with DHPS and DHFR inhibitors still in use. There is 
marked synergy of SDX (anti-DHPS) with PYR (anti-DHFR) and this 
combination (marketed as Fansidar®) is at present used as an 
intermittent preventive treatment in infants (IPTi) in some areas of 
Africa (Conteh et ai, 2010), and in the treatment of uncomplicated 
malaria in combination with artesunate and amodiaquine (WHO, 2010). 
Antimalarial antifolates have been well studied and their modes of
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action and mechanisms of resistance have been described in section
1.3.4. One of the most effective and best studied antifolate is the anticancer 
drug methotrexate (MTX). Although it is a potent inhibitor of DHFR it has 
not been deployed as an antimicrobial besides being shown to be effective 
against P. falciparum in vitro (Kiara et al., 2009, Nzila et al., 2010, Dar et 
aL, 2008, Huennekens, 1994).
A need for salvage of the folate precursor pABA by Plasmodium was first 
indicated in the 1960s when it was shown that Plasmodium berghei 
parasites had reduced growth when the mouse hosts were fed a pABA- 
deficient diet, with parasite growth returned to normal with the addition 
of pABA (Jacobs, 1964). P. falciparum parasites have been shown to be 
capable of salvaging exogenous folate precursors, pre-fonned folate and Ci 
substituted folate derivatives, as reviewed in section 1.3.2 (Kmngkrai et 
al, 1989b, Wang et al., 2004). However, there is also pharmacological and 
genetic evidence of de novo pABA synthesis via the shikimate pathway in 
P. falciparum (McConkey et al., 1994, Roberts et al., 1998). Unlike the 
malaria parasite, humans are unable to synthesise pABA de novo and also 
do not significantly utilise it. This makes pABA metabolism a useful 
potential chemotherapeutic target.
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Early in vitro methods used to investigate antimalarial drug activity in 
the 1970s proved difficult to use for the antifolate class of drugs even 
when they worked well for other major classes of antimalarials 
(Desjardins et al., 1979, Wang et al.y 1997b). It was noticed by 
Desjardins and colleagues that the RPMI-1640 used to culture the 
parasites in vitro had concentrations of pABA (1.0 mg/L) and folic acid 
(1.0 mg/L) in excess of the concentrations in the human host plasma. It 
was concluded that these substrates must have an effect on the action of 
the antifolate drugs (Desjardins et al., 1979). Subsequent in vitro studies 
have confirmed that salvage of folate substrates horn the medium reduces 
the sensitivity of the parasite to antifolate drugs (Watkins et al., 1985, Tan- 
ariya et al., 1987, Wang et al., 1999, Wang et al., 1997b). Work by Wang 
et al (1997b) showed that strictly controlled low levels of folate and pABA 
allowed reliable results to be obtained horn in vitro drug assays. The 
antagonism of antifolate dings by folate salvage has been assumed to be 
due to the salvaged folate substmtes bypassing steps in the de novo 
synthesis pathway (Hyde, 2005).
In this chapter the effects of the salvage of folate substmtes and products 
found in human plasma will be investigated on the antimalarials SDX and 
PYR, and the anticancer drug MTX. In order to investigate the effect of 
transport-mediated salvage of folate pathway substrates probenecid (PBN) 
was used as a membrane transport inhibitor. PBN inhibits organic anion
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transport and has previously been shown to chemo sensitise P. falciparum 
to antifolates and other antiinalarial agents (Sirotnak et aL, 2000, Nzila et 
al, 2003, Masseno et al., 2009). The possible effects of PBN on folate 
metabolism in P. falciparum are shown in figure 5.1.
As previous studies have shown folate salvage to antagonise antiinalarial 
antifolates all experiments carried out in this chapter utilised custom made 
folate and pABA-free RPMI-1640 and albumax II (which is folate and 
pABA-free) for the culture medium for P. falciparum instead of standard 
RPMI-1640 and serum respectively. This has been used in previous studies 
although it has generally been supplemented with low concentrations of 
folic acid for continuous culture (Wang et ah, 1997b). Investigations into 
the effect of the folate pathway substrates pABA, pABAGl, 5-MTHF and 
folic acid on antifolate drugs were performed using physiological 
concentrations. In humans the blood concentration of folate pathway 
substrates is as follows: pABA concentration is variable with a mean 
around 150 nM (Schapira et al, 1986); pABA monoglutamate is around 
160 nM (Lin et al, 2004); 5-MTHF (the predominant circulating folate 
product) is around 25nM (Duthie et al, 2010); and folic acid is around 0.5 
nM (McDowell et al, 2008). In previous work by Wang et al (1999) the 
effect of folic acid and pABA on SDX was examined, however, in that 
study the lowest concentration of folic acid used was 11 nM, and unlike the
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work canied out in tills chapter the effect of transport-mediated salvage 
was not investigated.
To check if there was any correlation between antagonism of antifolates by 
folate substrates and folate salvage by specific parasite transporters the 
substrate specificity of folate and pABA salvage was investigated using E. 
coli expression of two putative P. falciparum folate transporters, 
MAL8P1.13 (designated PfFTl) and PF11_0172 (designated PfFT2). 
These two likely folate transporters belong to the high affinity BT1 folate 
transporter group (TC 2.A.71) and were identified from the P. falciparum 
genomic database by Martin et al (2005). This group falls within the major 
facilitator superfamily (MFS) and members are found in protozoa, plants 
and cyanobacteria (Saier, 2000b, Saier et al, 1999c). Work by Martin et al 
(2005) showed that the two genes are maximally expressed in the late 
trophozoite and early schizont stages, which is consistent with the role of 
folates in DNA synthesis as these are the stages when DNA synthesis is at 
its highest (Hyde, 1990). A double gene knock out has been developed in 
E. coli, of a pABA synthesis enzyme (pabA) and the pABA and 
monoglutamated pABA transporter (abgT), to express and study folate 
transporters (Eudes et al, 2010) and this has been used to investigate the 
substrate specificity of PfFTl and PfFT2 using growth rescue experiments.
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Figure 5.1. The possible effect of PBN on folate metabolism in P. falciparum 
parasites. RBCs salvage exogenous folate derivatives via mammalian RFC. 
Parasite-induced NPP have also been shown to be a possible route of folates 
into the infected RBC (Wang et al., 2007). The parasites may take up these via 
their own folate transporters. PBN inhibits organic anion transporters and so 
may decrease the uptake of folate derivatives into the RBC and/or also inhibit 
the uptake of folate derivatives within the parasite, therefore decreasing the 
levels of folate derivatives within the parasite. Abbreviations: SDX, 
sulphadoxine, PYR, pyrimethamine; MTX, methotrexate; GTP, guanine 
triphosphate; HMP-PP, amino-hydroxy-methyl-dihydro-pteridine-
pyrophosphate; DHPS, dihydropteroate synthase; pABA, para-aminobenzoic 
acid; DHP, 7,8-dihydroteroate; DHF, 7,8-dihydrofolate; DHFR, dihydrofolate 
reductase; THF, 5,6,7,8-tetrahydrofolate; mTHF, methylene-tetrahydrofolate; 
DHF, dihydrofolate; dUMP, deoxyuridine monophosphate; TMP, thymidine 
monophosphate; Hey, homocysteine; met, methionine; PVM, parasitophorous 
vacuole membrane; PPM, parasite plasma membrane; NPP, new permeation 
pathway(s); RFC, reduced folate carrier; PfFTs, P. falciparum folate 
transporters; PBN, probenecid. Modified from Nzila et al (2004).
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5.2 Materials and Methods
5.2.1 Parasite Cultivation
Cultivation of parasites was earned out following the modified method 
of Trager and Jensen described in section 2.1 (Trager and Jensen, 1976). 
Culture medium made using folate and pABA-firee but otherwise 
standard RPMI-1640 was used (HyClone, TheimoScientific, UK) for all 
parasite cultivation and experiments as described in section 2.1. The 
3D7 strain of P. falciparum, originating from an airport malaria case at 
Schiphol, the Netherlands, was used for all in vitro sensitivity assays 
described in this chapter. Although the 3D7 strain has partial resistance 
to SDX, through a DHPS mutation at position 437 from alanine to 
glycine, it was used for the antagonism experiments as the SDX 
sensitive strain HB3 could not be grown acceptably in folate and 
pABA-ffee medium (Wang et al, 1997a). Attempts to culture the 
parasite strains VI/S and K1 in folate and pABA-ffee medium also 
resulted in poor growth, making them unsuitable for use in the 
antagonism experiments. The 3D7 strain grew acceptably in folate and 
pABA-ffee medium after approximately 5 to 7 asexual cycles, with 
growth observed to be only slightly slower than parasites maintained in 
standard folate and pABA complete medium otherwise under the same 
conditions. After successful adaption to the folate and pABA-ffee 
medium the 3D7 parasites appeared morphologically healthy. Using a
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strain that could be cultured in folate and pABA-free medium made it 
possible to examine substrate effects at their physiological levels.
5.2.2 Stocks of Inhibitors
Stocks of SDX (Sigma, UK) and PYR (Wellcome, UK) were made in 
DMSO. The working stocks of MTX and PBN (Sigma, UK) were made 
in 0.1 N sodium hydroxide and filtered through a 0.2 pm Millipore filter 
to ensure sterility. PBN was used at 150 pM in the experiments described 
in this chapter as this concentration had previously been shown to have no 
antimalarial effect (Nzila et ah, 2003).
5.2.3 Stocks of Folate Pathway Substrates
Stocks of the folate substrates pABA, pABA monoglutamate 
(pABAGl), folic acid and folinic acid (5-formylTHF) were made in 0.1 
N sodium hydroxide and filtered through a 0.2 pm Millipore filter to 
ensure sterility. The stock of 5-MTHF was made in 0.5 M potassium 
phosphate, pH 7.0, supplemented with 40 mM 2-mercaptoethanol, and 
filtered through a 0.2 pm Millipore filter to ensure sterility.
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5.2.4 Parasite Inocula Preparation
Parasites used for in vitro sensitivity assays were synchronised at ring 
stage, using 5 % w/v sorbitol (see section 2.1.4), one full asexual cycle 
before use. Inocula for use in the assays were diluted in culture medium 
to a final parasitaemia of 2 % (using uninfected RBCs washed 4 times 
in folate and pABA-free RPMI-1640 wash medium) and a haematocrit 
of 2 %, giving an end haematocrit in the assay of 1 % after 50 % 
dilution to give the final assay volume.
5.2.5 In Vitro Sensitivity Assay
Eight serial dilutions of SDX, PYR and MTX were made in folate and 
pABA-ffee culture medium with and without the folate pathway 
substrates being investigated. Four-fold serial dilutions of SDX and 
PYR were made, with respective starting concentrations of 8 mM and 2 
nM. Two fold serial dilutions of MTX were made with a starting 
concentration of 2 pM. The end concentrations of folate substrate 
pathway substrates were used at physiological levels as follows: 150 
nM pABA, 160 nM pABAG, 25 nM 5-MTHF and 0.5 nM folic acid. In 
the plates being used to investigate the effect of probenecid, dilutions of 
inhibitors were made with 300 pM probenecid (giving 150 pM end well 
concentration) in addition to the folate pathway substrates also being 
investigated.
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The assays were performed in flat-bottomed sterile 96-well tissue 
culture plates (Nunc). First, 50 jal of each drug dilution was added to 3 
wells, with concentration increasing from left to right in the 96-well 
plate. Each plate was used for two folate pathway substrates and one 
inhibitor, with rows B to D used for one substrate and E to G for 
another. In each plate column 1 was used for the negative growth 
control with 100 (.lM chloroquine present in the folate and pABA-free 
culture medium. Columns 6 and 11 were used as the positive growth 
control with 50 pi of the medium alone. Fifty pi of the prepared inocula 
was then added to each well taking the total volume in the well to 100 
pi. The outside wells in rows A and H and column 12 were not used as 
it is known that growth is poorer in these, instead 100 pi of sterile 
distilled water was added to all wells in these rows and columns to 
prevent evaporation in the neighbouring wells (figure 5.2). The plates 
were placed in a gas-tight, humidified incubation chamber and gassed 
for 3 minutes with the same gas mixture used for parasite growth (3 % 
CO2, 4 % O2 and 93 % N2), then incubated at 37 °C for 48 hours (one full 
asexual cycle).
Each experiment was carried out four to six times, with three replicates of 
each data point measurement within each experiment.
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5.2.6 Determination of IC5o
Plates were removed from the chambers after 48 hours and 100 (a.1 of 
lysis buffer combined with the fluorescent dye sybr green (0.2 \i\ sybr 
green / 1 ml lysis buffer). The lysis buffer contained Tris (20 mM, pH 
7.5); EDTA (5 mM); Saponin (0.008 % (w/v); Triton X-100 (0.08 % v/v) 
(Bennett et al., 2004). Plates were then incubated in the dark for 1 hour and 
subsequently read with a Varioskan fluorescence reader, at 485 nm 
excitation and 535 nm emission using Skanlt software. The mean values of 
the 3 repeats of each data point were calculated using Microsoft Excel. The 
relative growth of the parasites was then calculated by subtracting the 
mean background value (the mean of the negative growth control wells) 
and calculating the resulting number as a percentage of the maximum 
growth (the mean of the positive growth control wells). The best-fitting 
sigmoid curve and the 50% inhibitory concentration (IC50) were calculated 
using the Grafit Data and Analysis Graphics Program (Erithacus Software, 
UK). The experiments were conducted at least 4 times.
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Figure 5.2. Diagram of the layout of the 96-well plate used in the in vitro 
sensitivity assay.
5.2.7 E. coli expression of PfFTl and PfFT2 and growth 
assays
The E. coli strain BN 1163 with knockouts of the pabA and abgT genes 
(Klaus et ai, 2005, Eudes et ai, 2010) was used to study the uptake of 
folate substrates by the likely P. falciparum folate transporters MAL8P1.13 
(designated PfFTl) and PF110172 (designated PfFT2). The PfFTl and 
PfFT2 genes were synthesised with codon usage optimised for E. coli 
expression (GenScript Corp., Piscataway, NJ) with the first 49 and 35 
amino acids of PjVT\ and P/FT2 respectively replaced by codons 1-37 of 
the Synechocystis sp. PCC6803 gene slr0642 (Klaus et ai, 2005).
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These were cloned into the pLOIVOVHE plasmid between Notl and Sad 
sites (Axfman et al, 1992). A Shine-Dalgamo sequence also preceeded the 
PfFTl and PfFT2 genes in order to improve prokaryotic expression. 
Glycerol stocks of the E. coli BN1163 strain harbouring the PfFTl, PfFT2, 
a Synechocystis folate transporter (Slr0642), the human proton coupled 
folate transporter (hPCFT) or the human reduced folate earlier (hRFC) 
pLOI707HE recombinant constructs were kindly provided by Dr Enrique 
Salcedo-Sora.
For the growth assay E. coli BN1163 harbouring the pLOI707HE 
recombinant constructs and E. coli BN 1163 with the pLOI707HE plasmid 
alone were cultured in 96-microwell plates in minimal medium (M9 salts, 
0.1 mM CaCb, 0.5 mM MgSGu 0.4 % glucose, tetracycline 10 pg/mL, 
kanamycin 50 pg/mL, chloramphenicol 20 pg/mL). The wells were 
supplemented with folate substrates across a range of concentrations. Four 
wells were used for each concentration with each recombinant construct. 
Two fold dilutions of each substrate were made starting at 20 nM for 
pABA, 10 pM for pABAGl, and 20 pM for both folic acid and folinic 
acid. The plates were incubated overnight at 37 °C and the wells 
thoroughly mixed before the culture absorbance at ODeoo was measured 
with a Varioskan spectrophotometer using Skanlt software.
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5.2.8 Statistical Analysis of Results
Non-parametric tests were used as the distribution of values within each 
group was shown to be non Gaussian (using the Kohnogorov-Smirnov test, 
Graphpad InStat). The Mann-Whitney U test was used to establish whether 
there was a significant difference between the data. Bonferroni correction 
of p values was carried out where multiple comparisons were made to 
reduce the chances of type I errors occurring. Significance was counted 
with p values of <0.05.
205
5.3 Results
5.3.1 Sulphadoxine Antagonism by Folate Substrates
The effects of the folate pathway substrates and the organic anion transport 
inhibitor probenecid on the activity of SDX are summarised in table 5.1. 
The activity of SDX against P. falciparum 3D7 in the absence of folate is 
in the nM range, with a mean IC50 of 27.7 nM. The only folate substrate at 
physiological levels to antagonise SDX was pABA, increasing the IC50 
approximately 19 fold (p = 0.03). The activity of SDX with a combination 
of pABA and 5-MTHF was similar to that seen with only the addition of 
pABA. The IC50S of SDX with 5-MTHF and SDX with folic acid are 
similar' to that of SDX alone. The effect of the addition of pABA on SDX 
inhibition is presented in figure 5,3 as a right shift of the dose response 
curve.
Unexpectedly, PBN showed a summatory effect with SDX inhibition, with 
a further 17 fold decrease to the original IC50 value of SDX (p = 0.045, 
table 5.1) and a shift of the dose response curve to the left (figure 5.3). 
PBN also reduced the activity of SDX in combination with the folate 
substrates.
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IC50 (nM)
WITHOUT PROBENECID
SDX 27.7 ± 13.3
SDX + 150nM pABA 572.7 ± 145.2
SDX + 25nM 5-MTHF 23.3 ± 15.3
SDX + O.SnM Folic Acid 33.2 ±22.2
SDX + ISOnM pABA + 25nM 5-MTHF 578.21103.6
WITH PROBENECID
SDX 1.6 ±0.6
SDX + ISOnM pABA 158133.7 *
SDX + 25nM 5-MTHF 1.210.4
SDX + O.SnM Folic Acid 1.510.3
SDX + ISOnM pABA + 25nM 5-MTHF 156.2122.2 1
Table 5.1. Sulfadoxine IC5o values. SDX in folate and pABA-free culture media, 
with supplementation of pABA, 5-MTHF, folic acid or pABA and 5-MTHF 
combined. Carried out in the absence and presence of ISOpM probenecid. Values 
are represented as mean from four to six independent experiments on different 
days, with each data point in triplicate, ± standard deviation. Significance was 
calculated using the Mann-Whitney U test, Bonferroni corrected, and shown as * 
representing a p value < 0.05, comparing the supplemented groups with SDX 
alone or with SDX + PBN.
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Figure 5.3. Semi-logarithmic dose response graph of SDX concentration plotted 
against the percentage parasite growth, for SDX alone and in combination with 
150nM pABA, both in the absence and presence of 150jiM probenecid. Values 
are represented as mean from four to six independent experiments on different 
days, with each data point in triplicate, ± standard deviation.
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5.3.2 Pyrimethamine Antagonism by Folate Substrates
The effects of the folate substrates and PBN on the activity of PYR are 
summarised in table 5.2. The activity of PYR against P, falciparum 3D7 
with the absence of folates and pABA is in the pM range, with a mean IC50 
of 0.5 pM. The only folate substrate at physiological levels that appeared to 
antagonise PYR was pABA, increasing the IC50 91 fold. The IC50S of PYR 
with pABAGl, 5-MTHF or folic acid are similar to that of PYR alone. The 
activity of PYR with all folate substrates combined was similar to that seen 
with only the addition of pABA. The addition of pABA causes a shift of 
the dose response curve to the right (figure 5.4).
There is a slight, but not significant, increase in the inhibitory effect of 
PYR with the addition of PBN compared to PYR alone. There is no 
obvious shift of the dose response curve (figure 5.4) and the IC50 values are 
very low so we could not conclude that there was any definite summatory 
effect.
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ICS0(pM)
WITHOUT PROBENECID
PYR 0.4 ± 0.04
PYR + 150nM pABA 36.613.1
PYR + 160nM pABAG 1 0.410.03
PYR + 25nM 5-MTHF 0.3 1 0.03
PYR + 0.5nM Folic Acid 0.310.05
PYR + 150nM pABA + 25nM 5-MTHF 35.912.7 *
WITH PROBENECID
PYR 0.210.04
PYR + 150nM pABA 21.912.0*
PYR + 160nM pABAG 1 0.310.1
PYR + 25nM 5-MTHF 0.210.02
PYR + 0.5nM Folic Acid 0.210.01
PYR + 150nM pABA + 25nM 5-MTHF 20.3 1 0.9 *
Table 5.2. Pyrimethamine IC50 values. PYR in folate and pABA-free culture 
media, with supplementation of pABA, pABAG, 5-MTHF, folic acid or pABA 
and 5-MTHF combined. Carried out in the absence and presence of 150fiM 
probenecid. Values are represented as mean from four or five independent 
experiments on different days, with each data point in triplicate, ± standard 
deviation. Significance was calculated using the Mann-Whitney U test, 
Bonferroni corrected, and shown as * representing a p value < 0.05, comparing 
the supplemented groups with PYR alone or with PYR + PBN.
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Figure 5.4. Semi-logarithmic dose response graph of PYR concentration plotted 
against the percentage parasite growth, for PYR alone and in combination with 
150nM pABA, both in the absence and presence of 150pM probenecid. Values 
are represented as mean from four or five independent experiments on different 
days, with each data point in triplicate, ± standard deviation.
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5.3.3 Methotrexate Antagonism by Folate Substrates
The activity of MTX in the absence and presence of folate substrates was 
in the nM range, with MTX alone having a mean IC50 of 92.7 nM (table 
5.3). Supplementation with pABAGl, 5-MTHF or folic acid did not appear 
to cause an obvious change in the IC50 value. Supplementation with pABA 
did not significantly antagonise MTX, although a slight increase in the IC50 
value was observed. The activity of MTX with the addition of all folate 
substrates was similar to that seen with the addition of pABA alone. The 
effect of the addition of pABA on MTX inhibition does not cause a shift in 
the dose response curve (figure 5.4).
PBN causes a marginal, non significant, reduction of the MTX IC50 value 
but not enough for a summatory effect to be assumed (table 5.3). 
Probenecid does not cause the dose response curve to obviously shift from 
that seen with MTX alone or MTX with pABA (figure 5.5).
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IC5o (nM)
WITHOUT PROBENECID
MTX 92.7 ±6.7
MTX + 150nM pABA 106.5111.3
MTX + 160nM pABAGl 92.6 ±7.2
MTX + 25nM 5-MTHF 93.917.7
MTX + 0.5nM Folic Acid 94.8 ± 6.1
MTX+ 150nM pABA + 25nM 5-MTHF 121.118.9 *
WITH PROBENECID
MTX 84.7 1 5
MTX + 150nM pABA 147 114.6 *
MTX + 160nM pABAGl 96.713
MTX + 25nM 5-MTHF 97.3 110.1
MTX + 0.5nM Folic Acid 8415.8
MTX + 150nM pABA + 25nM 5-MTHF 159.5 113 *
Table 5.3. Methotrexate IC50 values. MTX in folate and pABA-free culture 
media, with supplementation of pABA, 5-MTHF, folic acid or pABA and 5- 
MTHF combined. Carried out in the absence and presence of 150pM 
probenecid. Values are represented as mean from five to seven independent 
experiments on different days, with each data point in triplicate, ± standard 
deviation. Significance was calculated using the Mann-Whitney U test, 
Bonferroni corrected, and shown as * representing a p value < 0.05, comparing 
the supplemented groups with MTX alone or with MTX + PBN.
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Figure 5.5. Semi-logarithmic dose response graph of MTX concentration plotted 
against the percentage parasite growth, for MTX alone and in combination with 
150nM pABA, both in the absence and presence of 150pM probenecid. Values 
are represented as mean from four to six independent experiments on different 
days, with each data point in triplicate, ± standard deviation.
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5.3.4 Expression of PfFTl and PfFT2 in E. coli and Growth 
Rescue Experiments with Folate Substrates
The E. coli strain BN 1163 with knockouts of the pabA and abgT genes was 
used to study the uptake of folate substrates by P. falciparum folate 
transporters MAL8P1.13 (PfFTl) and PF11_0172 (PfFT2). E. coli does 
not transport folates and the ability of this strain to synthesise or salvage 
pABA is impaired by the knockout of the pabA and abgT genes, allowing 
the potential effect of the salvage of folates or pABA by E. coli 
(ApabA/AabgT) expressing PfFTl or PfFT2 to be observed. As positive 
controls a Synechocystis folate transporter, Slr0642, (Eudes et aL, 2010) and 
two human folate transporters, hPCFT and hRFC, (Subramanian et aL, 
2008) were also expressed in E. coli {ApabA/AabgT). Figure 5.6 shows the 
growth curves of the E. coli {ApabA/AabgT) expressing PfFTl, PfFT2, 
Sli’0642, hPCFT or hRFC along with the plasmid only control (pLOI) in 
combination with increasing concentrations ofpABA, pABAGl, folic acid 
or folinic acid. Increasing concentrations of all substrates showed an 
increase in growth in the E. coli {ApabA/AabgT) expressing folate 
transporters with PfFT2 and the 2 human folate transporters showing the 
highest increase in growth compared to the plasmid only control. Out of all 
the substrates pABA was the most effective at increasing growth in all the 
E. coli {ApabA/AabgT) expressing folate transporters in comparison to the 
plasmid only control, with maximum bacterial growth observed at 20 nM.
212
The monoglutamated form of pABA (pABAGl) was the next most 
effective at increasing growth in all the E. coli {ApabA/AabgT) expressing 
folate transporters in comparison to the plasmid only control, with 
maximum bacterial growth observed at 2.5 pM. Folic acid and folinic acid 
both increased growth to the maximum level at 10 pM for all the E. coli 
{ApabA/AabgT) expressing folate transporters in comparison to the plasmid 
only control.
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Figure 5.6. Growth response of E. coli strain BN1163 (ApabA/AabgT) 
expressing PfFTI and PfFT2 to pABA, pABAGl, folic acid or folinic acid. 
Curves of E. coli strain BN1163 {ApabA/AabgT) expressing empty plasmid only 
(pLOI), synechocystis folate transporter (slr0642), P. falciparum folate 
transporters (PfFTI and PfFT2), human proton coupled folate transporter 
(hPCFT) or human reduced folate carried (hRFC) in combination with 
increasing concentrations of pABA, pABAGl, folic acid or folinic acid. OD^o 
on the y-axis represents culture growth based on the absorbance of the broth 
measured at 600 nM. Values are represented as mean from two experiments, 
with each data point repeated four times, ± standard error.
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5.4 Discussion
In this chapter the antagonistic effect of folate substrates and products on 
the antifolates SDX, PYR and MTX were investigated. At the 
physiological levels found in human plasma, pABA was the only folate 
substrate to antagonise SDX and PYR. pABA did not have a significant 
antagonistic effect on MTX. MTX is a very potent inhibitor of DHFR 
which might explain why salvage of folate substrates is unable to rescue 
the parasites to the same extent as that observed for SDX and PYR 
(Huennekens, 1994). The antagonistic effect of pABA at physiological 
concentrations suggests that it may be the relevant natural folate 
intermediate substrate for P. falciparum, at least for the 3D7 strain used in 
this study. This is further supported by the fact that pABA is the most 
efficient folate substrate at increasing the growth of P. coli (ApabA/AabgT) 
expressing P. falciparum folate transporters PfFTl or PfFT2. However, 
there is a possibility that the parasite could utilise other transporters to 
transport additional folate metabolic intermediates. Indeed, there is one 
other P. falciparum gene (PF10_0215) that has been putatively annotated 
as a member of the folate-biopterin transporter (FBT) family (Martin et al., 
2005). This gene shows significant sequence divergence from other known 
members of the FBT family, so it possible that it could transport different 
metabolites. The possibility that the parasite could express other
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transporters than PfFTl and PfFT2, that transport additional folate 
metabolic intermediates, was not tested in this study.
The lack of any antagonistic effect by 5-MTHF is interesting as this is the 
main folate product present in human plasma and it has occasionally been 
assumed to he the folate source for the parasite to salvage (Hyde, 2005). 
These results are, however, consistent with recent reports showing the lack 
of rescue by 5-MTHF of parasites under inhibition by antifolates (Ochong, 
2008, Nduati et ah, 2008). It is possible that the parasite actually has little 
access to the pre-formed 5-MTHF as this binds electrostatically to deoxy- 
haemoglobin in the RBC and becomes physically happed as the molecule 
picks up oxygen and switches quaternary structure (Wright et aL, 1998). 
This would force the parasite to rely on more available folate substrates, 
including pABA, and could account for the lack of antagonism observed 
with 5-MTHF. The effect of 5-MTHF on the growth of E. coli 
(ApabA/AabgT) expressing P, falciparum folate transporters PfFTl or 
PfFT2 was not tested and so parallels between salvage of 5-MTHF by 
PfFTl or PfFT2 and the lack of any antagonistic effect of 5-MTHF on the 
DHPS and DHFR inhibitors tested cannot be drawn.
The IC50 values obtained for SDX and PYR in the pABA and folate free 
culture medium were 27.7 nM and 0.4 pM respectively, both much lower 
than values previously reported in literature in the presence of folates and
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pABA. Previous work by Wang and colleagues on the P. falciparum 3D7 
strain gave a SDX IC50 value of approximately 48 pM when in the 
presence of folates and pABA (Wang et aL, 1997b). Reynolds and 
colleagues obtained a PYRIC50 value of 5 nM with the P. falciparum 3D7 
strain (Reynolds et al., 2007). The MTX IC50 value obtained in this study 
was 92,7 nM compared to the IC50 value of 49.9 nM previously reported 
for the P. falciparum 3D7 strain in the presence of folates and pABA 
(Kiara et al, 2009). The dramatic reduction in the SDX and PYR IC50 
values when the possibility of folate salvage (especially pABA) is 
withdrawn provides indirect evidence of the need for folate salvage. This 
requirement makes folate salvage still a relevant target for 
chemotherapeutic development.
PBN showed an unexpected summatory effect with SDX inhibition 
indicating that PBN may be restricting the parasite’s salvage of one or 
more metabolite that can help rescue the parasite horn the effect of SDX. 
As the folate cycle is linked to the methionine cycle, with 5-MTHF being 
the methyl donor for the conversion of homocysteine to methionine, 
methionine (which was still present in the RPMI-1640 used here) was 
considered to be a potential metabolite that PBN was inhibiting horn being 
transported into the parasite. Ideally this could have been further 
investigated but folate and pABA-free RPMI-1640 that was also free of 
methionine was not available at the time. No obvious summatory effect of
217
PBN was observed with PYR and MTX to the same extent as that noted
with SDX. This difference could be explained by the metabolite(s) whose 
transport is being reduced by PBN supplement the cell metabolism under 
SDX (DHPS) inhibition but not under MTX or PYR (DHFR) inhibition.
5.4.1 Critical Assessment
Relying on using only the 3D7 strain of P.falciparum was not ideal, but 
attempts at growing HB3, Vl/S and K1 in the folate and pABA-free 
medium were unsuccessful. The folate effect observed by Wang et al 
(1997) was shown to be variable between strains and to have a genetic 
basis (Wang et aL, 1999). Using several strains with different folate 
utilisation phenotypes would, therefore, have been useful in drawing 
conclusions on the effect of physiological concentrations folate pathway 
substrates on antifolate treatment. The 3D7 strain used here grew 
acceptably in folate and pABA-ffee medium with growth observed to be 
only slightly slower than parasites maintained in standard folate and 
pABA complete medium. This suggests that it may have adapted to rely 
on folate biosynthesis making it difficult to draw conclusions from the 
results about the relevance of folate pathway substrate salvage by P 
falciparum in general. One way around this would have been to use low 
levels of folic acid in the continuous culture of alternative strains and
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only transferring the parasites to folate and pABA-free culture medium 
one cycle before the in vitro sensitivity. This was used successfully by 
Wang et al (1997) but was not attempted during this study. The growth 
rescue experiments in E, coli (ApabA/AabgT) expressing P. falciparum 
folate transporters PfFTl or PfFT2 showed pABA to be the most efficient 
folate pathway substrate at rescuing growth. This does help to back up the 
assumption that pABA may be the relevant natural folate intennediate 
substrate for P. falciparum (at least for the 3D7 strain used in this study). 
Variation between strains also is expected to be in relation to the extent of 
pABA uptake rather than the salvage of different folate precursors and 
products altogether.
The investigation of the substrate preference of PfFTl and PfFT2 using E. 
coli (ApabA/AabgT) growth rescue experiments was deemed to be the best 
available method, even though it does not provide direct measurement of 
folate and pABA transport. Previous work by Dr Enrique Salcedo-Sora 
using the X. laevis oocyte expression system encountered problems with 
high backgrounds of pABA uptake by control oocytes, making it 
unsuitable for use (Salcedo-Sora et al, 2011). Using the bacterial system, 
however, still does not allow direct measurement of folate and pABA 
transport. This is due to the fact that only very low levels of protein 
expression and low levels of pABA and folate transport are required to 
salvage the E. coli {ApabA/AabgT) mutants. The concentrations of folate
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and pABA required to salvage the E. coli (ApabA/AabgT) mutants fall 
below the analytical sensitivity limits of available methods. This problem 
has been reported previously for studies on other BT1 homologues by 
other groups, with an inability to increase expression levels to those 
suitable for direct kinetic analysis reported (Eudes et al., 2010). The lack of 
a direct method to measure folate and pABA transport activity by PfFTl 
and PfFT2 led to the decision to use an indirect method, and E. coli growth 
rescue was deemed to be the most sensitive indirect method available.
Further repeats of the growth rescue experiments in E. coli {ApabA/AabgT) 
expressing P. falciparum folate transporters PfFTl or PfFT2 were required 
in order to provide more reliability of the results. These have since been 
carried out by Dr Enrique Salcedo Sora (Salcedo-Sora et al., 2011) and 
showed that, as with the results here, the folate precursor pABA was more 
efficient than pre-formed folate products at rescuing growth.
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CHAPTER 6
6.1 General Discussion
It is necessary to study the metabolite transport pathways of the malaria 
parasite P. falciparum in order to further the understanding of the parasite’s 
biology. As well as this crucial reason identifying and characterising the 
transport pathways may provide potential novel drug targets or drug 
delivery mechanisms (Biagini et al, 2005, Kirk and Saliba, 2007). This is 
especially valuable as chemotherapy remains one of the main management 
strategies in the fight against malaria and the usefulness of the current 
range of antimalarial drugs is seriously threatened by the emergence and 
spread of resistance. No P. falciparum membrane transporter has been 
shown unequivocally to be the site of action of any current antimalarials, 
but the P, falciparum Ca2+ SERCA pump PfATP6 is a proposed site of 
action of the antimalarial artemisinins (Eckstein-Ludwig et al, 2003, 
O'Neill et al., 2010).
The work in this thesis focuses on the transport of amino acids and folate 
pathway substrates. A broad ranging approach using the X. laevis oocyte 
heterologous expression system to screen a gene-specific cDNA library, of 
potential membrane proteins, and the putative amino acid transporter 
PFF 1430c for amino acid transport activity was used first. This was
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followed by a more targeted approach with the characterisation of 
methionine transport by P. falciparum infected RBCs and the free 
parasites. Finally, a biochemical approach to investigate the transport- 
mediated salvage of folate pathway substrates, by detennining then effects 
on antifolate drugs in vitro with and without a transport inhibitor, and a 
targeted investigation of the specificity of two likely P. falciparum folate 
transporters (PfFTl and PfFT2) was carried out.
The erythrocytic stage of the P, falciparum parasite requires an exogenous 
source of seven amino acids but no transporters facilitating the transport of 
these across the parasite plasma have not been previously identified at the 
molecular level (as discussed in section 1.4.5.4). Six putative amnio acid 
transporters have been annotated in the P. falciparum genome (Martin et 
al, 2005) but these have also not yet been functionally characterised. 
Chapter 3 focuses on the use of the X. laevis oocyte expression system to 
functionally characterise a gene-specific cDNA library of 48 putative 
membrane proteins and the previously annotated putative amino acid 
transporter PFF1430c (a member of the AAAP family) for the uptake of 
several amino acids. No definitive transport of amino acids by the cDNA 
library or PFF1430c was observed. However, this could have been due to 
several factors and may not necessarily mean that none of the expressed 
proteins are amino acid transporters. The main factor being that the 
erroneous use of very low substrate concentrations may have resulted in
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too low levels of transport to be detectible using scintillation counting (this 
problem has been discussed in section 3.4.1).
The PFF1430c putative amino acid transporter was identified from the P. 
falciparum genome database by Martin et al (2005) and shows similarity to 
members of the AAAP family. This family of transporters are found in 
eukaryotes and have been shown to transport auxin, single amino acids or 
multiple amino acids, with some having broad substrate specificities for 
naturally occurring amino acids (Saier, 2000a). PFF1430c appears to 
show most sequence similarity with AAAP transporters from other 
protozoans, yeast and mammals, including the human amino acid 
transporter A3 (hATA3) which transports neutral and cationic amino 
acids (Hatanaka et al., 2001). This informed the choice to investigate 
glutamine as a potential substrate as liATA3 shows structural similarity to 
members of the glutamine transporter family. Further research into the 
potential transport activities of this gene are necessary due to the 
inconclusive nature of the results presented in chapter 3. In contrast to 
PFF1430c the genes in the cDNA library were not identified through 
similarity to known amino acid transporters but were simply potential 
membrane transporters based on having three or more trans-membrane 
domains. As discussed in section 3.4.1, only twenty genes in the cDNA 
library contain six or more trans-membrane domains. In eukaryotes only 
three amino acid transporter gene families have fewer than ten trans-
223
membrane domains: the phospholemman (PLM) family of channel 
proteins have one trans-membrane domain; the metabolite:H+ symporter 
(MHS) family of the MFS superfamily have six, ten or twelve trans­
membrane domains; and the mitochondrial carrier (MC) family have six 
trans-membrane domains. This makes it highly unlikely that the genes 
containing fewer than six trans-membrane domains are amino acid 
transporters. The fact that none of the genes in the cDNA library are 
annotated as putative amino acid transporters makes it possible that they 
are transporters of other substrates. This could mean that the range of 
substrates investigated in chapter 3 was too narrow to discern any 
transport activity by these proteins. This is supported by the fact that 
several of the genes in the cDNA library show homology to genes in 
families other than amino acid transporter families.
The X. laevis oocyte expression system has previously been used to 
characterise several P. falciparum proteins and amino acid transporters 
(Gloss et al., 1997, Woodrow et aL, 2000, Downie et al, 2006). It has 
many attractive qualities and the reasons why it was chosen for this study 
are discussed in section 3.1. One concern for the use of the A laevis oocyte 
system is the potential for an endogenous transport system to mask any 
transport by the expressed protein. The X. laevis oocyte does have 
endogenous amino acid transport systems, although these have not all been 
fully characterised as yet. An alternative eukaryotic heterologous
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expression system is yeast; however this was deemed to be a less 
favourable model for functional characterisation of putative P. falciparum 
transport proteins, as yeast appears to have more problems with the AT- 
rich nature of the P. falciparum genome than the X. laevis oocyte does 
(Kirk et ai, 2005).
The lack of identification of amino acid transporters using the X laevis 
oocyte system led to a more targeted approach of characterising of 
methionine transport in P. falciparum parasitised RBCs and free 
trophozoites (chapter 4). Studying the transport of amino acids by P. 
falciparum parasitised RBCs and free parasites is also important as it 
allows the characterisation of the transport processes involved in the whole 
cell. The transport of isoleucine into trophozoite stage P. falciparum 
parasitised RBCs and free trophozoites has been characterised by Martin 
and Kirk (2007) and the findings of this study have been detailed in section 
1.4.4. A study by Cobbold et al (2011), published at the end of this thesis’ 
work, showed methionine to be taken up by trophozoite stage P. 
falciparum parasitised RBCs at a rate 15 fold higher than uninfected RBCs. 
This increased rate of uptake was attributed to the NPP rather than 
increased endogenous transport. In the study by Cobbold et al (2011) 
methionine was shown to be taken up by the parasite via a saturable ATP, 
Na+ and H+ independent system that is also temperature dependent.
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Methionine transport in the trophozoite stage P. falciparum parasite has 
also been canied out in this thesis (chapter 4). In contrast to the findings of 
Cobbold et al (2011), however, no increase in uptake of methionine was 
seen in parasitised RBCs compared to uninfected RBCs. This is a very 
unusual result, not only because of the discrepancy with the findings of 
Cobbold et al (2011), but because most other nutrients studied have been 
shown to be taken up at an increased rate by the parasitised RBC. More 
extensive experiments, with an appropriate control, would have to be 
carried out before definitive conclusions can be drawn from the results in 
chapter 4.
From the use of kinetic transport studies and specific transport inhibitors it 
was inferred that methionine is taken up by free P. falciparum parasites via 
one or more saturable systems showing partial similarity to the vertebrate 
system L. Methionine uptake was most effectively inhibited by cysteine 
and to a lesser degree by lysine and histidine. Despite the fact that 
methionine and cysteine contain a sulphur group it is unlikely that the 
transporter responsible requires the presence of a sulphur group for 
recognition, as the sulphur residue is in different environments in each of 
these amino acids. The inhibition by lysine and histidine also makes this 
theory unlikely.
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Methionine is required for several important processes within the parasite, 
including protein synthesis and methylation of protein, nucleic acids and 
lipids. The malaria parasite has been shown to have a functioning 
methionine synthase as well as a requirement for an exogenous source of 
methionine (Divo et aL, 1985, Krungkrai et al., 1989a, Asawamahasakda 
and Yuthavong, 1993). Methionine synthase converts homocysteine to 
methionine with the addition of a methyl group from the folate product 5- 
MTHF. This links the methionine cycle to the folate pathway, as the 
demethylation of 5-MTHF produces THF, which is recycled back through 
the folate one-carbon metabolism enzymes (see section 1.3.3 for more 
details).
Chapter 5 focuses on investigating the role of salvage of folate pathway 
substrates by detennining their effects on antifolate drugs in vitro and also 
by investigating the substrate specificity of two likely P. falciparum folate 
transporters (PfFTl and PfFT2). Physiological concentrations of folate 
pathways substrates were used in combination with the antifolate drugs 
SDX, PYR and MTX. There has been work previously carried out on the 
effect of exogenous folates on the antifolate antimalarials but these studies 
have generally used concentrations above physiological levels (Watkins et 
aL, 1985, Kinyanjui et al, 1999, Wang et al> 1999, Wang et al, 1997b). 
Previous studies have also only looked at the dynamics of folate salvage in 
the presence of antimalarial antifolates whereas the work in chapter 5 also
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looks at the effect of transport mediated salvage. The only folate pathway 
substrate found to antagonise SDX and PYR at physiological 
concentrations was pABA. The significance of pABA was highlighted 
again as it was the most efficient folate substrate at rescuing growth of E. 
coli (ApabA/AabgT) expressing P. falciparum folate transporters PfFTl or 
PfFT2.
The organic anion transport inhibitor PBN has been shown to 
chemosensitise parasites resistant to the antifolate antimalarials (Nzila et 
al, 2003, Nzila et al., 2004, Masseno et ah, 2009). The uptake of 
exogenous folate by P. falciparum infected RBCs and free parasites has 
also been shown to be inhibited by PBN (Wang et al, 2007), suggesting 
that the reversal of resistance is due to PBN blocking the transport of 
folates into the parasite and preventing the parasite overcoming the effect 
of the antifolates with salvaged folates. Initial analysis of the results in 
chapter 5 appeared to support this theoiy, as a reduction of the antagonism 
of SDX and PYR by pABA was observed with the addition of PBN. 
However, the addition of PBN also increases the inhibitory effect of SDX 
and PYR in the absence of folates so the experiments used in this study are 
not definitive enough to support the theory that PBN elicits its 
chemosensitising properties through blocking folate salvage. As the 
addition of PBN should inhibit organic anion transport, the similar effect of 
pABA with and without PBN could be due to pABA entering the
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intracellular parasite in another way, potentially via passive diffusion. This 
result is interesting when correlated with the fact that pABA is the most 
efficient folate substrate at increasing the growth of E. coli (ApabA/AabgT) 
expressing P. falciparum folate transporters PfFTl or PfFT2. The fact that 
pABA was the only folate pathway substrate to antagonise SDX and PYR, 
and that it was the most effective at rescuing growth of E. coli 
{ApabA/AabgT) expressing P. falciparum folate transporters PfFTl or 
PfFT2 suggests that it could be the most influential folate pathway 
substrate for the malaria parasite during the erythrocytic stages. This is an 
interesting observation as pABA is not significantly utilised or synthesised 
in humans making pABA salvage a potential target for chemotherapy. 
Targeting pABA salvage may improve the antimalarial efficacy of the 
antifolates SDX and PYR, and this could be achieved by blocking pABA 
salvage with inhibitors or using pABA-deficient diets.
As discussed previously the current antimalarial armamentarium is under 
threat due to the emergence and spread of resistance. To overcome this 
there is a need to find new drug targets or overcome resistance to current 
drugs. There are no current antimalarial drugs that target either amino acid 
transporters themselves or utilise them as drug delivery strategies. Despite 
this, there is precedence for drugs targeting amino acid transporters in other 
organisms. Drugs targeting members of the NSS family account for 2.7 % 
of all FDA approved drugs (Overington et al., 2006, Staines et al., 2010),
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with many widely known psychiatric drugs, including fluoxetine (Prozac), 
targeting NSS family members (Bingham and Napier, 2009). Three of the 
six putatively annotated amino transporters identified in the P. falciparum 
genome (PFB0435c, PFE0775c and PF11_0334) show similarity to 
members of the NSS family and so are of particular interest for further 
study (Martin et aL, 2005). The antimalarial antifolates are well known 
and characterised but they are becoming less useful with the spread of 
resistance. The reversal of resistance to current drugs is a good potential 
way to extend the usage of antimalarial drugs currently available. 
Transporters have been shown to be involved in reversing drug resistance 
(as discussed in section 1.4.3) so transport inhibitors may be good potential 
reversal agents of resistance to certain drugs. In the case of the antimalarial 
antifolates the organic anion transport inhibitor PBN has been shown to 
reverse resistance (Nzila et al, 2003, Nzila et al., 2004, Masseno et al, 
2009). Concentrations of PBN capable of chemosensitising parasites are 
easily and safely achieved in vivo in humans and clinical trials combining 
SP with PBN have been carried out in African children suffering from P. 
falciparum malaria (Sowunmi et al., 2004b, Sowunmi et al, 2004a). The 
results from these trials showed that PBN significantly increased the 
efficacy of SP. This infonnation is very interesting as it suggests that 
inhibiting Plasmodium anion transporters may be of clinical importance in 
the use of antimalarial antifolates (Nzila, 2006). This is therefore a topic of
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real clinical translational value that should encourage the research on 
agents capable of reversing antimalarial resistance.
6.2 Future Work
In order to determine if any of the genes in the cDNA library are actually 
transporters the X laevis oocyte expression system could be used to look 
again at these. This work should focus only on the nineteen genes with six 
or more trans-membrane domains. Using a wider range of substrates would 
also be useful as no genes in the cDNA library are currently annotated as 
amino acid transporters. Increasing the substrate concentrations to 
physiological levels would need to be done as the low substrate 
concentrations used in chapter 3 may have led to transport being present 
but undetectable. Any known endogenous transport by the X. laevis 
oocytes would also need to be taken into account. However, as the 
endogenous transport systems in Xenopus oocytes have not been 
characterised completely (Van Winkle, 1993) further characterisation of 
these would also be worthwhile future work. Using the X, laevis oocyte 
expression system to characterise PFF1430c more thoroughly and the other 
five putative amino acid transporters identified hi the P. falciparum 
genome is also worthwhile.
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There is a need to further investigate the transport of methionine by P. 
falciparum infected RBCs to ascertain whether the observation in chapter 
4, that the P. falciparum infected RBC does not have an increased rate of 
uptake of methionine compared to uninfected RBCs, is correct. This result 
is at odds with that observed for other nutrients and the results from 
Cobbold et al (2011) so further work, including appropriate controls, is 
needed. More comprehensive characterisation of the transport of 
methionine is also required, in both P. falciparum infected RBCs and free 
parasites. This should examine energy dependence, ion dependence, the 
effect of temperature (to allow the Ea to be calculated, which will give 
more information on the nature of transport) and the profile of inhibition 
by other amino acids and classical transport inhibitors. Only methionine 
and isoleucine transport have been characterised in P. falciparum infected 
RBCs and free parasites. These are potentially the most interesting, and 
relevant, as the parasite cannot rely on degradation of haemoglobin alone 
for these. However, in vitro growth of the parasite has been shown to rely 
on the presence of a further five amino acids: cysteine, glutamic acid, 
glutamine, proline and tyrosine. Therefore, characterisation of the transport 
of these would prove to be useful future work.
Only the 3D7 strain of P. falciparum was used in the antagonism 
experiments in chapter 5. The 3D7 strain has been successfully cultured 
continuously in folate and pABA-free medium which allowed the effects
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of low levels of folates at physiological concentrations to be examined. 
Other strains were unable to be grown in this medium and so were not used 
in chapter 5. However, it may be possible to culture other strains by 
following the protocol described by Wang et al (1997b) in which parasites 
are cultured in medium containing low levels of folic acid then transferred 
to folate and pABA-free medium one cycle before being used for an in 
vitro drug sensitivity assay. This would be useful future work as it would 
allow strains with different folate utilisation phenotypes to be used and 
examine the extent of pABA salvage for these as well as 3D7. It would 
also be useful to further investigate the observed summatory effect of PBN 
with SDX by eliminating other potential nutrients from the culture medium 
that may be being blocked from being salvaged.
233
REFERENCES
ABDALLA, S. H., PASVOL, G. (ed.) 2004. Malaria: A Hematological 
Perspective, London: Imperial College Press.
ALKER, A. P., LIM, P., SEM, R., SHAH, N, K., YI, P., BOUTH, D. M., 
TSUYUOKA, R., MAGUIRE, J. D., FANDEUR, T., ARIEY, F., 
WONGSRI CHAN ALAI, C. & MESHNICK, S. R. 2007. Pfindrl 
and in vivo resistance to artesunate-mefloqnine in falciparum 
malaria on the Cambodian-Thai border. Am J Prop Med Hyg, 76, 
641-7.
ALKHALIL, A., COHN, J. V., WAGNER, M. A., CABRERA, J. S, 
RAJAPANDI, T. & DESAI, S. A. 2004. Plasmodium falciparum 
likely encodes the principal anion channel on infected human 
erythrocytes. R/ood, 104,4279-86.
ALLEN, J. & KIRK, K. 2004. The membrane potential of the 
intraerythrocytic malaria parasite Plasmodium falciparum. J Biol 
Chem, 279, 11264-11272.
ALTSCHUL, S. F, MADDEN, T. L., SCHAFFER, A. A., ZHANG, J, 
ZHANG, Z., MILLER, W. & LIPMAN, D. J. 1997. Gapped 
BLAST and PSI-BLAST: a new generation of protein database 
search programs. Nucl Acids Res., 25, 3389-3402.
ALTSCHUL, S. F., WOOTTON, J. C., GERTZ, M., AGARWALA, R., 
MORGULIS, A., SCHAFFER, A. A. & YU, Y.-K. 2005. Protein 
database searches using compositionally adjusted substitution 
matrices. Febs J, 272, 5101-5109.
ANGIER, R. B., BOOTHE, J. H., HUTCHINGS, B. L., MOWAT, J. H., 
SEMB, J., STOKSTAD, E. L., SUBBAROW, Y., WALLER, C. 
W., COSULICH, D. B., FAHRENBACH, M. J., HULTQUIST, M. 
E., KUH, E., NORTHEY, E. H., SEEGER, D. R., SICKELS, J. P. 
& SMITH, J. M., JR. 1945. Synthesis of a Compound Identical 
with the L. Casei Factor Isolated horn Liver. Science, 102,227-8.
ANSORGE, I., BENTING, J, BHAKDI, S. & LINGELBACH, K. 1996. 
Protein sorting in Plasmodium falciparum-mfscted. red blood cells 
permeabilised with the pore forming streptolysin O. Biochem J, 
315,307-314.
ANSORGE, L, PAPROTKA, K., BHAKDI, S. & LINGELBACH, K. 
1997. Permeabilization of the erythrocyte membrane with 
streptolysin O allows access to the vacuolar membrane of 
Plasmodium falciparum and a molecular analysis of membrane 
topology. Mol Biochem Parasitol, 84,259-261.
ARFMAN, N., WORRELL, V. & INGRAM, L. O. 1992. Use of the tac 
promoter and laclq for the controlled expression of Zymomonas
234
mobilis fermentative genes in Escherichia coli and Zymomonas 
mobilis. Journal of Bacteriology, 174, 7370-7378.
ASAWAMAHASAKDA, W. & YUTHAVONG, Y. 1993. The methionine 
synthesis cycle and salvage of methyltetrahydrofolate from host red 
cells in the malaria parasite {Plasmodium falciparum). 
Parasitology, 107, 1-10.
ATAMNA, H. & GINSBURG, H. 1997. The malaria parasite supplies 
glutathione to its host cell—investigation of glutathione transport 
and metabolism in human erythrocytes infected with Plasmodium 
falciparum. Eur JBiochem, 250, 670-9.
BAILEY, L. B. (ed.) 2010. Folate in health and disease, Boca Raton, FL: 
CRC Press.
BANYAL, H. S. & INSELBURG, J. 1986. Plasmodium falciparum: 
induction, selection, and characterization of pyrimethamine- 
resistant mutants. Exp Parasitol, 62, 61-70.
BARKER, G. A. & ELLORY, J. C. 1990. The identification of neutml 
amino acid transport systems. Exp Physiol, 75, 3-26.
BARRETT, M. P. & FAIRLAMB, A. H. 1999. The biochemical basis of 
arsenical-diamidine cross-resistance in African trypanosomes. 
Parasitol Today, 15,136-140.
BARRETT, M. P., ZHANG, Z. Q., DENISE, H., GIROUD, C. & BALTZ, 
T. 1995. A diamidine-resistant Trypanosoma eqiriperdumclone 
containes a P2 purine transporter with reduced substrate afinity. 
Mol Biochem Parasitol, 73, 223-229.
BASCO, L. K. & RINGWALD, P. 2003. In vitro activities of piperaquine 
and other 4-amino quinolines against clinical isolates of 
Plasmodium falciparum in Cameroon. Antimicrob Agents 
Chemother, 47, 1391-4.
BELITSKY, B. R., GUSTAFSSON, M. C., SONENSHEIN, A. L. & VON 
WACHENFELDT, C. 1997. An Irp-like gene of Bacillus subtilis 
involved in branched-chain amino acid transport. Journal of 
Bacteriology, 179, 5448-5457.
BELLE, R., MAROT, J. & OZON, R. 1976. Nature of progesterone action 
on amino acid uptake by isolated full-grown oocyte of Xenopus 
laevis. Biochim Biophys Acta, 419, 342-348.
BENNETT, T. N, PAGUIO, M., GLIGORIJEVIC, B, SEUDIEU, C, 
KOSAR, A. D., DAVIDSON, E. & ROEPE, P. D. 2004. Novel, 
Rapid, and Inexpensive Cell-Based Quantification of Antimalarial 
Drug Efficacy. Antimicrob Agents Chemother, 1807-1810.
BERMINGHAM, A. & DERRICK, J. P. 2002. The folic acid biosynthesis 
pathway in bacteria: evaluation of potential for antibacterial drug 
discovery. Bioessays, 24,637-48.
BIAGINI, G. A., BRAY, P. G., SPILLER, D. G., WHITE, M. R. & 
WARD, S. A. 2003a. The digestive food vacuole of the malaria
235
parasite is a dynamic intracellular CA2+ store. J Biol Chem, 278, 
27910-5.
BIAGINI, G. A., O’NEILL, P. M., NZILA, A., WARD, S. A. & BRAY, P. 
G. 2003b. Antimalarial chemotherapy: young guns or back to the 
future? Trends Parasitol, 19, 479-87.
BIAGINI, G. A., PASINI, E. M., HUGHES, R., DE KONING, H. P., 
VIAL, H. L, O’NEILL, P. M., WARD, S. A. & BRAY, P. G. 2004. 
Characterization of the choline carrier of Plasmodium falciparum', a 
route for the selective delivery of novel antimalarial drugs. Blood, 
104, 3372-7.
BIAGINI, G. A., WARD, S. A. & BRAY, P. G. 2005. Malaria parasite 
transporters as a drug-delivery strategy. Trends Parasitol, 21, 299- 
301.
BINGHAM, M. & NAPIER, S. 2009. Overview: transporters as targets for 
drug discovery. Topics in Medicinal Chemistry, 4,1-13.
BJORKMAN, A. & PHILLIPS-HOWARD, P. A. 1990. Drug-resistant 
malaria: mechanisms of development and inferences for malaria 
control. Trans R Soc Trop Med Hyg, 84,323-4.
BRAY, P. G, MARTIN, R. E, TILLEY, L., WARD, S. A., KIRK, K. & 
FIDOCK, D. A. 2005a. Defining the role of PfCRT in Plasmodium 
falciparum chloroquine resistance. Mol Microbiol, 56, 323-33.
BRAY, P. G., WARD, S. A. & O'NEILL, P. M. 2005b. Quinolines and 
artemisinin: chemistry, biology and history. Curr Top Microbiol 
Immunol, 295, 3-38.
BRITTON, W. J. & LOCKWOOD, D. N. 2004. Leprosy. Lancet, 363, 
1209-19.
BROER, A., HAMPRECHT, B. & BROER, S. 1998. Discrimination of 
two amino acid activities in 4F2 heavy chain expressing Xenopus 
laevis oocytes. Biochem J, 333, 549-554.
BRUCE-CHWATT, L. J. 1981. Alphonse Laveran's discovery 100 years 
ago and today's global fight against malaria. Journal of the Royal 
Society of Medicine, 74, 531-536.
BRUCE-CHWATT, L. J. 1989. History of malaria from prehistory to 
eradication, Edinburgh Churchill Livingstone.
BUNNAG, D., KANDA, T, KARBWANG, J, THIMASARN, K, 
PUNGPAK, S. & HARINASUTA, T. 1996. Artemether or 
artesunate followed by mefloquine as a possible treatment for 
multidrug resistant falciparum malaria. Trans R Soc Trop Med Hyg, 
90,415-7.
BUSCH, W. & SAIER, M. H., JR. 2002. The transporter classification 
(TC) system, 2002. Critical Reviews in Biochemistry and 
Molecular Biology, 37,287-337.
BZIK, D, J., LI, W. B., HORII, T. & INSELBURG, J. 1987. Molecular 
cloning and sequence analysis of the Plasmodium falciparum
236
dihydro folate reductase-thymidylate synthase gene. Proc Natl Acad 
Sci USA, 84, 8360-4.
CABANTCHIK, Z. I. 1990. Properties of permeation pathways induced in 
the human red cell membrane by malaria parasites. Blood Cells, 16, 
421-32.
CABANTCHIK, Z. L. 1989. Altered membrane transport of malaria- 
infected erythrocytes: a possible pharmacologic target. Blood, 74, 
1464-71.
CARMARGO, L. M., DE OLIVEIRA, S, BASANO, S. & GARCIA, C. 
R. 2009. Antimalarials and the fight against malaria in Brazil. Ther 
Clin RiskManag, 5, 311-7.
CARRUTHERS, A. & MELCHOIR, D. L. 1988. Effects of lipid 
environment on membrane transport: the human erythrocyte sugar 
transport protein/lipid bilayer system. Annual Review of 
Physiology, 50,257-271.
CARTER, N. S., BEN MAMOUN, C., LIU, W., SILVA, E. O., 
LANDFEAR, S. M., GOLDBERG, D. E. & ULLMAN, B. 2000. 
Isolation and functional characterization of the PfNTl nucleoside 
transporter gene tfom Plasmodium falciparum. J Biol Chem, 275, 
10683-91.
CARTER, N. S., BERGER, B. J. & FAIRLAMB, A. H. 1995. Uptake of 
diamidine drugs by the P2 nucleoside transporter in melarsen- 
sensitive nadn -resistant Trypanosoma brucei. J Biol Chem, 270, 
28153-28157.
CARTER, N. S. & FAIRLAMB, A. H. 1993. Arsenical-resistant 
trypanosomes lack an unusual adenosine transporter. Nature, 361, 
173-176.
CHEN, L. 1991. Recent studies on antimalarial efficacy of piperaquine and 
hydroxypiperaquine. Chin Med J (Engl), 104,161-3.
CHOI, I. & MIKKELSEN, R. B. 1990. Plasmodium falciparum'. 
ATP/ADP transport across the parasitophorous vacuolar and 
plasma membranes. Exp Parasitol, 71,452-462.
CHRAIBI, A. & HORISBERGER, J. D. 2002. Na self inhibition of human 
epithelial Na channel: temperature dependence and effect of 
extracellular proteases. J Gen Physiol, 120, 133-145.
CHRISTENSEN, H. N. 1985. On the strategy of kinetic discrimination of 
amino acid transport systems. JMembr Biol, 84, 97-103.
CHRISTENSEN, H. N., HANDLOGTEN, M. E., LAM, L, TAGER, H. S. 
& ZAND, R. 1969. A bicyclic amino acid to improve 
discriminations among transport systems. J Biol Chem, 244, 1510- 
20.
CHRISTOPHERS, S. R. & FULTON, J. D. 1939. Expemnents with 
isolated malaria parasites {Plasmodium knowlesi) free from red 
cells. Ann Trop Med Parasitol, 33, 161-170.
237
GLOSS, E. L, GRAF, P., HABERMEIER, A., CUNNINGHAM, J. M. & 
FORSTERMANN, U. 1997. Human cationic amino acid 
transporters hCAT-1, hCAT-2A, and hCAT-2B: thi*ee related 
earners with distinct transport properties. Biochemistry, 36, 6462-8.
CLYDE, D. F., MOST, H., MCCARTHY, V. C. & VANDERBERG, J. P. 
1973. Immunization of man against sporozite-induced falciparum 
malaria. Am J Med Sci, 266,169-77.
COATNEY, G. R. 1963. Pitfalls in a discovery: the chronicle of 
chloroquine. Am J Trop MedHyg, 12, 121-8.
COBBOLD, S. A., MARTIN, R. E. & KIRK, K. 2011. Methionine 
transport in the malaria parasite Plasmodium falciparum. Int J 
Parasitol, 41, 125-35.
COLLINS, W. E. & JEFFERY, G. M. 2007. Plasmodium malariae: 
Parasite and disease. Clinical Microbiology Reviews, 20, 579-592.
CONTEH, L., SICURI, E., MANZI, F, HUTTON, G, OBONYO, B., 
TEDIOSI, F., BIAO, P, MASIKA, P., MATOVU, F., OTIENO, 
P., GOSLING, R. D., HAMEL, M., ODHIAMBO, F. O., 
GROBUSCH, M. P., KREMSNER, P. G, CHANDRAMOHAN,
D. , APONTE, J. J., EGAN, A, SCHELLENBERG, D., MACETE,
E, SLUTSKER, L., NEWMAN, R. D., ALONSO, P, 
MENENDEZ, C. & TANNER, M. 2010. The cost-effectiveness of 
intennittent preventive treatment for malaria in infants in Sub- 
Saharan Africa. PLoS ONE, 5, el0313.
COOMBS, G. H., GOLDBERG, D. E., KLEMBA, M., BERRY, C, KAY, 
J. & MOTTRAM, J. C. 2001. Aspartic proteases of Plasmodium 
falciparum and other parasitic protozoa as drug targets. Trends 
Parasitol, 17, 532-7.
COWMAN, A. F. & CRABB, B. S. 2007. Functional genomics: 
identifying drug targets for parasitic diseases. Trends Parasitol, 23, 
589-595.
COX-SINGH, J. & SINGH, B. 2008. Knowlesi malaria: newly emergent 
and of public health importance? Trends Parasitol, 24, 406-410.
COX, F. E. G. (ed.) 1993. Modem parasitology: a textbook of 
parasitology, Oxford: Blackwell Science, Ltd.
CRANMER, S. L., CONANT, A. R., GUTTERIDGE, W. E. & 
HALESTRAP, A. P. 1995. Characterization of the enhanced 
transport of L- and D-lactate into human red blood cells infected 
with Plasmodium falciparum suggests the presence of a novel 
saturable lactate proton cotransporter, J Biol Chem, 270, 15045-52.
DAR, O., KHAN, M. S. & ADAGU, I. 2008. The potential use of 
methotrexate in the treatment of falciparum malaria: In vitro assays 
against sensitive and multidrug-resistant falciparum strains. 
Japanese Journal of Infectious Diseases, 61,210-211.
238
DAS, K. C, VIRDI, J. S. & HERBERT, H. 1992. Survival of the dietarily 
deprived: folate deficiency protects against malaria in primates. 
Blood, 80, Suppl 1: 281a.
DAVIS, T. M., HUNG, T. Y., SIM, I. K., KARUNAJEEWA, H. A. & 
ILETT, K. F. 2005. Piperaquine: a resurgent antimalarial drug. 
Drugs, 65, 75-87.
DE KONING, H. P., ANDERSON, L. F., STEWART, M., 
BURCHMORE, R. J. S., WALLACE, L. J. M. & BARRETT, M.
P. 2004. The trypanocide diminazine aceturate is accumulated 
predominantly through the TbATl purine transporter: additional 
insights on diamidine resistance in African trypanosomes. 
Antimicrob Agents Chemother, 48,1515-1519.
DE KONING, H. P., BRIDGES, D. J. & BURCHMORE, R. J. 2005. 
Purine and pyrimidine transport in pathogenic protozoa: from 
biology to therapy. FEMS Microbiol Rev, 29, 987-1020.
DEAN, M., HAMMON, Y. & CHIMINI, G. 2001. The human ATP- 
binding cassette (ABC) transporter superfamily. Journal of Lipid 
Research, 42, 1007-1017.
DECHERF, G., EGEE, S., STAINES, H. M., ELLORY, J. C. & 
THOMAS, S. L. 2004. Anionic channels in malaria-infected 
human red blood cells. Blood Cells Mol Dis, 32, 366-71. 
DERBYSHIRE, E. T., FRANNSEN, F. J., DE VRIES, E., MORIN, C., 
WOODROW, C. J., KRISHNA, S. & STAINES, H. M. 2008. 
Identification, expression and characterisation of a Babesia bovis 
hexose transporter. Mol Biochem Parasitol, 161, 124-129.
DESAI, S. A., KROGSTAD, D. J. & MCCLESKY, E. W. 1993. A 
nutrient-permeable channel on the intraerythrocytic malaria 
parasite. Nature, 362, 643-646.
DESAI, S. A. & ROSENBERG, R. 1997. Pore size of the malaria 
parasite's nutrient channel. Proc Natl Acad Sci USA, 94, 2045- 
2049.
DESJARDINS, R. E., CANFIELD, C. J., HAYNES, J. D. & CHULAY, J. 
D. 1979, Quantitative assessment of antimalarial activity in vitro by 
a semiautomated microdilution technique. Antimicrob Agents 
Chemother, 16,710-718.
DIAZ DE LEON, A. 1937. Treatment of malaria with sulfonamide 
compounds. Publ Hlth. Rep., Wash.,, 52, 1460-1462.
DITTRICH, S., MITCHELL, S. L., BLAGBOROUGH, A. M., WANG,
Q, WANG, P., SIMS, P. F. & HYDE, J. E. 2008. An atypical 
orthologue of 6-pyravoyltetrahydropterin synthase can provide the 
missing link in the folate biosynthesis pathway of malaria parasites. 
Mol Microbiol, 61, 609-618.
DIVO, A. A., GEARY, T. G., DAVIS, N. L. & JENSEN, J. B. 1985. 
Nutritional requirements of Plasmodium falciparum in culture. I.
239
Exogenously supplied dialyzable components necessary for 
continuous growth. JProtozool, 32, 59-64.
DOBROWOLSKI, A, SOBCZAC-ELBOURNE, I. & LOLKEMA, J. S. 
2007, Membrane topology prediction by hydropathy profile 
alignment: membrane topology of the NaC^)-glutamate transporter, 
GltS. Biochemistry, 46,2326-2332.
DOBSON, P. B. & KELL, D. B. 2008. Canier-mediated cellular uptake of 
pharmaceutical drugs: and exception or a rule? Nat Rev Drug 
Discov, 7, 205-220.
DOWNIE, M. J., EL BISS ATI, K., BOBENCHIK, A. M., LOCHLAIMM,
L, N., AMERIK, A, ZUFFEREY, R, KIRK, K. & MAMOUN, C. 
B. 2010. PfNT2, a pennease of the equilibrative nucleoside 
transporter family in the endoplasmic reticulum of Plasmodium 
falciparum. J Biol Chem, 285, 20827-20833.
DOWNIE, M. J., SALIBA, K. J, BROER, S., HOWITT, S. M. & KIRK, 
K. 2007. Purine nucleobase transport in the intraerythrocytic 
malaria parasite. Int J Parasitol
DOWNIE, M. J., SALIBA, K. J, BROER, S., HOWITT, S. M. & KIRK, 
K. 2008. Purine nucleobase transport in the intraerythrocytic 
malaria parasite. Int J Parasitol, 38,203-209.
DOWNIE, M. J., SALIBA, K. J., HOWITT, S. M., BROER, S. & KIRK, 
K. 2006. Transport of nucleosides across the Plasmodium 
falciparum parasite plasma membrane has characteristics of 
PfENTl. Mol Microbiol, 60, 738-48.
DUTHIE, S. L, HORGAN, G., DE ROOS, B., RUCKLIDGE, G., REID,
M. , DUNCAN, G., PIRIE, L, BASTEN, G. P. & POWERS, H. J. 
2010. Blood folate status and expression of proteins involved in 
immune fimction, inflammation, and coagulation: Biochemical and 
proteomic changes in the plasma of humans in response to long- 
term synthetic folic acid supplementation. Journal of Proteome 
Research, 9, 1941-1950.
DYER, M., JACKSON, M., MCWHINNEY, C., ZHAO, G. & 
MIKKELSEN, R. B. 1996. Analysis of a cation-transporting 
ATPase of Plasmodium falciparum. Mol Biochem Parasitol, 78, 1- 
12.
ECKSTEIN-LUDWIG, U, WEBB, R. J., VAN GOETHEM, I. D., EAST, 
J. M., LEE, A. G., KIMURA, M., O’NEILL, P. M., BRAY, P. G., 
WARD, S. A. & KRISHNA, S. 2003. Artemisinins target the 
SERCA of Plasmodium falciparum. Nature, 424, 957-61.
EGAN, T. J. & KASCHULA, C. H. 2007. Strategies to reverse drug 
resistance in malaria. Curr Opin Infect Dis, 20, 598-604.
EGGELING, L. & SAHM, H. 2003. New ubiquitous translocators: amino 
acid export by Corynebacterium glutamicum. Archives of 
Microbiology, 180, 155-160.
240
ELFORD, B. C.> COWAN, G. M. & FERGUSON, D. J. 1995. Parasite- 
regulated membrane transport processes and metabolic control in 
malaria-infected erythrocytes. Biochem J, 308 (Pt 2), 361-74.
ELFORD, B. C, HAYNES, J. D., CHULAY, J. D. & WILSON, R. J. 
1985. Selective stage-specific changes in the permeability to small 
hydrophilic solutes of human erythrocytes infected with 
Plasmodium falciparum. Mol Biochem Parasitol, 16,43-60.
ELLIOTT, J. L., SALIBA, K. J. & KIRK, K. 2001. Transport of lactate 
and pyruvate in the intraerythrocytic malaria parasite, Plasmodium 
falciparum. Biochem J, 355, 733-9.
ELLIS, J, CARLIN, A, C, S., WU, J., LIU, J. & ROSEN, B. P. 1995. 
Topological analysis of the lysine-specific permease of Escherichia 
coli. Microbiology, 141, 1927-1935.
ENAYATI, A. & HEMINGWAY, J. 2010. Malaria management: past, 
present and future. Annual Review of Entomology, 55, 569-91.
ENGEL, P., KRAMER, R. & UNDEN, G. 1994. Transport of C4- 
dicarboxylates by anaerobically grown Escherichia colt energetics 
and mechanism of exchange, uptake and efflux. Eur J Biochem, 
222, 605-614.
EUDES, A., KUNJI, E. R. S., NOIRIEL, A., KLAUS, S. M. J., VICKERS, 
T. J„ BEVERLEY, S. M., GREGORY, J. F. & HANSON, A. D. 
2010. Identification of Transport-critical Residues in a Folate 
Transporter fiom the Folate-Biopterin Transporter (FBT) Family. 
Journal of Biological Chemistry, 285,2867-2875.
EYLES, D. E., HOO, C. G, WARREN, M. & SANDOSHAM, A. A. 
1963. Plasmodium Falciparum Resistant to Chloroquine in 
Cambodia. Am J Prop Med Hyg, 12, 840-3.
FALCO, E. A., GOODWIN, L. G., HITCHINGS, G. H., ROLLO, I. M. & 
RUSSELL, P. B. 1951. 2:4-diaminopyrimidines- a new series of 
antimalarials. Br J Pharmacol Chemother, 6,185-200.
FAMIN, O. & GINSBURG, H. 2002. Differential effects of 4- 
ammoquinoline-containing antimalarial drugs on hemoglobin 
digestion in Plasmodium falciparum-mfeoXQd, erythrocytes. 
Biochem Pharmacol, 63, 393-8.
FERONE, R. 1977. Folate metabolism in malaria. Bull World Health 
Organ, 55,291-8.
FERONE, R, BURCHALL, J. J. & HITCHINGS, G. H. 1969. 
Plasmodium berghei dihydro folate reductase. Isolation, properties, 
and inhibition by antifolates. Mol Pharmacol, 5,49-59.
FIDOCK, D. A, NOMURA, T., TALLEY, A. K., COOPER, R. A, 
DZEKUNOV, S. M, FERDIG, M. T., URSOS, L. M., SIDHU, A. 
B., NAUDE, B, DEITSCH, K. W., SU, X. Z., WOOTTON, J. C., 
ROEPE, P. D. & WELLEMS, T. E. 2000. Mutations in the P. 
falciparum digestive vacuole transmembrane protein PfCRT and
241
evidence for their role in chloroquine resistance. Mol Cell, 6, 861- 
71.
FISCHER, W. N., LOO, D. D.} KOCH, W., LUDEWIG, U., BOORER, K. 
J., TEGEDER, M., RENTSCH, D., WRIGHT, E. M. & 
FROMMER, W. B. 2002. Low and high affinity amino acid H+- 
contransporters for cellular import of neutral and charged amino 
acids. The Plant Journal: For Cell And Molecular Biology, 29, 
717-731.
FIVELMAN, Q. L., ADAGU, I. S. & WARHURST, D. C. 2007. Effects 
of piperaquine, chloroquine, and amodiaquine on drug uptake and 
of these in combination with dihydro artemisinin against drug- 
sensitive and -resistant Plasmodium falciparum strains. Antimicrob 
Agents Chemother, 51,2265-7.
FOLEY, M. & TILLEY, L. 1998. Quinoline antimalarials: mechanisms of 
action and resistance and prospects for new agents. Pharmacol 
Ther, 79, 55-87.
FOOTE, S. J. & COWMAN, A. F. 1994. The mode of action and the 
mechanism of resistance to antimalarial drugs. Acta Prop, 56, 157- 
71.
FORWARD, J., BEHRENDT, M. C, WYBORN, N. R., R, C. & KELLY, 
D. J. 1997. The TRAP transporters: a new family of periplasmic 
solute transport systems encoded by the dctPQM genes of 
Rhodobacter capsulatus and by homologues in diverse Gram­
negative bacteria. Journal of Bacteriology, 179, 5482-5493.
FRANCIS, P., CHUNG, J. J., YASUI, M., BERRY, V., MOORE, A., 
WYATT, M. K., WISTOW, G., BHATTACHARYA, S. S. & 
AGRE, P. 2000. Functional impairment of lens aquaporin in two 
families with dominantly inherited cataracts. Human Molecular 
Genetics, 9, 2329-2334.
FREMEAU, R. T., JR, CARON, M. G. & BLAKELY, R. D. 1992. 
Molecular cloning and expression of a high affinity L-proline 
transporter expressed in putative glutamatergic pathways of rat 
brain. Neuron, 8, 915-926.
GARDNER, M. J, HALL, N, FUNG, E, WHITE, O, BERRIMAN, M, 
HYMAN, R. W„ CARLTON, J. M, PAIN, A, NELSON, K. E„ 
BOWMAN, S, PAULSEN, I. T, JAMES, K, EISEN, J. A, 
RUTHERFORD, K, SALZBERG, S. L, CRAIG, A, KYES, S, 
CHAN, M. S, NENE, V, SHALLOM, S. J, SUH, B, 
PETERSON, J, ANGIUOLI, S, PERTEA, M, ALLEN, J, 
SELENGUT, J, HAFT, D, MATHER, M. W, VAIDYA, A. B, 
MARTIN, D. M, FAIRLAMB, A. H, FRAUNHOLZ, M. J, 
ROOS, D. S, RALPH, S. A, MCFADDEN, G. I, CUMMINGS, 
L. M, SUBRAMANIAN, G. M, MUNGALL, C, VENTER, J. C, 
CARUCCI, D. J, HOFFMAN, S. L„ NEWBOLD, C, DAVIS, R. 
W., FRASER, C. M. & BARRELL, B. 2002. Genome sequence of
242
the human malaria parasite Plasmodium falciparum. Nature, 419, 
498-511.
GARNHAM, P. C. C. 1966. Malaria Parasites And Other Haemosporidia, 
Oxford, Blackwell Scientific Publications.
GEARY, T. G., DIVO, A. A. & JENSEN, J. B. 1985. Nutritional 
requirements of Plasmodium falciparum in culture. II. Effects of 
antimetabolites in a semi-defined medium. JProtozool, 32, 65-9.
GENTON, B, BETUELA, I, FELGER, I., AL-YAMAN, F., ANDERS, 
R. F., SAUL, A., RARE, L., BAISOR, M., LORRY, K., BROWN, 
G. V., PYE, D., IRVING, D. O., SMITH, T. A., BECK, H. P. & 
ALPERS, M. P. 2002. A recombinant blood-stage malaria vaccine 
reduces Plasmodium falciparum density and exerts selective 
pressure on parasite populations in a phase 1 -2b trial in Papua New 
Guinea. J Infect Dis, 185, 820-7.
GERO, A. M. & HALL, S. T. 1997. Plasmodium falciparum: transport of 
entantiomers of nucleosides into Sendai-treated trophozoites. Exp 
Parasitol, 86,228-31.
GERO, A. M. & KIRK, K. 1994. Nutrient transport pathways in 
Plasmodium-mi&ctQd erythrocytes: what and where are they? 
Parasitol Today, 10,395-9.
GERO, A. M. & O'SULLIVAN, W. J. 1990. Purines and pyrimidines in 
malarial parasites Blood Cells, 16,467-484.
GERO, A. M. & WOOD, A. M. 1991. New nucleoside transport pathways 
induced in the host erythrocyte membrane of malaria and Babesia 
infected cells. Adv Exp Med Biol, 309A, 169-72.
GINSBURG, H., KUTNER, S., KRUGLIAK, M. & CABANTCHIK, Z. I. 
1985. Characterization of permeation pathways appearing in the 
host membrane of Plasmodium falciparum infected red blood cells. 
Mol Biochem Parasitol, 14, 313-22.
GINSBURG, H. & STEIN, W. D. 1987. Biophysical analysis of novel 
transport pathways induced in red blood cell membranes. JMembr 
Biol, 96,1-10.
GOLBY, P, KELLY, D. J., GUEST, J. R. & ANDREWS, S. C. 1998. 
Topological analysis of DcuA, and anaerobic C4-dicarboxylate 
transporter of Escherichia coli. Journal of Bacteriology, 180, 4821- 
4827.
GOODYER, I. D., HAYES, D. J. & EISENTHAL, R. 1997. Efflux of 6- 
deoxy-D-glucose from Plasmodium falciparum-mfecXod. 
erythrocytes via two saturable carriers. Mol Biochem Parasitol, 84, 
229-239.
GOSS, T. J, SHWEIZER, H. P. & DATTA, P. 1988. Molecular 
characterization of the tdc operon of Escherichia coli K-12. 
Journal of Bacteriology, 170, 5352-5359.
GREENWOOD, B. & TARGETT, G. 2009. Do we still need a malaria 
n&ccvlMI Parasite Immunology, 31, 582-586.
243
GREENWOOD, D. 1995. Conflicts of interest: the genesis of synthetic 
antimalarial agents in peace and war. JAntimicrob Chemother, 36, 
857-72.
GRIFFITTS, T. H. D. 1937. Malaria Control—Comments on the Past and 
Future. Am J Public Health Nations Health, 27, 120-124,
GUASTELLA, J., BRECHA, N., WEIGMANN, G, LESTER, H. A. & 
DAVIDSON, N. 1992. Cloning, expression and localization of a rat 
brain high-affinity glycine transporter. Proc Natl Acad Sci USA, 
89,7189-7193.
GORDON, J. B., LANE, C. D., WOODLAND, H. R. & MARBAIX, G. 
1971. Use of Frog Eggs and Oocytes for the Study of Messenger 
RNA and its Translation in Living Cells. Nature, 233, 177-182.
HAQUE, A. & GOOD, M. F. 2009. Malaria vaccine research: lessons from 
2008/9. Future Microbiol, 4, 649-54,
HARINASUTA, T., SUNTHARASAMAI, P. & VIRAVAN, C. 1965. 
Chloroquine-resistant falciparum malaria in Thailand. Lancet, 2, 
657-60.
HASNE, M. P. & BARRETT, M. P. 2000. Transport of methionine in 
Trypanosoma bruceibrucei. MolBiochem Parasitol, 111, 299-307.
HATANAKA, T., HUANG, W., LING, R, PRASAD, P. D., 
SUGAWARA, M., LEIBACH, F. H. & GANAPATHY, V. 2001. 
Evidence for the transport of neutral as well as cationic amino acids 
by AT A3, a novel and live-specific subtype of amino acid transport 
system A. Biochim Biophys Acta, 1510,10-17.
HAY, S. L, GUERRA, C. A., GETHING, P. W., PATIL, A. P., TATEM, 
A. J., NOOR, A. M., KABARIA, C. W„ MANH, B. H., 
ELYAZAR, I. R. F, BROOKER, S., SMITH, D. L., MOYEED, R. 
A. & SNOW, R. W. 2009. A World Malaria Map: Plasmodium 
falciparum Endemicity in 2007. PLoSMed, 6, el000048.
HAY, S. L, GUERRA, C. A., TATEM, A. J., NOOR, A. M. & SNOW, R. 
W. 2004. The global distribution and population at risk of malaria: 
Past, present, and future. Lancet Infectious Diseases, 4, 327-336.
HEIDRICH, H. G., MREMA, J. E, VANDER JAGT, D. K., REYES, P. & 
RIECKMANN, K. H. 1986. Isolation of intracellular parasites 
{Plasmodium falciparum) from culture using ffee-flow 
electrophoresis: separation of the free parasite according to stage. J 
Parasitol, 68,443-450.
HEMPELMANN, E., MOTTA, C., HUGHES, R., WARD, S. A. & 
BRAY, P. G. 2003. Plasmodium falciparum’, sacrificing membrane 
to grow crystals? Trends Parasitol, 19,23-6.
HENRY, M., ALIBERT, S., ORLANDI-PRADINES, E., BOGREAU, H., 
FUSAI, T., ROGIER, G, BARBE, J. & PRADINES, B. 2006. 
Chloroquine resistance reversal agents as promising antimalarial 
drugs. Curr Drug Targets, 7, 935-48.
244
HILLE, B. 1978. Ionic channels in excitable membranes. Current problems 
and biophysical approaches. Biophys J, 22,283-294.
HOFFBRAND, A. V. & WEIR, D. G. 2001. The history of folic acid. Br J 
Haematol, 113, 579-89.
HOLMGREN, G., GIL, J. P., FERREIRA, P. M., VEIGA, M. I., 
OBONYO, C. O. & BJORKMAN, A. 2006. Amodiaquine resistant 
Plasmodium falciparum malaria in vivo is associated with selection 
of pfcrt 76T and pfmdrl 86Y. Infect Genet Evol, 6, 309-14.
HOPPE, H. C, COETZEE, J. & LOUW, A. I. 1992. Plasmodium 
falciparum: isolation of intact and erythrocyte-free trophozoites 
from sorbitol lysates. Parasitology, 104, 379-385.
HOSHINO, T., KOSE, K. & URATANI, Y. 1990. Cloning and nucleotide 
sequence of the gene braB coding for the sodium-coupled 
branched-chain amino acid canier of Pseudomonas aeruginosa 
PAO. Molecular Genetics And Genomics, 220, 461-467.
HSU, L. C., CHIOU, T. J. & BUSH, D. R. 1993. Cloning a plant amino 
acid transporter by functional complementation of a yeast amnio 
acid transport mutant. Proc Natl Acad Sci U S A, 90, 7441-7445.
HUENNEKENS, F. M. 1994. The methotrexate stoiy: A paradigm for 
development of cancer chemotherapeutic agents. Advances in 
Enzyme Regidation, 34,397-402.
HYDE, J. E. 1990. The dihydro folate reductase-thymidylate synthetase 
gene in the drug resistance of malaria parasites. Pharmacol Ther, 
48, 45-59.
HYDE, J. E. 2005. Exploring the folate pathway in Plasmodium 
falciparum. Acta Prop, 94, 191-206.
HYDE, J. E. 2007. Drug-resistant malaria - an insight. Febs J, 274, 4688- 
98.
ISNARD, A. D., THOMAS, D. & SURDIN-KERJAN, Y. 1996. The study 
of methionine uptake in Saccharomyces cerevisiae reveals a new 
family of amino acid permeases. JMol Biol, 262,473-84.
JACK, D. L., PAULSEN, I. T. & SAIER, M. H, JR. 2000. The amino 
acid/polyamine/organocation (APC) superfamily of transporters for 
amino acids, polyammes and organocations. Microbiology, 146, 
1797-1814.
JACOBS, R. L. 1964. Role ofp-aminobenzoic acid m Plasmodium berghei 
infection in the mouse. Exp Parasitol, 15, 213-225.
JANICK, P. A., GRUNWALD, G. B. & WOOD, J. M. 1977. The effects 
of N-ethyknaleimide on active amino acid transport in Escherichia 
coli. Biochim Biophys Acta, 464, 328-37.
JANSE, C. J., VAN DER KLOOSTER, P. F., VAN DER KAAY, H. L, 
VAN DER PLOEG, M. & OVERDULVE, J. P. 1986. DNA 
synthesis in Plasmodium berghei during asexual and sexual 
development. Mol Biochem Parasitol, 20, 173-82.
245
JEWELL, H., MAGGS, J. L., HARRISON, A. C., ONEILL, P. M., 
RUSCOE, J. E. & PARK, B. K. 1995. Role of hepatic metabolism 
in the bio activation and detoxication of amodiaquine. Xenobiotica, 
25, 199-217.
JOET, T., ECKSTEIN-LUDWIG, U, MORIN, C. & KRISHNA, S. 2003. 
Validation of the hexose transporter of Plasmodium falciparum as a 
novel drug target. Proc Natl Acad Sci U SA, 100, 7476-9.
JOET, T. & KRISHNA, S. 2004. The hexose transporter of Vlasmodium 
falciparum is a worthy drug target. Acta Prop, 89, 371-4.
JUNG, H, RUBENHAGEN, R., TEBBE, S, LEIFKER, K, THOLEMA, 
N., QUICK, M. & SCHMID, R. 1998. Topology of the NaVproline 
transporter of Escherichia coli. JBiol Chem, 273,26400-26407.
KAIN, K. C. 2003. Current status and replies to frequently posed questions 
on atovaquone plus proguanil (Malarone) for the prevention of 
malaria. BioDrugs, 17 Suppl 1,23-8.
KANAANI, J. & GINSBURG, H. 1988. Compartment analysis of ATP in 
malaria infected erythrocytes. Biochemlnt, 17,451-459.
KANAANI, J. & GINSBURG, H. 1989. Metabolic interconnection 
between the human malarial parasite Plasmodium falciparum and 
its host erythrocyte. Regulate of ATP levels by means of an 
adenylate translocator and adenylate kinase. J Biol Chem, 264, 
3194-9.
KANAANI, J. & GINSBURG, H. 1991. Transport of lactate in 
Plasmodium falciparum-mfQctGd. human erythrocytes. J Cell 
Physiol, 149,469-476.
KEATES, R. A, CULHAM, D. E., VERNIKOVSKA, Y. L, ZUIJANI, A. 
J., BOGGS, J. M. & WOOD, J. M. 2010. Transmembrane helix I 
and periplasmic loop 1 of Escherichia coli ProP are involved in 
osmosensing and osmoprotectant transport. Biochemistry, 49, 
8847-8856.
KEELING, P. J., PALMER, J. D,, DONALD, R. G., ROOS, D. S, 
WALLER, R. F. & MCFADDEN, G. I. 1999. Shikimate pathway 
in apicomplexan parasites. Nature, 397, 219-20.
KENNERKNECHT, N., SAHM, H., YEN, M. R., PATEK, M., SAIER, 
M. H., JR. & EGGELING, L. 2002. Export of L-isoleucine from 
Corynebacterium glutamicum: a two-gene-encoded member of a 
new translocator family. Journal of Bacteriology, 184, 3947-3956.
KIARA, S. M., OKOMBO, J., MASSENO, V., MWAI, L., OCHOLA, I., 
BORRMANN, S. & NZILA, A. 2009. In vitro activity of antifolate 
and polymorphism in dihydrofolate reductase of Plasmodium 
falciparum isolates from the Kenyan coast: Emergence of parasites 
with He-164-Leu mutation. Antimicrob Agents Chemother, 53, 
3793-3798.
KIHAMIA, C. M. & GILL, H. S. 1982. Chloroquine-resistant falciparum 
malaria in semi-immune African Tanzaniana. Lancet, 2, 43.
246
KILAMA, W. L. 2009. Health research ethics in public health: Trials and 
implementation of malaria mosquito control strategies. Acta Trap, 
112.
KINYANJUI, S. M., MBERU, E. K, WINSTANLEY, P. A., JACOBUS, 
D. P. & WATKINS, W. M. 1999. The antimalarial triazine 
WR99210 and the prodrug PS-15: folate reversal of in vitro activity 
against Plasmodium falciparum and a non-antifolate mode of 
action of the prodrug. Am J Trop Med Hyg, 60,943-7.
KIRK, K. 2001. Membrane transport in the malaria-infected erythrocyte. 
Physiol Rev, 81,495-537.
KIRK, K. 2004. Channels and transporters as drug targets in the 
Plasmodium-infected erythrocyte. Acta Prop, 89, 285-98.
KIRK, K, ASHWORTH, K. I., ELFORD, B. C, PINCHES, R. A. & 
ELLORY, J. C. 1991. Characteristics of 86Rb+ transport in human 
erythrocytes with Plasmodium falciparum. Biochim Biophys Acta, 
1061,305-308.
KIRK, K., HORNER, H. A., ELFORD, B. C, ELLORY, J. C. & 
NEWBOLD, C. I. 1994. Transport of diverse substrates into 
malaria-infected erythrocytes via a pathway showing functional 
characteristics of a chloride channel. JBiol Chem, 269, 3339-47.
KIRK, K, HORNER, H. A. & KIRK, J. 1996. Glucose uptake in 
Plasmodium faldparum-mfQCtQd. erythrocytes is an equilibrative 
not an active process. Mol Biochem Parasitol, 82, 195-205.
KIRK, K, HOWITT, S. M., BROER, A., SALIBA, K. J. & DOWNIE, M. 
J. 2009. Purine uptake in Plasmodium: transport versus 
metabolism. Trends Parasitol, 25,246-249.
KIRK, K„ MARTIN, R. E., BROER, S., HOWITT, S. M. & SALIBA, K. 
J. 2005. Plasmodium permeomics: membrane transport proteins in 
the malaria parasite. Curr Top Microbiol Immunol, 295, 325-56.
KIRK, K. & SALIBA, K. J. 2007. Targeting nutrient uptake mechanisms 
in Plasmodium. Curr Drug Targets, 8,75-88.
KIRK, K. & STRANGE, K. 1998. Functional properties and physiological 
roles of organic solute channels. Annual Review of Physiology, 60, 
719-739.
KITRON, U. & SPIELMAN, A. 1989. Suppression of transmission of 
malaria through source reduction: antianopheline measures applied 
in Israel, the United States, and Italy. Rev Infect Dis, 11, 391-406.
KLAUS, S. M. J., KUNJI, E. R. S., BOZZO, G. G., NOIRIEL, A., DE LA 
GARZA, R. D., BASSET, G. J. C., RAVANEL, S., REBEILLE, 
F., GREGORY, J. F., Ill & HANSON, A. D. 2005. Higher Plant 
Plastids and Cyanobacteria Have Folate Gamers Related to Those 
of Trypanosomatids. J. Biol. Chem., 280,38457-38463.
KOLAKOVICH, K. A., GLUZMAN, I. Y., DUFFIN, K. L. & 
GOLDBERG, D. E. 1997. Generation of hemoglobin peptides in 
the acidic digestive vacuole of Plasmodium falciparum implicates
247
peptide transport in amino acid production. Mol Biochem Parasitol, 
87, 123-35.
KREMSNER, P. G. & KRISHNA, S. 2004. Antimalarial combinations. 
Lancet, 364,285-94.
KRISHNA, S., WEBB, R. & WOODROW, C. 2001a. Transport proteins 
of Plasmodium falciparum: defining the limits of metabolism. Int J 
Parasitol, 31,1331-42.
KRISHNA, S., WOODROW, C., WEBB, R., PENNY, J., TAKEYASU, 
K., KIMURA, M. & EAST, J. M. 2001b. Expression and 
functional characterization of a Plasmodium falciparum Ca2+- 
ATPase (PfATP4) belonging to a subclass unique to apicomplexan 
organisms. JBiol Chem, 276, 10782-7.
KRISHNA, S. & WOODROW, C. J. 1999. Expression of parasite 
transporters in Xenopus oocytes. Novartis Found Symp, 226, 126- 
39; discussion 139-44.
KRISHNA, S., WOODROW, C. J., BURCHMORE, R. J., SALIBA, K. J. 
& KIRK, K. 2000. Hexose transport in asexual stages of 
Plasmodium falciparum and kinetoplastidae. Parasitol Today, 16, 
516-21.
KRUGLIAK, M., ZHANG, J. & GINSBURG, H. 2002. Intraerythrocytic 
Plasmodium falciparum utilizes only a fraction of the amino acids 
derived from the digestion of host cell cytosol for the biosynthesis 
of its proteins. Mol Biochem Parasitol, 119,249-256.
KRUNGKRAI, J., WEBSTER, H. K. & YUTHAVONG, Y. 1989a. 
Characterization of cobalamin-dependent methionine synthase 
purified from the human malarial parasite, Plasmodium falciparum. 
Parasitol Res, 75, 512-7.
KRUNGKRAI, J., WEBSTER, H. K. & YUTHAVONG, Y. 1989b. De 
novo and salvage biosynthesis of pteroylpentaglutamates in the 
human malaria parasite, Plasmodium falciparum. Molecular and 
Biochemical Parasitology, 32, 25-38.
KRUNGKRAI, J., WEBSTER, H. K. & YUTHAVONG, Y. 1990. Folate 
and cobalamin metabolism m Plasmodium falciparum. 6, 388-391.
KRUNGKRAI, J., YUTHAVONG, Y. & WEBSTER, H. K. 1985. 
Guanosine triphosphate cyclohydrolase in Plasmodium falciparum 
and other Plasmodium species. Mol Biochem Parasitol, 17, 265-76.
KUMAR, N. & ZHENG, H. 1990. Stage-specific gametocytocidal effect in 
vitro of the antimalaria drug qinghaosu on Plasmodium falciparum. 
Parasitol Res, 76,214-8.
LAMBROS, C. & VANDERBERG, J. P. 1979. Synchronization of 
Plasmodium falciparum erythrocytic stages in culture. J Parasitol, 
65, 418-20.
LANDFEAR, S. M. 2010. Glucose transport in parasitic protozoa. 
Methods Mol Biol, 637,245-262.
248
LANTERI, C. A., STEWART, M. L., BROCK, J. M., ALIBU, V. P., 
MESHNICK, S. R., TIDWELL, R. R. & BARRETT, M. P. 2006. 
Roles for the Trypanosoma brucei P2 transporter in DB75 uptake 
and resistance. Mol Pharmacol, 70, 1585-1592.
LAUER, S. A., RATHOD, P. K., GHORI, N. & HALDAR, K. 1997. A 
membrane network for nutrient import in red cells infected with the 
malaria parasite. Science, 276, 1122-5.
LEE, C. S., SALCEDO, E., WANG, Q, WANG, P, SIMS, P. F. & 
HYDE, J. E. 2001. Characterization of three genes encoding 
enzymes of the folate biosynthetic pathway in Plasmodium 
falciparum. Parasitology, 122 Pt 1, 1-13.
LEHANE, A. M., SALIBA, K. J., ALLEN, R. J. & KIRK, K. 2004. 
Choline uptake into the malaria parasite is energized by the 
membrane potential. Biochem Biophys Res Commun, 320, 311 -7.
LIN, Y, DUEKER, S. R., FOLLETT, J. R., FADEL, J. G., ARJOMAND, 
A., SCHNEIDER, P. D., MILLER, J. W., GREEN, R, 
BUCHHOLZ, B. A, VOGEL, J. S, PHAIR, R. D. & CLIFFORD, 
A. J. 2004. Quantitation of in vivo human folate metabolism. 
American Journal of Clinical Nutrition, 80, 680-691.
LIU, Q. & DUNLAP, J. C. 1996. Isolation and analysis of the arg-13 gene 
of Neurospora crassa. Genetics, 143, 1163-1174.
LO, R. S., SAID, H. M., UNGER, T. F., HOLLANDER, D. & MILEDI, R. 
1991. An endogenous canier-mediated uptake system for folate in 
oocytes of Xenopus laevis. Proceedings. Biological sciences / The 
Royal Society, 246,161-165.
LOO, D. D., HIRAYAMA, B. A., MEINILD, A. K., CHANDY, G., 
ZEUTHEN, T. & WRIGHT, E. M. 1999. Passive water and ion 
transport by cotransporters. J Physiol, 518,195-202.
MACLEOD, P. R. & MACLEOD, R. A. 1992. Identification and sequence 
of a NaC^-linked gene from the marine bacterium Alteromonas 
haloplanktis which functionally complements the dagA gene of 
Escherichia coli. Mol Microbiol, 6, 2673-2681.
MAITLAND, K, MAKANGA, M. & WILLIAMS, T. N. 2004. 
Falciparum malaria; current therapeutic challenges. Curr Opin 
Infect Dis, 17,405-12.
MARCIANI, P., CASTAGNA, M., BONASORO, F., CARNEYALI, M. 
D. C. & SACCHI, V. F. 1998. Leucine transport in Xenopus laevis 
oocytes: Functional and morphological analysis of different 
defolliculation procedures. Comparative Biochemistry and 
Physiology Part A, 119, 1009-1017.
MARTIN, R., HENRY, R., ABBEY, J., CLEMENTS, J. & KIRK, K. 
2005. The 'permeome' of the malaria parasite: an overview of the 
membrane transport proteins of Plasmodium falciparum. Genome 
Biology, 6, R26.
249
MARTIN, R. E. & KIRK, K. 2007. Transport of the essential nutrient 
isoleucine in human erythrocytes infected with the malaria parasite 
Plasmodium falciparum. Blood, 109,2217-24.
MARTIN, R. E., MARCHETTI, R. V., COWAN, A. L, HOWITT, S. M., 
BROER, S. & KIRK, K. 2009. Chloroquine Transport via the 
Malaria Parasite’s Chloroquine Resistance Transporter. Science, 
325, 1680-1682.
MARTIN, R. S., HENNINGSEN, R. A., SUEN, A.,
APPARSUNDARAM, S, LEUNG, B., JIA, Z., KONDRU, R. K. 
& MILLA, M. E. 2008. Kinetic and thermodynamic assessment of 
binding of serotonin transporter inhibitors. J Pharmacol Exp Ther, 
'ill, 991-1000.
MASSENO, V., MURIITHI, S. & NZILA, A. 2009. In vitro 
chemosensitization of Plasmodium falciparum to antimalarials by 
verapamil and probenecid. Antimicrob Agents Chemother, 53, 
3131-3134.
MAUREL, C, REIZER, J., SCHROEDER, J. I., CHRISPEELS, M. J. & 
SAIER, M. H., JR. 1994. Functional characterisation of the 
Escherichia coli glycerol faclilitator, GlpF, in Xenopus oocytes. J 
Biol Chem, 269, 11869.
MCCONKEY, G. A., ITTARAT, L, MESHNICK, S. R. & 
MCCUTCHAN, T. F. 1994. Auxotrophs of Plasmodium 
falciparum dependent on p-aminobenzoic acid for growth. Proc 
Natl Acad Sci USA, 91,4244-4248.
MCCORMICK, G. J., CANFIELD, C. J. & WILLET, G. P. 1971. 
Plasmodium Imowlesi: in vitro evaluation of antimalarial activity of 
folic acid inhibitors. Exp Parasitol, 30, 88-93.
MCDOWELL, M. A., LACKER, D. A., PFEIFFER, C. M., MULINARE, 
J, PICCIANO, M. F., RADER, J. I, YETLEY, E. A., KENNEDY- 
STEPHENSON, J. & JOHNSON, C. L. 2008. Blood folate levels: 
the latest NHANES results. NCHS data brief 1-8.
MCKERROW, J. H., SUN, E, ROSENTHAL, P. J. & BOUVIER, J, 1993. 
The proteases and pathogenicity of parasitic protozoa. Annual 
Review of Microbiology, 47, 821-853.
MILLER, R. L., IKRAM, S, ARMELAGOS, G. J., WALKER, R., 
HARER, W. B., SHIFF, C. J., BAGGETT, D., CARRIGAN, M. & 
MARET, S. M. 1994. Diagnosis of Plasmodium falciparum 
infections in mummies using the rapid manual ParaSight(TM)-F 
test. Trans R Soc Prop Med Hyg, 88, 31-32.
MITA, T., KANEKO, A., LUM, J. K., BWIJO, B., TAKECHI, M., 
ZUNGU, I. L, TSUKAHARA, T, TANABE, K., 
KOBAYAKAWA, T. & BJORKMAN, A. 2003. Recovery of 
chloroquine sensitivity and low prevalence of the Plasmodium 
falciparum chloroquine resistance transporter gene mutation K76T
250
following the discontinuance of chloroquine use in Malawi. Am J 
TropMedHyg, 68,413-5.
MITCHELL, H. K., SNELL, E. E. & WILLIAMS, R. J. 1941. The 
concentration of "folic acid"
JAm Chem Soc, 63, 2284
MNYONE, L. L., KIRBY, M. J, MPINGWA, M. W., LWETOIJERA, D. 
W., KNOLS, B. G, TAKKEN, W, KOENRAADT, C. J. & 
RUSSELL, T. L. 2010. Infection of Anopheles gambiae 
mosquitoes with entomopathogenic fungi: effect of host age and 
blood-feeding status. Parasitol Res.
MOORMAN, J. K, PALMER, J. D., JOHN, J. E., DURIEUX, M. E. & 
JONES, L. R. 1992. Phospholemman expression induces a 
hyperpolarization-activated chloride current in Xenopus oocytes. J 
Biol Chem, 267, 14551-12554.
MORRISON, B. W, MOORMAN, J. R., KOWDLEY, G. C, 
KOBAYASHI, Y. M., JONES, L. R. & LEDER, P. 1995. Mat-8, a 
novel phospholemman-like protein expressed in human breast 
tumors, induces a chloride conductance in Xenopus oocytes. J Biol 
Chem, 270,2176-2183.
MUELLER, A. K., LABAIED, M., KAPPE, S. H. & MATUSCHEWSKI, 
K. 2005. Genetically modified Plasmodium parasites as a 
protective expemnental malaria vaccine. Nature, 433, 164-7.
MUELLER, E. A., VAN VUGT, M., KIRCH, W., ANDRIANO, K., 
HUNT, P. & DE PALACIOS, P. I. 2006. Efficacy and safety of the 
six-dose regimen of aitemether-lumefantrine for treatment of 
uncomplicated Plasmodium falciparum malaria in adolescents and 
adults: a pooled analysis of individual patient data from 
randomized clinical trials. Acta Prop, 100, 41-53.
MUTURI, E. J., BURGESS, P. & NOVAK, R. J. 2008. Malaria vector 
management: where have we come from and where are we headed? 
Am J Prop MedHyg, 78, 536-7.
NAKAO, T., YAMATO, I. & ANRAKU, Y. 1987. Nucleotide sequence of 
putPl, the pro line carrier gene of Escherichia coli K12. Molecular 
Genetics And Genomics, 208, 70-75.
NANDINENI, M. R. & GOWRISHANKAR, J. 2004. Evidence for an 
arginine exporter encoded by yggA (argO) that is regulated by the 
LysR-type transcriptional regulator ArgP in Escherichia coli. 
Journal of Bacteriology, 186, 3539-3546.
NDUATI, E, DIRIYE, A., OMMEH, S., MWAI, L., KIARA, S., 
MASSENO, V., KOKWARO, G. & NZILA, A. 2008. Effect of 
folate derivatives on the activity of antifolate drugs used against 
malaria and cancer. Parasitology Research, 102, 1227-1234.
NEIDHART, F. C. 1996. Escherichia coli and salmonella: cellular and 
molecular biology, Washington, American Society for 
Microbiology.
251
NOSTEN, F., VAN VUGT, M., PRICE, R, LUXEMBURGER, C, 
THWAY, K. L., BROCKMAN, A., MCGREADY, R., TER 
KUILE, F, LOOAREESUWAN, S. & WHITE, N. J. 2000. Effects 
of aitesunate-mefloqume combination on incidence of Plasmodium 
falciparum malaria and mefloquine resistance in western Thailand: 
a prospective study. Lancet, 356,297-302.
NYALWIDHE, J., BAUMEISTER, S., HIBBS, A. R, TAWILL, S, 
PAPAKRIVOS, J., VOLKER, U. & LINGELBACH, K. 2002. A 
nonpermeant biotin derivative gains access to the parasitophorous 
vacuole in Plasmodium falciparum-mfQcXQ& erythrocytes 
permeabilized with streptolysin O. JBiol Chem, 277,40005.
NZILA, A. 2006. The past, present and future of antifolates in the 
treatment of Plasmodium falciparum infection. J Antimicrob 
Chemother, 57,1043-54.
NZILA, A., MBERU, E., BRAY, P, KOKWARO, G., WINSTANLEY, 
P., MARSH, K. & WARD, S. 2003. Chemosensitization of 
Plasmodium falciparum by probenecid in vitro. Antimicrob Agents 
Chemother, 47,2108-2112.
NZILA, A., OKOMBO, J, BECKER, R. P., CHILENGI, R., LANG, T. & 
NIEHUES, T. 2010. Anticancer agents against malaria: time to 
revisit? Trends Parasitol, 26,125-129.
NZILA, A., WARD, S. A., MARSH, K., SIMS, P. F. & HYDE, J. E. 
2005a. Comparative folate metabolism in humans and malaria 
parasites (part I): pointers for malaria treatment from cancer 
chemotherapy. Trends Parasitol, 21,292-8.
NZILA, A., WARD, S. A., MARSH, K, SIMS, P. F. & HYDE, J. E. 
2005b. Comparative folate metabolism in humans and malaria 
parasites (part II): activities as yet untargeted or specific to 
Plasmodium. Trends Parasitol, 21, 334-9.
NZILA, A. M, KOKWARO, G., WINSTANLEY, P. A, MARSH, K. & 
WARD, S. A. 2004. Therapeutic potential of folate uptake 
inhibition in Plasmodium falciparum. Trends Parasitol, 20, 109- 
112.
O'NEILL, P. M., BARTON, V. E. & WARD, S. A. 2010. The molecular 
mechanism of action of artemisinin—the debate continues. 
Molecules, 15, 1705-21.
O'NEILL, P. M, BRAY, P. G., HAWLEY, S. R, WARD, S. A. & PARK, 
B. K. 1998. 4-Amino quinolines—past, present, and future: a 
chemical perspective. Pharmacol Ther, 77, 29-58.
OCHONG, E. 2008. Novel contributions to understanding the mechanism 
of folate transport and anti-folate resistance in Plasmodium 
falciparum. PhD, University of Liverpool.
OCHONG, E. O., VAN DEN BROEK, I. V., KEUS, K. & NZILA, A. 
2003. Short report: association between chloroquine and 
amodiaquine resistance and allelic variation in the Plasmodium
252
falciparum multiple drug resistance 1 gene and the chloroquine 
resistance transporter gene in isolates from the upper Nile in 
southern Sudan. Am J Trap Med Hyg, 69,184-7.
OLLIARO, P. & MUSSANO, P. 2003. Amodiaquine for treating malaria. 
Cochrane Database Syst Rev, CD000016.
OVERINGTON, J. P, AL-LAZIKANI, B. & HOPKINS, A. L. 2006. How 
many drug targets are there? Nat Rev Drug Discov, 5, 993-996.
PARKER, M. D., HYDE, R. J, YAO, S. Y., MCROBERT, L., CASS, C. 
E., YOUNG, J. D., MCCONKEY, G. A. & BALDWIN, S. A. 
2000. Identification of a nucleoside/nucleobase transporter from 
Plasmodium falciparum, a novel target for anti-malarial 
chemotherapy. Biochem J, 349, 67-75.
PENNY, J. I., HALL, S. T, WOODROW, C. J., COWAN, G. M, GERO, 
A. M. & KRISHNA, S. 1998. Expression of substrate-specific 
transporters encoded by Plasmodium falciparum in Xenopus laevis 
oocytes. Mol Biochem Parasitol, 93, 81-9.
PERKINS, S. L. & AUSTIN, C. C. 2009. Four new species of Plasmodium 
from New Guinea lizards: integrating morphology and molecules. J 
Parasitol, 95,424-33.
PERNIL, R., PICOSSI, S., MARISCAL, V., HERRERO, A. & FLORES, 
E. 2008. ABC-type amino acid transporters Bgt and N-II of 
Anabaena sp. strain PCC 7120 share ATPase subunit and are 
expressed in vegetative cells and heterocysts. Mol Microbiol, 61, 
1067-1080.
PETER, H., WEIL, B., BURKOVSKI, A., KRAMER, R. & MORBACH, 
S. 1998. Corynebacterium glutamicum is equipped with four 
secondary earners for compatible solutes: identification, 
sequencing and characterisation of the proline/ectosine uptake 
system, ProP, and the ectosine/proline/glycine betaine earner, EctP. 
Journal of Bacteriology, 180, 6005-6012.
PETERSON, D. S., WALLIKER, D. & WELLEMS, T. E. 1988. Evidence 
that a point mutation in dihydrofolate reductase-thymidylate 
synthase confers resistance to pyrimethamine in falciparum 
malaria. Proc Natl Acad Sci USA, 85, 9114-8.
PICOSSI, S., MONTESINOS, M. L., PERNIL, R., LICHTLE, G, 
HERRERO, A. & FLORES, E. 2005. ABC-type neutral amino acid 
pennease N-I is required for optimal diazotrophic growth and is 
repressed in the heterocysts of Anabaena sp. strain PCC 7120. Mol 
Microbiol, 57,1582-1592.
PRESTON, G. M., CARROLL, T. P., GUGGINO, W. B. & AGRE, P. 
1992. Appearance of water channels in Xenopus oocytes expressing 
red cell CHIP28 protein. Science, 256, 385-387.
QUASHIE, N. B., DORIN-SEMBLAT, D., BRAY, P. G., BIAGINI, G. 
A., DOERIG, G, RANFORD-CARTWRIGHT, L. C. & DE 
KONING, H. P. 2008. A comprehensive model of purine uptake by
253
the malaria parasite Plasmodium falciparum', identification of four 
purine transport activities in intraerythrocytic parasites. Biochem J, 
411,287-295.
QUASHIE, N. B., RANFORD-CARTWRIGHT, L. C. & DE KONING, 
H. P. 2010. Uptake of purines m Plasmodium falciparum-mfQciQd 
human erythrocytes is mostly mediated by the human equilibrative 
nucleoside transporter and the human facilitative nucleobase 
transporter. Malar J, 9,36.
RABUS, R., JACK, D, L, KELLY, D. J. & SAIER, M. H., JR. 1999. 
TRAP transporters: an ancient family of extracytoplasmic solute 
receptor-dependent secondary active transporters. Microbiology, 
145,3431-3445.
RAGER, N, MAMOUN, C. B., CARTER, N. S, GOLDBERG, D. E. & 
ULLMAN, B. 2001. Localization of the Plasmodium falciparum 
PfNTl nucleoside transporter to the parasite plasma membrane. J 
Biol Chem, 276,41095-41099.
REED, M. B., SALIBA, K. J., CARUANA, S. R., KIRK, K. & 
COWMAN, A. F. 2000. Pghl modulates sensitivity and resistance 
to multiple antimalarials in Plasmodium falciparum. Nature, 403, 
906-9.
REYES, P., RATHOD, P. K, SANCHEZ, D. J., MREMA, J. E., 
RIECKMANN, K. H. & HEIDRICH, H. G. 1982. Enzymes of 
purine and pyrimidine metabolism from the human malaria 
parasite, Plasmodium falciparum. Mol Biochem Parasitol, 5, 275- 
90.
REYNOLDS, J., EL BISSAU, K., BRANDENBURG, J., GUNZL, A. & 
MAMOUN, C. 2007. Antimalarial activity of the anticancer and 
proteasome inhibitor bortezomib and its analog ZL3B. BMC 
Clinical Pharmacology, 7,13.
RITCHIE, J. W. A. & TAYLOR, P. M. 2001. Role of System L permease 
LAT1 in amino acid and iodothyronine transport in placenta. 
Biochem J, 356,719-725.
ROBERTS, F., ROBERTS, C. W., JOHNSON, J. J, KYLE, D. E, 
KRELL, T., COGGINS, J. R, COOMBS, G. H, MILHOUS, W. 
K, TZIPORI, S., FERGUSON, D. J. P., CHAKRABARTI, D. & 
MCLEOD, R. 1998. Evidence for the shikimate pathway in 
apicomplexan parasites. Nature, 393, 801-805.
ROSENBERG, R. 1982. Na-independent and Na-dependent transport of 
neutral amino acids in the human red blood cell. Acta Physiol 
Scand, 116, 321-30.
SAIER, M. H., JR. 2000a. Families of transmembrane transporters 
selective for amino acids and their derivatives. Microbiology, 146, 
1775-1795.
254
SAIER, M. H., JR. 2000b. A functional-phylogenetic classification system 
for transmembrane solute transporters. Microbiology and 
Molecular Biology Reviews, 64, 354-411.
SAIER, M. EL, JR., BEATTY, J. T., GOFFEAU, A., HARLEY, K. T., 
HEIJNE, W. R, HUANG, S. C., JACK, D. L, JAHN, P. S, LEW, 
K., LIU, J., PAO, S. S., PAULSEN, I. T., TSENG, T. T. & VIRK, 
P. S. 1999a. The major facilitator superfamily. J Mol Microbiol 
Biotechnol, 1, 257-79.
SAIER, M. R, JR., ENG, B. R, FARE), S., J., G., HAGGERTY, D. A., 
HUTCHINSON, W. J., JACK, D. L., LAI, E. C., LIU, H. J., 
NUSINEW, D. P., OMAR, A. M., PAO, S. S., PAULSEN, I. T., 
QUANG, J. A., SLIWINSKI, M., TSENG, T. T., WACHI, S. & 
YOUNG, G. B. 1999b. Phylogenetic characterization of novel 
transport protein families revealed by genome analyses. Biochim 
Biophys Acta, 1422, 1-56.
SAIER, M. R, JR., YEN, M. R., NOTO, K., TAMANG, D. G. & 
ELKAN, C. 2009. The transporter classification database: recent 
advances. NucL Acids Res., 37, 274-278.
SAIER, M. H. J., BEATTY, J. T., GOFFEAU, A., HARLEY, K. T., 
HEIJNE, W. H. M., HUANG, S.-C., JACK, D. L., JAHN, P. S., 
LEW, K, LIU, J, PAO, S. S., PAULSEN, I. T., TSENG, T.-T. & 
VIRK, P. S. 1999c. The Major Facilitator Superfamily. Journal of 
molecular microbiology and biotechnology, 1, 257-279.
SALCEDO-SORA, J. E, OCHONG, E., BEVERIDGE, S., JOHNSON,
D, , NZILA, A., BIAGINI, G. A, STOCKS, P. A., ONEILL P, M., 
KRISHNA, S., BRAY, P. G. & WARD, S. A. 2011. The molecular 
basis of folate salvage in Plasmodium falciparum: Characterization 
of two folate transporters. JBiol Chem, 286,44659-44668.
SALCEDO, E., CORTESE, J. F., PLOWS, C. V., SIMS, P. F. & HYDE, J.
E. 2001. A bifiinctional diliydro folate synthetase— 
folylpolyglutamate synthetase in Plasmodium falciparum identified 
by functional complementation in yeast and bacteria. Mol Biochem 
Parasitol, 112, 239-52.
SALIBA, K. J., HORNER, H. A. & KIRK, K. 1998. Transport and 
metabolism of the essential vitamin pantothenic acid in human 
erythrocytes infected with the malaria parasite Plasmodium 
falciparum. JBiol Chem, 273, 10190-5.
SALIBA, K. J. & KIRK, K. 1999. pH regulation in the intracellular 
malaria parasite, Plasmodium falciparum. H(+) extrusion via a v- 
type h(+)-atpase. JBiol Chem, 274,33213-9.
SALIBA, K. J. & KIRK, K. 2001. H+-coupled pantothenate transport in 
the intracellular malaria parasite. JBiol Chem, 276,18115-21.
SALIBA, K. J., MARTIN, R. E, BROER, A., HENRY, R. I, 
MCCARTHY, C. S., DOWNIE, M. J., ALLEN, R. J., MULLIN, 
K. A, MCFADDEN, G. I, BROER, S. & KIRK, K. 2006.
255
Sodium-dependent uptake of inorganic phosphate by the 
intracellular malaria parasite. Nature, 443, 582-5.
SARSERO, J. P. & PITTARD, A. J. 1995. Membrane topology analysis of 
Escherichia coli K-12 Mtr permease by alkaline phosphatase and 
[3-galactosidase fusions. Journal of Bacteriology, 177,297-306.
SARSERO, J. P, WOOKEY, P. J., GOLLNICK, P., YANOFSKY, C. & 
PITTARD, A. J. 1991. A new family of integral membrane 
proteins involved in transport of aromatic amino acids in 
Escherichia coli. Journal of Bacteriology, 173, 2331-3234.
SCHAPIRA, A., BYGBJERG, I. C. & JEPSEN, S. 1986. The 
susceptibility of Plasmodium falciparum to sulfadoxine and 
pyrimethamine: Correlation of in vivo and in vitro results. 
American Journal of Tropical Medicine and Hygiene, 35, 239-245.
SCHELLENBERG, K. A. & COATNEY, G. R. 1961. The influence of 
antimalarial drugs on nucleic acid synthesis in Plasmodium 
gallinaceum and Plasmodium berghei. Biochem Pharmacol, 6, 
143-52.
SHAO, Z.-Q., LIN, R. T. & NEWMAN, E. B. 1994, Sequencing and 
characterization of of the sdaCB operon in Escherichia coli K-12. 
Eur J Biochem, 222, 901-907.
SHERMAN, I. W. 1977. Transport of amino acids and nucleic acid 
precursors in malarial parasites. Bull World Health Organ, 55,211- 
25.
SHERMAN, I. W. 1988. The Wellcome Trust lecture. Mechanisms of 
molecular trafficking in malaria. Parasitology, 96 Suppl, S57-81.
SHERMAN, I. W. (ed.) 1998. Malaria: Parasite Biology, Pathogenesis 
and Protection, Washington: American Society For Parasitology
SIBLEY, C. H„ HYDE, J. E„ SIMS, P. F., PLOWE, C. V., KUBLIN, J. 
G„ MBERU, E. K., COWMAN, A. F., WINSTANLEY, P. A., 
WATKINS, W. M. & NZILA, A. M. 2001. Pyrimethamine- 
sulfadoxine resistance in Plasmodium falciparum: what next? 
Trends Parasitol, 17, 582-8.
SIGEL, E. & MINIER, F. 2005. The Xenopus oocyte: system for the study 
of functional expression and modulation of proteins. Mol Nutr 
Food Res, 49,228-34.
SIMIC, P, WILLUHN, J., SAHM, H. & EGGELING, L. 2002. 
Identification of glyA (encoding serine hydroxymethyltransferase) 
and its use together with the exporter TlrrE to increase L-threoning 
accumulation by Corynebacterium glutamicum. Applied And 
Environmental Microbiology, 68, 3321-3327.
SINGH, B., SUNG, L. K., MATUSOP, A., RADHAKRISHNAN, A., 
SHAMSUL, S. S. G., COX-SINGH, J., THOMAS, A. & 
CONWAY, D. J. 2004. A large focus of naturally acquired 
Plasmodium knowlesi infections in human beings. The Lancet, 363, 
1017-1024.
256
SIRAWARAPORN, W, PRAPUNWATTANA, P., SIRAWARAPORN, 
R., YUTHAVONG, Y. & SANTI, D. V. 1993. The dihydro folate 
reductase domain of Plasmodium falciparum thymidylate synthase- 
diliydrofolate reductase. Gene synthesis, expression, and anti­
folate-resistant mutants. JBiol Chem, 268,21637-44.
SIROTNAK, F. M., WENDEL, H. G., BORNMANN, W. G. B., TONG, 
W. P., MILLER, V. A, SCHER, H. I. & KRIS, M. G. 2000. Co­
administration of probenecid, an inhibitor of a cMOAT/MRP-like 
plasma membrane ATPase, greatly enhanced the efficacy of a new 
10-deazaaminopterin against human solid tumors in vivo. Clinical 
Cancer Research, 6, 3705-3712.
SLAVIC, K., KRISHNA, S., DERBYSHIRE, E. & STAINES, H. M. 
2011. Plasmodial sugar transporters as anti-malarial drug targets 
and comparisons with other protozoa. Malar J, 10, 165-174.
SLAVIC, K, STRASCHIL, U., REINIGER, L., DOERIG, C., MORIN, 
C., TEWARI, R. & KRISHNA, S. 2010. Life cycle studies of the 
hexose transporter of Plasmodium species and genetic validation of 
then essentiality. Mol Microbiol, 75,1402-1413.
SORIANO-GARCIA, J. F., TORRAS-LLORT, M., FERRER, R. & 
MORETO, M. 1998. Multiple pathways for L-methionine transport 
in brush-border membrane vesicles Rom chicken jejunum. J 
Physiol, 509 ( Pt 2), 527-39.
SOWUNMI, A, ADEDEJI, A. A., FATEYE, B. A. & FEHINTOLA, F. A. 
2004a. Comparative effects of pyrimethamine-sulfadoxine, with 
and without probenecid, on Plasmodium falciparum gametocytes in 
children with acute, uncomplicated malaria. Ann Prop Med 
Parasitol, 98, 873-8.
SOWUNMI, A., FEHINTOLA, F. A., ADEDEJI, A. A., GBOTOSHO, G. 
O., FALADE, C. O., TAMBO, E., FATEYE, B. A., HAPPI, T. C. 
& ODUOLA, A. M. 2004b. Open randomized study of 
pyrimethamine-sulphadoxine vs. pyrimethamine-sulphadoxine plus 
probenecid for the treatment of uncomplicated Plasmodium 
falciparum malaria in children. Prop Med Int Health, 9, 606-14.
STAINES, H. M., ASHMORE, S., FELGATE, H., MOORE, J., 
POWELL, T. & ELLORY, J. C. 2006. Solute transport via the new 
permeability pathways in Plasmodium falciparum-mfooted human 
red blood cells is not consistent with a simple single-channel 
model. Blood, 108, 3187-94.
STAINES, H. M, DERBYSHIRE, E. T., SLAVIC, K., TATTERSALL, 
A., VIAL, H. & KRISHNA, S. 2010. Exploiting the therapeutic 
potential of Plasmodium falciparum solute transporters. Prends 
Parasitol, 26,284-296.
STAINES, H. M., ELLORY, J. C. & CHIBALE, K. 2005. The new 
permeability pathways: targets and selective routes for the
257
development of new antimalarial agents. Comb Chem High 
Throughput Screen, 8, 81-8.
STAINES, H. M, ELLORY, J. C. & KIRK, K. 2001. Perturbation of the 
pump-leak balance for Na(+) and K(+) in malaria-infected 
erythrocytes. Am J Physiol Cell Physiol, 280, Cl 576-87.
STAINES, H. M., POWELL, T., THOMAS, S. L. & ELLORY, J. C. 2004. 
Plasmodium falcipanim-mAucQ<\ channels, Int JParasitol, 34, 665- 
73.
STAINES, H. M., RAE, C. & KIRK, K. 2000. Increased permeability of 
the malaria-infected erythrocyte to organic cations. Biochim 
BiophysActa, 1463,88-98.
STEFFES, C., ELLIS, J., WU, J. & ROSEN, B. P. 1992. The lysP gene 
encodes the lysme-specific permease. Journal of Bacteriology, 174, 
3242-3249.
STEFFGEN, J., KOEPSELL, H. & SCHWARZ, W. 1991. Endogenous L- 
glutamate transport in oocytes of Xenopus laevis. Biochim Biophys 
Acta, 1066,14-20.
STEWART, M. L., KRISHNA, S., BURCHMORE, R. J., BRUN, R., DE 
KONING, H. P., BOYKIN, D. W., TIDWELL, R. R,, HALL, J. E. 
& BARRETT, M. P. 2005. Detection of arsenical drug resistance in 
Trypanosoma brucei with a simple fluorescence test. Lancet 366, 
486-487.
SUBRAMANIAN, V. S., REIDLING, J. C. & SAID, H. M. 2008. 
Differentiation-dependent regulation of the intestinal folate uptake 
process: studies with Caco-2 cells and native mouse intestine. Am J 
Physiol Cell Physiol, 295, C828-835.
SUMMERS, R. L. & MARTIN, R. E. 2010. Functional characteristics of 
the malaria parasite's "chloroquine resistance transporter". 
Virulence, 1, 304-308.
TAN-ARIYA, P., BROCKELMAN, C. R. & MENABANDHU, C. 1987. 
Optimal concentration of p-aminobenzoic acid and folic acid in the 
in vitro assay of antifolates against Plasmodium falciparum. 
American Journal of Tropical Medicine and Hygiene, 37, 42-48.
TARGETT, G, A. & GREENWOOD, B. M. 2008. Malaria vaccines and 
their* potential role in the elimination of malaria. Malar J, 7.
TAYLOR, P. M., HUNDAL, H. S. & RENNIE, M. J. 1989. Transport of 
glutamine in Xenopus laevis oocytes: Relationship with transport of 
other amino acids. JMembrBiol, 112, 149-157.
TAYLOR, P. M., KAUR, S., MACKENZIE, B. & PETER, G. J. 1996. 
Amino-acid-dependent modulation of amino acid transport in 
Xenopus laevis oocytes. J Exp Biol, 199, 923-31.
TAYLOR, W. R. & WHITE, N. J. 2004. Antimalarial drug toxicity: a 
review. DrugSaf 27,25-61.
TER KUILE, F., WHITE, N. J., HOLLOWAY, P., PASVOL, G. & 
KRISHNA, S. 1993. Plasmodium falciparum', in vitro studies of
258
the pharmacodynamic properties of drugs used for the treatment of 
severe malaria. Exp Parasitol, 16, 85-95.
TOLNER, B., POOLMAN, B, WALLACE, B. & KONINGS, W. N. 
1992. Revised nucleotide sequence of the gltP gene, which encodes 
the proton-glutamate-aspartate transport protein of Escherichia coli 
K-12. Journal of Bacteriology, 174, 2391-2393.
TRACER, W. & JENSEN, J. B. 1976. Human malaria parasites in 
continuous culture. Science, 193, 673-675.
TRACER, W., WILLIAMS, J. & GILL, G. S. 1992. Extracellular 
development, in vitro, of the erythrocytic cycle of Plasmodium 
falciparum. Parasitol Today, 8, 384-387.
TRAGER, W., WILLIAMS, J. & GILL, G. S. 1996. Extracellular 
development of the erythrocytic stages of Plasmodium falciparum. 
Methods In Cell Science 18, 219-227.
TRAGER, W, ZUNG, J. & TERSHAKOVEC, M. 1990. Initial 
extracellular development in vitro of erythrocytic stages of malaria 
parasites. Proc Natl Acad Sci USA, 87, 5618-5622.
TRIGLIA, T. & COWMAN, A. F. 1994. Primary strocture and expression 
of the dihydropteroate synthetase gene of Plasmodium falciparum. 
Proc Natl Acad Sci USA, 91, 7149-53.
TRIGLIA, T. & COWMAN, A. F. 1999a. The mechanism of resistance to 
sulfa drugs in Plasmodium falciparum. Drug Resist Updat, 2, 15- 
19.
TRIGLIA, T. & COWMAN, A. F. 1999b. Plasmodium falciparum', a 
homologue of p-aminobenzoic acid synthetase. Exp Parasitol, 92, 
154-8.
TROTSCHEL, C., DEUTENBERG, D., BATHE, B, BURKOVSKI, A. & 
KRAMER, R. 2005. Characterization of methionine export in 
Corynebacterium glutamicum. Journal of Bacteriology, 187, 3786- 
3794.
TUNNICLIFF, G. 1994. Amino acid transport by human erythrocyte 
membranes. Comp Biochem Physiol Comp Physiol, 108,471-8.
TUSNADY, G. E. & SIMON, I. 2001. The HMMTOP transmembrane 
topology prediction server. Bioinformatics, 17, 849-850.
UPSTON, J. M. & GERO, A. M. 1995. Parasite-induced permeation of 
nucleosides in Plasmodium falciparum malaria. Biochim Biophys 
Acta, 1236,249-58.
VALDERRAMOS, S. G. & FIDOCK, D. A. 2006. Transporters involved 
in resistance to antimalarial drugs. Trends Pharmacol Sci, 27, 594- 
601.
VAN SCHALKWYK, D. A, WALDEN, J. C. & SMITH, P. J. 2001. 
Reversal of chloroquine resistance in Plasmodium falciparum using 
combinations of chemosensitizers. Antimicrob Agents Chemother, 
45,3171-4.
259
VAN WINKLE, L. J. 1993. Endogenous amino acid transport systems and 
expression of mammalian amino acid transport proteins in Xenopus 
oocytes. Biochim Biophys Acta, 1154, 157-172.
VAN WINKLE, L. J. 1999. Biomembrane Transport, London, Academic 
Press.
VERY, A. A. & GAYMARD, F. 1995. Expression of a cloned plant K+ 
channel in Xenopus oocytes: analysis of macroscopic currents. 
Plant J, 7, 321-332.
VRLJIC, M., GARG, J., BELLMAN, A., WACHI, S, FREUDL, R., 
MALECKI, M. J., SAHM, H., KOZINA, V. J., EGGELING, L. & 
SAFER, M. H., JR. 1999. The LysE superfamily: topology of the 
lysine exporter LysE of Corynebacterium glutamicum, a paradigm 
for a novel superfamily of transmembrane solute translocators. 
Microbiol Biotechnol, 1,327.
VRLJIC, M., SAHM, H. & EGGELING, L. 1996. A new type of 
transporter with a new type of cellular function: L-lysine export 
from Corynebacterium glutamicum. Mol Microbiol, 22, 815-826.
WAGNER, C. A., BROER, A., ALBERS, A., GAMPER, N., LANG, F. & 
BROER, S. 2000a. The heteromeric amino acid transporter 
4F2hc/LATl is associated m Xenopus oocytes with a non-selective 
cation channel that is regulated by the serine/threonine kinase sgk- 
1. Journal of Physiology, 526, 35-46.
WAGNER, C. A., FRIEDRICH, B, SETIAWAN, L, LANG, F. & 
BROER, S. 2000b. The use of Xenopus laevis oocytes for the 
functional characterisation of heterologously expressed membrane 
proteins. Cell Physiol Biochem, 10,1-12.
WALLACE, B, YANG, Y. J., HONG, J. S. & LUM, D. 1990. Cloning 
and sequencing of a gene encloding a glutamate and aspartate 
earner of Escherichia coli K-12. Journal of Bacteriology, 172, 
3214-3220.
WANG, P., BROBEY, R. K. B., HORII, T., SIMS, P. F. G. & HYDE, J. E. 
1999. Utilization of exogenous folate in the human malaria parasite 
Plasmodium falciparum and its critical role in antifolate drug 
synergy. Mol Microbiol, 32, 1254-1262.
WANG, P., LEE, C. S., BAYOUMI, R, DJIMDE, A., DOUMBO, O., 
SWEDBERG, G., DAO, L. D., MSHINDA, H., TANNER, M, 
WATKINS, W. ML, SIMS, P. F. G. & HYDE, J. E. 1997a. 
Resistance to antifolates in Plasmodium falciparum monitored by 
sequence analysis of dihydropteroate synthetase and dihydrofolate 
reductase alleles in a large number of field samples of diverse 
origins. Mol Biochem Parasitol, 89, 161-177.
WANG, P., NIRMALAN, N., WANG, Q., SIMS, P. F. & HYDE, J. E. 
2004. Genetic and metabolic analysis of folate salvage in the 
human malaria parasite Plasmodium falciparum. Molecular and 
Biochemical Parasitology, 135, 77-87.
260
WANG, P., SIMS, P. F. G. & HYDE, J. E. 1997b. A modified in vitro 
sulfadoxine susceptibility assay for Plasmodium falciparum 
suitable for investigating Fansidar resistance. Parasitology, 115, 
223-230.
WANG, P, WANG, Q, SIMS, P. F. & HYDE, J. E. 2007. 
Characterisation of exogenous folate transport in Plasmodium 
falciparum. Mol Biochem Parasitol, 154, 40-51.
WARHURST, D. G, CRAIG, J. C, ADAGU, I. S., GUY, R. K, 
MADRID, P. B. & FIVELMAN, Q. L. 2007. Activity of 
piperaquine and other 4-amino quinoline antiplasmodial drugs 
against chloroquine-sensitive and resistant blood-stages of 
Plasmodium falciparum. Role of beta-haematin inhibition and drag 
concentration in vacuolar water- and lipid-phases. Biochem 
Pharmacol, 73, 1910-26.
WATKINS, W. M., MBERU, E. K., WINSTANLEY, P. A. & PLOWE, C. 
V. 1997. The efficacy of antifolate antimalarial combinations in 
Africa: a predictive model based on phaimacodynamic and 
phannacokinetic analyses, Parasitol Today, 13,459-64.
WATKINS, W. M., SIXSMITH, D. G., CHULAY, J. D. & SPENCER, H. 
C. 1985. Antagonism of sulfadoxine and pyrimethamine 
antimalarial activity in vitro by p-aminobenzoic acid, p- 
aminobenzoylglutamic acid and folic acid. Molectdar and 
Biochemical Parasitology, 14, 55-61.
WATSON, J. 2002. Pneumocystis carinii: where me we now? J HIV Ther, 
7, 8-12.
WHITE, N. J. 1994. Mefloquine. Bmj, 308, 286-7.
WHO. 2008. World malaria report 2008. WHO/HTM/GMP/2008.1 
[Online].
WHO 2010. Guidelines For The Treatment of Malaria. Second ed.: World 
Health Organisation.
WINSTANLEY, P, WATKINS, W, MUHIA, D., SZWANDT, S, 
AMUKOYE, E. & MARSH, K. 1997. Chlorproguanil/dapsone for 
uncomplicated Plasmodium falciparum malaria in young children: 
phannacokinetics and therapeutic range. Trans R Soc Trop Med 
Hyg, 91, 322-7.
WINTER, C. G. & CHRISTENSEN, H. N. 1964. Migration of Amino 
Acids across the Membrane of the Human Erythrocyte. Journal of 
Biological Chemistry, 239, 872-878.
WOLFERSBERGER, M. G. 1994. Uniporters, symporters and antiporters. 
J Exp Biol, 196, 5-6.
WOODROW, C. J., BURCHMORE, R. J. & KRISHNA, S. 2000. Hexose 
penneation pathways in Plasmodium falciparum-miQQXQ& 
erythrocytes. Proc Natl Acad Sci USA, 97, 9931-6.
261
WOODROW, C. J., PENNY, J. I. & KRISHNA, S. 1999. Intraerythrocytic 
Plasmodium falciparum expresses a high affinity facilitative 
hexose transporter. J Biol Chem, 274, 7272-7.
WOOKEY, P. J. & PITTARD, A. J. 1988. DNA sequence of the gene 
(tyrP) encoding the tyrosine-specific transport system of 
Escherichia coli. Journal of Bacteriology, 170,4946-4949.
WRIGHT, A. J, FINGLAS, P. M. & SOUTHON, S. 1998. Erythrocyte 
folate analysis: a cause for concern? Clinical Chemistry, 44, 1886- 
1891.
YOUNG, G. B., JACK, D. L., SMITH, D. W. & SAIER, M. H., JR. 1999. 
The amino acid/auxin:proton symport permease family. Biochim 
BiophysActa, 1415,306-322.
ZAKATAEVA, N. P., ALESHIN, V. V., TOKMAKOVA, I. L, 
TROSHIN, P. V. & LIVSHITS, V. A. 1999. The novel 
transmembrane Escherichia coli proteins involved in amino acid 
efflux. FEES Lett, 452, 228-232.
ZHANG, W. & KABACK, H. R. 2000. Effect of lipid phase transistion on 
the lactose permease from Escherichia coli. Biochemistry, 39, 
14538-14542.
ZHOU, J. J., THEODOULOU, F. L., MULDIN, L, INGEMARSSON, B. 
& MILLER, A. J. 1998. Cloning and functional characterisation of 
a Brassica napus transporter that is able to transport nitrate and 
histidine. J Biol Chem, 273, 12017-12023.
262
